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PREFACE 
 
 
 Polyunsaturated fatty acids (PUFA) have become a focus in both nutritional 
sciences and medical studies in the evaluation of risk factors for cardiovascular diseases, 
dyslipidemias, diabetes, obesity, and other diseases.  Studies have disclosed that 
unsaturated fatty acids can offer health benefits which include reducing cardiovascular 
death rates, lowering blood pressure, and promoting other positive health effects for 
patients.   However, other studies have demonstrated the involvement of unsaturated fatty 
acids in oxidative stress and the development of atherosclerosis and other diseases.  With 
these known connections of fatty acids to various diseases, the development of a direct, 
inexpensive, and routine colorimetric assay for the measurement of the concentration of 
serum lipids would enable routine monitoring to incorporate fully the PUFA as a risk 
factor for any disease.  An accurate colorimetric assay combined with chemometric 
analysis has been developed that can routinely measure serum and synthetic mixture 
levels of cholesterol and PUFA simultaneously.  This method provides for a more 
comprehensive unsaturated lipids’ panel for serum which may be added to the current 
cholesterol and lipoprotein panel for inclusion in disease risk assessment models.  
Although this study is a beginning and further testing will be required on a wide range of 
human serum samples, it is hoped that the addition of both quantitative and qualitative 
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data resulting from the assay may not only be applied in routine clinical tests of humans 
but may be used in other fields such as food analysis.   
 Since a dissertation is not the single effort of just one person, I would like to take 
this time to express my gratitude and appreciation to all the people who have helped me 
reach this milestone.  My advisor, Dr. Neil Purdie, was not only my research advisor but 
also a mentor for the kind of professor whom I hope to become in the future.  His 
commitment to the development of the assay, his ability to teach students at many levels, 
and his extensive chemical knowledge provide everything a graduate could hope to have 
in his or her advisor.  The support, knowledge, and wonderful research opportunities that 
Dr. Purdie provided me during my time in his laboratory have made me a research 
chemist; and I am grateful.  Dr. A. David Marias, a collaborator from the University of 
Cape Town, was my research advisor during a semester working in his clinic on the 
development of this assay.  The time he spent sharing with me the possible medical 
applications of this procedure and his constant assistance and commitment since my 
departure to the further development of the assay were invaluable.  The members of the 
University of Cape Town’s Lipid Clinic, who assisted on the project, welcomed me not 
only to their lab, but also to their homes, during my visit there and inspired me both as a 
chemist and as a person.  I hope that one day I will be able to return their kindness.  I 
would like to thank the Director of the Oklahoma State University Wellness Center, 
Robin Purdie, and the members of the staff of the Wellness Center who have assisted 
with the development of the assay through the years.  Dr. Barry Lavine, a second 
collaborator, taught me the application of a number of chemometric methods and his 
assistance helped greatly. Through their informative conversations, Dr. Mark Rockley 
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and Dr. Lionel Raff provided me with an understanding of wavelength selection and 
neural networks that proved to be instrumental in this research. I would like to 
acknowledge two additional members of my committee, Dr. Andrew Mort and Dr. Allen 
Apblett, for their time and efforts in serving on a doctoral committee.  Thanks also to the 
other faculty members of the Department of Chemistry and Physics and, especially, the 
staff of the Department of Chemistry for all of their assistance during my time at 
Oklahoma State University. The much appreciated financial support of the Department of 
Chemistry and the UCT Lipid Clinic has made my graduate studies at OSU possible. 
 Prior to attending Oklahoma State University, I had the opportunity to have two 
great mentors whose encouragement led me to a career in the sciences.  Kathleen 
McCleary, my high school chemistry teacher, combined the learning of chemistry with 
practical and enjoyable activities.  She has been a constant supporter of me during my 
education ever since, and I am grateful for her inspiration and friendship.  Dr. Candee 
Chambers, my undergraduate advisor, exposed me to the field of physical chemistry 
during my first summer of college. Those experiences led me to choose chemistry as my 
major, and, hopefully, now, as a lifelong career. 
 My friends, who helped keep my life in balance, need to be thanked for their 
patience and kindness.  Tracy Evan, my best friend for over 10 years, has been through it 
all with me.  Her ability to make me laugh, her emails and cards, and all of the other 
innumerable ways she brought me up when I was down were greatly appreciated.  My 
OSU friends, both inside and outside the department, assisted me by not only being a 
sounding board but also taught me how to be a better person and citizen of the world.  
Pauline Aad, Bill Alley, Dany and Maya Doughan, Antoine El Khoury, Michel 
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Goldstein, Christina Hummel-Meyer, Pedro Lima, Nizam Najd, Tarek Trad, Nevin Uras 
and Jannah Zubaidi each need to be thanked for their friendship and assistance.  
  Words cannot really express how grateful I am to my family for their love and 
constant support. Blessed with two wonderful parents, I would not be where I am today 
without their encouragement. I only hope that someday they will really understand how 
much they have done for me and that I will be able to repay them in some way. Thanks to 
my brother Chad for his sense of humor and his constant reminders about what is truly 
important in life.  Also, I would like to thank my Grandfather Cornelius Reilly and my 
extended family for their continual thoughts and prayers.   
 Finally, I would like to dedicate this work to my grandparents who unfortunately 
passed away: Grandmother Margaret Reilly, Grandmother Hilda Harris; and, especially, 
my Grandfather Ralph Harris who encouraged me from the beginning to get an 
education. Grandpa was a very intelligent man and role model who always told me that I 
could finish my degree. 
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CHAPTER I  
 
 
INTRODUCTION 
 
 Coronary heart disease, hypercholesterolemia, obesity, metabolic syndrome, 
diabetes, insulin resistance, and cancer are all health conditions that are a top priority for 
research laboratories and are often discussed in the news in Westernized societies.  A 
broad search is underway to find clinical factors that can be used to detect, predict, 
diagnose, and monitor these health conditions.  One such set of factors are 
polyunsaturated fatty acids, which have been examined for positive and negative effects 
on the conditions listed above and many others.  Although polyunsaturated fatty acids can 
be detected by chromatographic methods, a low cost method to quantify polyunsaturated 
fatty acids in serum samples with little to no separation or sample preparation would 
enable polyunsaturated fatty acids to be monitored and detected during routine clinical 
serum analysis.   Using a reagent system previously developed by the Purdie laboratory, 
the calibration and application of a possible routine clinical assay for the detection of 
polyunsaturated fatty acids was attempted. 
 Lipids are approximately 25 to 45% of the dietary energy consumed in most 
developed societies.1  The fatty acids in the diet are important for not only the storage and 
transportation of energy but also serve as the basis for cellular membranes, biologically 
active compounds such as eicosanoids, and nuclear receptor interactions.  In particular, 
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the omega-3 and omega-6 fatty acids, named due to the location of the last double bonds 
from the end of the carbon chain, have been the focus of research studies for their health 
effects   The long chain fatty acids, such as linoleic acid and others, are considered 
essential nutrients because they must be consumed in the diet since no in vivo path can 
produce them.  Omega-6 fatty acids are found in vegetables, vegetable oils, and meats.  
Omega-3 fatty acids which are consumed in the human diet through fish or fish products 
and dietary supplements of fish oil capsules and other forms have become major sources 
for these nutrients.  The trend in the Western diet has been shifted from a low ratio of 
omega-6:omega-3 fatty acids to a high ratio.1  The alteration to this ratio and the 
increased rates of coronary heart disease, diabetes, obesity, and cancer in these societies 
have raised questions focusing on the possibility of an association between these two 
observations.1 
 Since the mid-1960s, polyunsaturated fatty acids, especially the longer chain 
compounds, have been studied for their role in the prevention or onset of obesity, 
coronary heart disease, and other health conditions.  The development of coronary heart 
disease and atherosclerosis occurs over a period of time and can be the result of other 
conditions that contribute to their development.  Metabolic syndrome is a collection of 
related conditions that were determined to originate from metabolic changes that can lead 
to the development of atherosclerotic cardiovascular disease and diabetes.  The 
conditions include high waist circumference and elevated cholesterol, triglyceride, and 
glucose levels.  Elevated free fatty acids are included due to their link to insulin 
resistance.2   
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 Insulin resistance is one prevailing pathological pathway for the development of 
metabolic syndrome and dyslipidemias.2-8 An increase in the concentration of fatty acids 
in serum is a major contributor to the development of insulin resistance.  Fatty acids in 
serum can be from adipose tissue, triglycerides, or the products from lipoprotein lipase.3 
Insulin plays a role in both processes. Once the excess fatty acid reaches insulin sensitive 
tissues such as muscles, they inhibit the glucose intake on the insulin mediated pathway.3 
In the liver, elevated free fatty acids increase the glucose, triglycerides, and the very low 
and low density lipoproteins, and decrease the high density lipoproteins released.3 All of 
these markers are offered as current measures for the definition of metabolic syndrome, 
except the reason for the causes of these changes, which are the concentrations of the free 
fatty acids.   
 Recent studies have begun to look at the effects of a particular sub-set of fatty 
acids, polyunsaturated fatty acids (PUFA), and their potential to prevent the onset of 
insulin resistance and, therefore, the prevention of metabolic syndrome and the other 
conditions that may develop.  Omega-3 fatty acids, particularly fish oil, and to a lesser 
extent omega-6 fatty acids have been linked to the prevention and the mediation of 
insulin resistance.5-8 More studies have associated the dietary intake of fish oil which is 
primarily composed of omega-3 fatty acids with the prevention of the symptoms of 
insulin resistance. The omega-3 fatty acids found in fish oil have been used in dietary 
studies and have lowered triglyceride (TG) and very low density lipoproteins (VLDL) 
serum levels which are related to both insulin resistance and coronary heart disease risk 
factors.5-7 One interesting study completed by Stene and Joner that focused on fish oil 
intake demonstrated that the risk of the development of type I diabetes mellitus was 
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lowered through the consumption of cod liver oil during the first year of life.9  Other 
studies have demonstrated that fish oil can slow the onset of diabetes through delays in 
the progression of glucose intolerance.5-7  All of the beneficial effects of the 
polyunsaturated fatty acids are related to their anti-inflammatory, antithrombotic, and 
antiarrhythmic properties. 
 The relationship of PUFA with coronary heart disease (CHD) has been the subject 
of numerous research studies. Miettinen et al. revealed that linoleic acid, arachidonic 
acid, and eicosapentaenoic acids (EPA) were lower in the phospholipids of subjects who 
sustained a severe cardiac event that was either fatal or non-fatal as compared to subjects 
who did not suffer a heart problem.10  In a similar study examining the fatty acid 
composition of plasma cholesteryl esters and phospholipids in subjects with CHD, Wang 
et al. discovered that there were higher percentages of stearic acid, dihomo-gamma-
linolenic acid  and total saturated fatty acids, and lower percentages of arachidonic acid 
and total polyunsaturated fatty acids.11 In a review of clinical and epidemiological 
studies, it was stated that the fatty acids that protect against CHD are linoleic acid, 
linolenic acid, EPA, and docosahexaenoic acid (DHA).12  Recent studies offer conflicting 
results.  In two dietary studies involving men who were either recovering from a 
myocardial infarction (MI) or had stable angina, the experimental intent was to 
investigate the effect of increasing the intake of fatty acids in fish either through 
consumption of fish or fish oil supplements. The study revealed mixed results.  In one set, 
the fatty acid increase with the MI patients decreased the mortality of the subjects in the 
two year follow-up.13  In the angina set, the patients who ate fish did not show a decrease 
in mortality; and the patients who consumed fish oil supplements actually had a higher 
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risk of a cardiac event or sudden death.13  The discrepancies may be due to the use of 
capsules versus the consumption of actual fish, variations in conditions, or other possible 
differences in the mechanisms that need to be examined further.13   
In an additional examination of the consumption of dietary PUFA, it was 
demonstrated that the serum linoleic acid and the PUFA concentration were negatively 
correlated to the overall mortality from cardiovascular events in male subjects.14  Hooper 
et al. completed a metanalysis of randomized controlled trials and cohort studies that 
revealed no clear positive effect on total mortality from cardiovascular events when there 
was an increase in dietary omega-3 fatty acids.15  The authors state that while the 
evidence is not clear, it is not yet appropriate to alter the dietary recommendation of 
increasing the intake of omega-3; but further research and evaluation should be 
completed.15  Even treatment with statins for the lowering of cholesterol to decrease the 
risk of CHD has an effect on the PUFA in serum.  The relative percentages of linoleic 
acid and alpha-linolenic acid decreased while arachidonic acid and docosahexaenoic acid 
increased.16, 17 
   In the current regulated methods for the detection of cholesterol and PUFA, each 
is measured independently of the other.  The routine method for the measurement of 
cholesterol is a simple enzymatic test that is used in every clinical laboratory.  The 
enzymatic test is standardized against the Center for Disease Control (CDC) reference 
method that is based on the Liebermann-Burchard reagent which reacts directly with 
cholesterol for the color development.18  For PUFA analyses in serum, there currently is 
no standard reference method.  The majority of studies use GC (gas chromatography) 
methods. This method first involves the extraction of the fatty acids using either the 
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method developed by Foche in the 1950’s or an altered method by various authors.19-26  
One such alternative is by a 2:1 methanol:hexane extraction.16  In a comparison of 
methods for lipid extraction, the most popular solvent, 2:1 chloroform-methanol (v/v), 
was only able to extract 90% of the triglycerides which can alter the percentage of PUFA 
detected in the GC method.24  The fatty acid samples are then reacted with acetyl chloride 
and heated for one hour at 100 °C to be converted into methyl esters.20  The calibrations 
require the addition of an internal reference, such as methyl docosatrienoate, to the 
sample.16  The relative amount of each fatty acid is determined by dividing individual 
peak areas by the sum of all the fatty acid peaks.16  The resulting units are neither 
molarities nor mg/dL, except where GC is combined with mass spectrometry.  
Alternative methods include combining mass spectrometry with nuclear magnetic 
resonance.  Problems that hinder the technique from becoming a clinical method are the 
possibility of errors in the extraction, the methylation, the difficulty in obtaining 
meaningful concentrations, and the labor intensity of the procedures. These limitations 
strengthen the case for the development of a simple and direct method that does not 
require separation and reacts directly with the polyunsaturated fatty acids. 
 The use of colorimetric reactions for clinical detection and quantification has been 
the key reaction for the development of a number of routine clinical tests.  Cholesterol, 
triglycerides, and free fatty acids all have colorimetric reactions that involve enzymes and 
eventual color reactions for the quantification of these compounds.  As previously 
mentioned, cholesterol can be directly quantified by the Liebermann-Burchard (L-B) 
reaction, which is the Center for Disease Control standard reaction for cholesterol.  The 
Purdie reaction which was developed as a modification of the L-B reagents was first 
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published in 1991 for the quantification of the lipoprotein particles of cholesterol, low-
density lipoprotein (LDL), high-density lipoprotein (HDL), and very low-density 
lipoprotein (VLDL).27, 28  After modification and further analysis, the reaction system 
was determined to react with –CH2-CH=CH- complexes, including steroids, terpenes, and 
polyunsaturated fatty acids, in addition to cholesterol.29-33  The products of the reaction 
have intense absorptions in the visible region from 350 to 550 nm that vary based on the 
location and number of complexes. The spectra are additive when multiple analytes are 
present, and have no significant interferences in serum except for lyzed serum samples 
where red blood cells have entered the sample. 29-33    
 The goal of this research project was to develop a simple, direct alternative 
method for the determination of the polyunsaturated fatty acids in addition to cholesterol 
in serum and possibly other samples that contain these analytes.  Previous attempts to 
measure these components using the Purdie reagent system have been reported.31  Initial 
attempts by the Purdie laboratory to determine the concentrations using multiple linear 
regressions (MLR) did not yield acceptable results.   Using the information of past 
attempts and having acquired a new understanding of the reaction system and 
chemometric methods, the intent of this study was to determine the concentration of all 
seven components believed to be reacting with the assay performed with in serum.  
Additionally, the spectral patterns from a collection of serum spectra from a collaborating 
laboratory were analyzed for a possible diagnostic test for dyslipidemias. 
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CHAPTER II  
 
 
CHOLESTEROL AND POLYUNSATURATED FATTY ACIDS AND THEIR 
RELATIONSHIP WITH CARDIOVASCULAR DISEASE 
 
I. Cholesterol 
 Cholesterol, along with fatty acids, composes the membranes of animal and 
human cells, is a precursor of bile acids and steroid hormones such as progesterone and 
testosterone, and is a major component of the nervous system including the brain.   The 
basic structure of cholesterol, pictured in Figure II.1, is a derivative of the 
perhydrocyclopentanophenanthrene skeleton. Its molecular weight is 387 g/mol.     
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Figure II.1: Structure for cholesterol 
 
 Cholesterol can be formed endogenously through the following synthesis: acetate 
to mevalonate, to isopentyl pyrophosphate, to squalene, and finally to cholesterol.34    The 
rate-limiting enzyme of this synthesis is 3-hydroxy-3methylglutaryl-CoA reductase 
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which produces mevalonate.18  The synthesis primarily occurs in the liver but can also 
occur in the intestine.34  A typical adult on a low cholesterol diet will produce 300 to 
1000 mg of cholesterol a day.18  Formation of cholesterol by the body is the primary 
source, with diet as a secondary source.  It is estimated that the average American diet 
includes 350 to over 450 mg of cholesterol per day.18  Meat, eggs, dairy products, and 
poultry are the major sources of cholesterol.  
 The reactions of cholesterol occur mainly on the hydroxyl group, at the double 
bond, or at carbon 7.  These reactions result in the formation of bile acids to aid the 
digestion of lipids, to the synthesis of steroid hormones, or to the formation of Vitamin 
D.34  The formation of bile acids is the important elimination step to remove lipids from 
the body.  A fraction of the total cholesterol is in the form of cholesteryl esters resulting 
from a condensation of the alcohol group with long chain fatty acids.  Cholesteryl esters 
are approximately 70% of the total serum cholesterol and are important in the high lipid 
carrying capacity of the lipoproteins.18  The esterification is catalyzed by lecithin-
cholesterol acyltransferase (LCAT) in plasma and acylcholesterol acyltransferase 
(ACAT) inside the cell.  LCAT will continue to esterify plasma cholesterol even after 
blood collection so immediate analysis or sample cooling is necessary if determination of 
esterified and nonesterified cholesterol is essential.18 
II. Lipoproteins 
 Cholesterol, triglycerides, phospholipids, and a group of apoproteins are the major 
components of lipoproteins.  Triglycerides (TG) are molecules with a glycerol backbone 
that have three fatty acids attached.  Phospholipids are molecular complexes with a 
carbon backbone that can be glycerol, nitrogen containing alcohol, fatty acids, and a 
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phosphate group.  The basic structure of a lipoprotein particle is a core of cholesteryl 
esters and triglycerides surrounded by a monolayer of phospholipids and free cholesterol, 
which are more polar to allow the particle to be soluble in aqueous plasma.  There are 
five major categories of lipoproteins based on their composition and physical properties 
which are summarized in Table II-1. 
 
Table II-1:  Physical properties of the major lipoproteins  
 
Composition and Density of Human Lipoproteins18, 34, 35 
 Chylomicron VLDL IDL LDL HDL 
Density 
(g/mL) 
<0.95 0.95-
1.006 
1.006-
1.019 
1.019-
1.063 
1.063-
1.210 
Diameter 
(nm) 
75-1,200 30-80 25-35 18-25 5-12 
Components 
(% dry weight) 
     
Protein 1-2 10 18 25 33 
Triglycerol 83 50 31 10 8 
Cholesterol and 
Cholesteryl esters 
8 22 29 46 30 
Phospholipids 7 18 22 22 29 
Apolipoproteins 
(* denotes major) 
A-I*, A-II,  
B-48*,  
C-I*,C-II*,C-
III*, 
E 
B-100*,  
C-I*,C-
II*,C-
III*,  
E* 
B-100*, 
C-I, C-
II, C-III, 
E* 
B-100* A-I*,A-
II*,  
C-I, C-
II, C-III, 
D, E 
 
 Chylomicrons are the initial lipoproteins formed in the intestine and are the 
largest in size.  These particles are mostly composed of lipids which are primarily in the 
form of triglycerides.  The apoproteins are apo A-I, A-II, C-I, C-II, C-III, E, and a 
fragment of apoB-100, apo B-48.  Once formed, the particle is transferred to the 
lymphatic system for distribution to the rest of the body.35  In adipose tissue and muscle, 
lipoprotein lipase catalyzes the hydrolysis of the triglycerides.35  The remainder of the 
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chylomicron particle is sent to the liver.  Chylomicrons are highest in concentration 
immediately following a meal, and the half-life for the removal of these particles is four 
to five minutes with none present in the twelve hour fasting blood samples normally 
collected in lipid analysis.18   
 The liver generates VLDL which supply the cells with fatty acids and is also the 
source of HDL.  Once the cells release the fatty acids from the VLDL, the lipoprotein 
forms intermediate density (IDL) and eventually LDL.  VLDL particles are released by 
the liver through capillaries to the extrahepatic tissues.35  These large, high percentage 
TG lipoproteins have apo B-100, C-I, C-II, C-III, and E as their apoproteins. Like the 
chylomicrons, the TG is hydrolyzed by lipoprotein lipase resulting in a reduction in 
diameter and the removal of the apo C proteins.18 The new particle is the third 
classification, IDL resulting from VLDL having a clearance value of 1 to 3 hours.18 
 IDL is converted into LDL by the action of lipoprotein lipase, and its cholesteryl 
ester composition is increased by cholesteryl ester transfer protein from high density 
lipoprotein resulting in high cholesterol content.  About 60% of total cholesterol is LDL 
cholesterol.18  On top of the monolayer, apoprotein B-100 surrounds the outside surface.  
LDL that is absorbed by cells is degraded in the lysosomes by lysosomal acid lipases.  
Once released from the lipoprotein, ACAT is activated for the formation of cholesteryl 
esters which can be stored in the cell. Approximately half of the lipids present in LDL are 
PUFA.36  A number of antioxidants including alpha and gamma tocopherol, beta and 
alpha carotene, lycopene, and others are present to protect the fatty acids from 
oxidation.36  LDL particles are able to stay in circulation for about 3 days.18  LDL 
cholesterol particles can be classified into subfractions based on size, density, 
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composition of lipids, susceptibility to oxidation, and affinity for the apoB/E receptor 
resulting in small, dense LDL and large, less dense LDL.18 
 HDL lipoprotein structure is similar to LDL, but the composition of the proteins 
and lipids is different.  The properties of HDL that are different include the following: an 
increase in density (1.063 to 1.210 g/mL), the particle size is smaller in diameter, an 
increase in the percentage of protein, and a decrease in the lipid percentage.  The major 
apolipoproteins that compose HDL are A-I, AII, C-I, C-II, C-II, D, and E. HDL contains 
20-30% of the total serum cholesterol.18  HDL has the major role in the reverse 
cholesterol transport mechanism by removing cholesterol from tissue and taking it to the 
liver for removal in bile as bile acid or free cholesterol.37  There is evidence that HDL 
also protects LDL from oxidation.37  HDL2 and HDL3 are two subclasses of this 
lipoprotein which are separated based on density.18  VLDL can lead to the production of 
HDL3 which can have the cholesterol components converted to cholesteryl ester by 
LCAT to form the larger HDL2 particle.18 
 A special class of lipoprotein is Lipoprotein(a) (Lp(a)).  Lp(a) has a similarity to 
LDL in lipid composition with the major apolipoprotein being apo B-100.18  
Additionally, Lp(a) contains apolipoprotein(a) which is a carbohydrate-rich protein that is 
attached to apo B-100 by a disulfide bond.18  The particles have a density of 1.040-1.130 
g/mL and a diameter of 25-30 nm.18  The major lipids are cholesteryl esters and 
phospholipids.18   
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III. Coronary Heart Disease (CHD) and Cholesterol 
 Coronary heart disease (CHD), also called coronary artery disease (CAD) and 
atherosclerotic heart disease, is a disease that is characterized by the accumulation of 
plaque on the walls of arteries.  Atherosclerosis is a condition where the build up of 
plaque on the walls of the arteries leads to a narrowing of the path for the blood to flow.  
If the artery were to become blocked completely, the patient could experience a stroke or 
myocardial infarction. An increase in LDL levels leads to an increase in the LDL rate of 
entry into the artery walls and in the adhesion of monocytes circulating in the blood to the 
endothelial cells.36 38 39  Inside the intimal region of the artery walls, the LDL is in an 
environment that does not have sufficient anti-oxidants to protect its components from 
oxidation.  In blood and tissue, there is a high concentration of antioxidants and 
antioxidant enzymes, such as human serum paraoxonase; but in the walls of the arteries, 
the LDL is only equipped with the limited concentration of anti-oxidants that are in its 
complex, such as alpha-tocopherol and beta-carotene. 36 40  If the LDL becomes oxidized, 
the particles can be absorbed by macrophages and smooth muscle cells to form foam 
cells. 36 38 39  Growth of the foam cells is caused by the oxidized LDL entering the cells 
through a scavenger pathway which lacks control. 36 38 39  Stage one of atherogenesis is 
the development of these foam cells.39  Stage two is development of the core of the 
plaque that develops on the artery walls.41  The final stage called thrombosis eventually 
leads to the breaking of the artery wall.41   
 The free radicals that attack LDL can modify all of the components present.  
Oxidized LDL has altered properties ranging from the lack of anti-oxidants that are 
consumed to a decrease in the fatty acids and total cholesterol.36 40  After the anti-
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oxidants are consumed, the free radicals can modify the PUFAs and cholesterol.  The 
products from the reactions include oxysterols, lipid hydroperoxides, hydroxides, 
conjugated dienes, and aldehydes.36 38 42  The products of lipid peroxidation are also 
damaging to proteins; and, as a result,  apolipoprotein B also undergoes modifications.43  
The oxidants can attack the amino acids which results in a break in the peptide chain; or 
the aldehydes that are generated as part of the lipid oxidation can establish acid side 
chains to the proteins38 40    The products of both the lipid oxidation and the protein 
oxidation are used to monitor both in vitro and in vivo oxidative stress damage to 
lipoproteins.  The generation of oxygen free radicals, the presence of lipid substrates, and 
the activity of antioxidants are three control factors for the oxidation of LDL.44   
 There is evidence that HDL also protects LDL from oxidation.37  In human serum 
experiments, the lipids in HDL are oxidized by peroxyl radicals first and then LDL.37   It 
has also been shown that HDL can protect LDL from both copper (Cu+2) and iron (Fe3+) 
mediated oxidation.37   Like oxidized LDL, oxidized HDL has different physiological 
effects.  When HDL becomes oxidized, it inhibits the lipoprotein’s ability to remove 
cholesterol from tissue.45  Oxidized HDL has been observed in plaques from arteries in 
addition to oxidized LDL, which suggests HDL has the possibility of being both a benefit 
and a risk factor in the development of atherosclerosis.45   
IV. Treatment Interventions 
 The National Cholesterol Education Program (NCEP) supported by the National 
Institutions of Health (NIH) released a third report on the detection, evaluation, and 
treatment of high cholesterol in adults (Adult Treatment Panel III, ATP III) in 2001.  The 
report states that elevated LDL cholesterol is the major risk factor for CHD which was 
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determined by a number of experimental animal tests, laboratory investigations, 
epidemiology, and genetic forms of hypercholesterolemia.46  Patients are assessed into 
three CHD risk categories: highest risk: LDL cholesterol greater than or equal to 130 
mg/dL, middle level: LDL levels between 100-129 mg/dL, and lowest: LDL cholesterol 
less than 100 mg/dL.  ATP-III recommends that an LDL concentration below 100 mg/dL 
lowers a person’s risk of developing CHD and suggests treatments to obtain these 
levels.46  Elevated LDL cholesterol levels can be a secondary dyslipidemia and 
conditions such as diabetes, hypothyroidism, chronic liver failure, liver disease, and drug-
elevated values must be excluded first.46  Additional risk factors for CHD are smoking, 
hypertension, low HDL cholesterol, family history, and age which are also considered in 
assessing treatment.46  According to ATP-III, HDL values are inversely connected with 
the risk of CHD; and  patient values should be higher than 60 mg/dL to maintain 
satisfactory health.46  Besides the cholesterol in the lipoprotein particles, there are 
additional biomarkers that are being considered for use in relation to CHD.  The ratio of 
the apoproteins apoB/apoA-1, C-reactive protein, and LDL particle size have shown a 
direct relationship with CHD.47-51 
 A statin, the most widely used drug treatment for hypercholesterolemia, is a 3-
hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) reductase inhibitor which blocks 
the formation of mevalonate.  After being released almost twenty years ago, statins have 
proven to be effective in the lowering of cholesterol and low density lipoprotein 
cholesterol (LDL-C) concentrations and contributed to a reduction in the mortality rates 
of CHD patients.46  Administering bile acid sequestrants is a second drug option.  Bile 
acid sequestrants reduce serum cholesterol levels by increasing the excretion of the bile 
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acids from the body.  The resulting effect is the liver then must convert more cholesterol 
into bile acid, reducing the total cholesterol.  Fibric acids lower TG and raise HDL levels 
and, as a result, lower the LDL cholesterol concentration.46  Nicotinic acid, a form of 
vitamin B, is a fourth drug option.46 
 Dietary treatments include the increased intake of plant sterols.  Plant sterols are 
similar to cholesterol with only side chain variations, but they are poorly absorbed by the 
intestine.  The daily intake of plant sterols is 200-300 mg.18  A dose of 5 to 15 g/d of 
plant sterols can inhibit the absorption of dietary cholesterol and can be used as a 
treatment for hypercholesterolemia.18   The ATP-III has recommended a therapeutic diet 
change which reduces the intake of saturated fats and cholesterol and the inclusion of 
plant sterols and fiber.46  Additional lifestyle changes of weight reduction and increased 
exercise are recommended.46 
V. Dyslipidemias 
 Elevated lipoprotein concentrations can be related to genetic or diet induced 
hyperlipoproteinemias.  Lipoprotein disorders are divided into primary or secondary 
varieties.  Sources of secondary hyperlipoproteinemias must be eliminated before 
considering primary ones.  Secondary causes can be divided into five sources: diet, 
diabetes, other metabolic disorders, drugs, and non-metabolic diseases.52  Dietary sources 
include excess saturated fat or calorie intake, weight gain, and eating disorders such as 
anorexia, in which the body has overproduced lipoproteins to compensate for the lack of 
nutrients.52  Drug treatment for cardiovascular disease, endocrine function, and 
antiretroviral drug therapy can alter the lipid profile.52  Diabetes, both Types I and II, 
insulin resistance, hypothyroidism, and other metabolic disorders have raised TG levels, 
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decreased HDL-C levels, and elevated LDL-C levels; especially when the condition is 
not controlled.52  Liver and renal diseases can alter lipoproteins concentrations as well.52   
Each of these five secondary dyslipidemias needs to be treated first before a diagnosis of 
primary dyslipidemia can be considered.  
 The clinical primary dyslipidemias are classified into six phenotypes based on 
their patterns of total cholesterol (TC), LDL, HDL, TG and apolipoprotein levels.  
Fredrickson et al. proposed the classification, and it was adopted by the World Health 
Organization in 1970.53  Table II-2 summarizes the types.  The Fredrickson Types were 
commonly used but have been replaced with the genetic lipoprotein disorders described 
in Table II-3.53 
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Table II-2: Fredrickson classification 
Fredrickson Classification of Lipid Disorders53 
Type Elevated 
Particles 
Associated Clinical 
Disorders 
Serum Total 
Cholesterol 
Concentration 
Serum, Total 
Triglycerides 
Concentration 
I Chylomicrons Lipoprotein lipase 
deficiency, 
apolipoprotein C-II 
deficiency 
normal greatly 
increased 
IIa LDL Familial 
hypercholesterolemia,  
Polygenic 
hypercholesterolemia,  
nephrosis 
hypothyroidism, 
familial combined 
hyperlipidemia 
greatly 
increased 
normal 
IIb LDL, VLDL Familial combined 
hyperlipidemia 
greatly 
increased 
increased 
III IDL Dysbetalipoproteinemia increased increased 
IV VLDL Familial 
hypertriglyceridemia, 
familial combined 
hyperlipidemia, 
sporadic 
hypertriglyceridemia, 
diabetes 
normal to 
increased 
greatly 
increased 
V Chylomicrons, 
VLDL 
Diabetes increased greatly 
increased 
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Table II-3: Major genetic lipoprotein disorders 
Major Genetic Lipoprotein Disorders53 
Disorder Principal 
Plasma 
Abnormality 
Fredrickson 
Classification 
Clinical Features Estimated 
Frequency 
Heterozygous 
familial 
hypercholesterolemia 
Increased 
LDL only 
IIa Tendinous 
xanthomas, 
Corneal arcus, 
Premature CAD, 
Family history of 
hypercholesterolemia 
0.2% of general 
population; 
5% of MI survivors 
<60 yr old 
Familial defective 
apolipoprotein B 
Increased 
LDL 
IIa Same as 
heterozygous familial 
hypercholesterolemia 
Same as 
heterozygous familial 
hypercholesterolemia 
Familial combined 
hyperlipidemia 
1/3: increased 
LDL 
1/3: increased 
VLDL 
1/3: increased 
LDL and 
VLDL 
 
IIa 
 
IV 
 
IIb 
Usually > 30 yr old 
Often overweight 
Usually no 
xanthomas 
Premature CAD 
Different generation 
have different 
lipoprotein 
abnormalities 
0.5% of general 
population 
15% of MI survivors 
< 60 yr old 
Polygenic 
hypercholesterolemia 
increased 
LDL 
IIa Premature CAD 
No xanthomas 
No family history of 
hypercholesterolemia 
Unknown 
Familial 
hypertriglyceridemia 
increased 
VLDL; TG 
concentration 
(200-1000 
mg/dL) 
IV Often overweight 
> 30 yr old 
Often diabetic 
Hyperuricemic 
May or may not have 
premature CAD 
Determined by family 
history and HDL-C 
1% of general 
population 
5% of MI survivors 
<60 yr old 
Severe 
hypertriglyceridemias 
increased 
Chylomicrons 
and VLDL; 
(> 1,000 
mg/dL) 
V Usually middle-aged 
Often obese 
Often hyperuricemic 
Usually diabetic 
Risk for recurrent 
pancreatitis 
Unknown 
Familial hypoalpha-
lipoproteinemia 
decreased 
HDL; 
<30 mg/dL in 
males; 
< 35 mg/dL in 
females 
none Premature CAD 1% of general 
population 
25-30% of patients 
with premature CAD 
Dysbeta-
lipoproteinemia 
increased 
IDL;increased 
chylomicron 
remnants; 
TC: 250-500 
mg/dL 
TG:250-600 
mg/dL 
III Yellow palmar 
creases 
Palmar xanthomas 
Tuberoeruptive 
xanthomas 
Premature CAD 
Uncommon 
3% of MI survivors 
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 Type I is a deficiency in lipoprotein lipase activity resulting in the inability to 
convert chylomicrons into chylomicron remnants.  Since chylomicrons are TG rich, the 
disorder is marked by hypertriglyceridemia.  Cholesterol and the remaining lipoproteins 
are in the normal to low range.  Clinical signs of the disorder included eruptive 
xanthomas when TG levels reach 2000 to 4000 mg/dL and attacks of pancreatitis which 
present in childhood.18  The condition is genetic and is extremely rare.  The occurrence 
rate is about one in a million.18  Due to the lack of the other lipoproteins, especially LDL, 
Type I patients do not have high occurrences of CHD or atherosclerotic development.53   
 Type II is divided into two sub-classifications, Type IIa and IIb.  Type IIa can be 
heterozygous familial hypercholesterolemia, familial defective apolipoprotein B, familial 
combined hyperlipidemia, and polygenic hypercholesterolemia.53  Familial 
hypercholesterolemia (FH) is an important condition that was studied by Brown and 
Goldstein to examine LDL receptors in the body.54  Homozygotes have little to no LDL 
receptors, and heterozygotes have about half of the normal count. 54  This lack of 
receptors prevents the liver and cells from normal removal of LDL from serum, resulting 
in the high levels.18  IDL is also increased because its entry into the liver is also 
controlled by LDL receptors allowing for more IDL to be converted into LDL in the 
plasma.18  The dyslipidemia appears to result from increased production of VLDL.  
Homozygotes have an average of 680 mg/dL of cholesterol compared with the 
heterozygotes having 300 mg/dL.34  The condition can produce xanthomas, which are fat 
deposits that are usually found on knees, ankles, hands, and other joints.  Type IIa can be 
familial combined hyperlipidemia (FCHL) with increased levels of TC and LDL-C and 
normal to low concentrations of HDL.18  Type IIb has the additional elevated levels of 
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TG.  Type IV has elevated levels of TC and TG.18  The disorder is genetic occurring in 1 
out of 100 people but can be induced by diet and other disorders such as diabetes.18  
Familial defective apolipoprotein B is an inherited abnormality of apoB that interferes 
with the binding of LDL receptor which leads to premature development of coronary 
artery disease.53  Polygenic hypercholesterolemia expresses as an elevated LDL 
concentration that presents with no family history or physical characteristics like 
xanthomas.53 
 Dysbetalipoproteinemia Type III, is a genetic disorder characterized by a defect in 
apoE binding resulting in increases in TC, TG, and apoE concentrations.55-57  The 
chylomicrons and VLDL remnants are not efficiently removed resulting in the cholesterol 
rich lipoproteins that predisposes patients to premature development of artherosclerotic 
disease55-57.  Hormonal and environmental factors, diabetes, renal failure and other 
diseases can bring the onset of dysbetalipoteinemia.55-57  Physical signs of the conditions 
include tuboeruptive cutaneous and tendinous xanthomata and palmar crease 
xanthomas.55-57  Non-denaturing polyacrylamide gradient gel electrophoresis of the apo B 
containing particles, the apoB/TC ratio, and genetic confirmation are means to confirm a 
diagnosis.55, 56  
 Familial hypertriglyceridemia, Type IV, is defined by a moderate increase in TG, 
a slight increase in TC, and a slight to moderate decrease in HDL.18  The VLDL particles 
are larger in size in this condition resulting in the elevated TG levels and decreased lipase 
activity.53  This genetic condition occurs in 1% of the population.53  Familial combined 
hyperlipidemia can also present as a Fredrickson Type IV where the VLDL is elevated 
and apo-B production is increased.53   
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 Severe hypertriglyceridemia, Type V, is an increase in chylomicrons and VLDL 
which results in an elevated level of TG as well.  It is a combination of dietary fat, lipase 
activity, and other apoprotein variations.18  Rarely seen in children, it is presented in 
adulthood with the development of xanthomas, pancreatitis, and abnormal glucose 
tolerance with hyperinsulinism.18   Although genetically inherited, the exact genetic 
expression is not known. 18 
VI.  Fatty Acids 
 Fatty acids are biological molecules that serve as building blocks for cell 
membranes and as a source of energy. Their metabolites are also precursors for 
prostaglandins, thromboxanes, and leukotrienes.  Fatty acids are simple carbon chains 
with a carboxylic acid functional group at one end.  Fatty acids can exist as free fatty 
acids, non-esterified fatty acids (NEFA); or through esterification reactions the fatty acids 
can be synthesized into phospholipids such as phosphatidylcholine, triglycerides, and 
cholesteryl esters which can be formed into parts of the lipoprotein partials.  Serum lipids 
are found in lipoproteins, and the fatty acids in these lipoproteins not only reflect dietary 
intake, but also are closer to metabolic sites of cholesterol regulation.  Fatty acids are 
necessary for biological functions, but the human body cannot produce all of the fatty 
acids. Therefore, most must be acquired through diet.  Due to their involvement in a 
number of mechanisms and the fact that they must be in the human diet, fatty acids have 
become the focus of a number of studies attempting to determine their relationship to 
diseases from cardiovascular disease to mental illnesses. 
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A.  Fatty Acid Structure, Nomenclature, Dietary Sources, and Metabolism 
1. Fatty Acid Structure and Nomenclature 
 Fatty acids are classified based as either saturated or unsaturated.  Saturated fatty 
acids contain all single bonds between carbons in the chain.  Unsaturated fatty acids 
contain one or more double bonds.  Molecules with only one double bond are referred to 
as monounsaturated fatty acid (MUFA).  Those with more than one double bond are 
PUFA.  A shorthand notation of the basic structure is (A:B) where A is the number of 
carbons and B is the number of double bonds.  The omega classification of PUFA is the 
most common reference for these types of molecules and is based on the location of the 
last double bond from the end of the chain away from terminal methyl group. Omega-9 
(n-9), for example, is oleic acid (18:1).  Omega-6 (n-6) fatty acids include cis-9,12-
octadecadienoic acid, common name, linoleic acid (LA) (18:2); cis,cis,cis-6,9,12-
octadecatrienoic acid, common name, γ-linolenic acid (GLA) (18:3); cis,cis,cis,cis-
5,8,11,14-Eicosatetraenoic acid, common name, arachidonic acid (AA) (20:4); and 
conjugated linoleic acid (CLA) (18:2).  Conjugated linoleic acid exists as a number of 
different isomers of which cis-9, trans-11, trans-10, cis-12, trans-9, trans-11, and trans 10, 
trans-12-octadecadienoic acid are the major forms.  The active form of CLA is 
considered to be cis-9, trans-11.58  Omega-3 (n-3) fatty acids include cis,cis,cis-9,12,15-
octadecatrienoic acid, common name, α-linolenic acid (ALA) (18:3); all cis-5,8,11,14,17-
eicosapentaenoic acid (EPA) (20:5), and all cis-4,7,10,13,16,19-docosahexaenoic acid 
(DHA) (22:6).  All structures of these compounds are shown in Figure II-2.  The 
formation of trans fatty acids occurs during the industrial hydrogenation process of 
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vegetable oils.  The unsaturated fats formed have one or more double bonds that have the 
trans-configuration.   
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Figure II.2: Structures of MUFA and PUFA 
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2. Dietary Sources of Fatty Acids 
 Due to the importance of fatty acids in the formation and properties of cell 
membranes, they are essential for human and animal development.  Saturated fatty acids 
are primarily consumed in the diet from animal fat in the form of meat and dairy 
products.  Sources of high concentrations of saturated fats include butter, lard, milk, and 
milk products such and cream and cheese.59  Plant sources of saturated fat include 
cottonseed oil, palm oil, and coconut oil.59  Saturated fatty acids occur naturally in the 
animal and human body, and all forms do not need to be consumed.  The essential fatty 
acids are LA and ALA which can be metabolized to form additional acids.  MUFAs, such 
as oleic acid, are not considered essential since they are able to be derived through other 
precursors.60  The unsaturated fatty acids can be consumed in the form of plant oil, fish 
oil, and seafood.  MUFAs are highest in olive oil, avocados, and nuts such as peanuts and 
almonds.59  Omega-6 fatty acids are found in high concentrations in corn, safflower, and 
sunflower oils.59  CLA is primarily found in animal sources and processed animal 
products due to Δ9-desaturase production of CLA in lactating cows and the exogenous 
production of CLA by rumen bacterium Butyrivibrio fibrisolvens.58, 61  High amounts of 
CLA are found in lamb and various forms of beef.58  Poultry and seafoods are lower in 
CLA, but turkey is an exception with 2.5 ± 0.04 mg of CLA/g of fat.58 Processed cheeses 
and milk products such as buttermilk and condensed milk have amounts ranging from 2.9 
to 7.1 mg/g of fat.58  Plant oils, which are high in LA, have only a small concentration of 
CLA.  ALA, an omega-3 fatty acid, is found in flaxseed, soybean, walnut, and grapeseed 
oils.59  The additional omega-3 fatty acids, DHA and EPA, are found in marine animals 
such as salmon, tuna, flounder, and shellfish.62  Trans fatty acids, which form as a result 
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of the hydrogenation of vegetable oils, are primarily found in packaged snack goods, 
margarines, fast foods, and bakery products.  The average consumption of these fatty 
acids is 4 to 7 % of the total fat in a typical diet in industrialized countries.63 
 The consumption of these fatty acids in humans has changed in the last few 
decades.  Early human beings who consumed wild animals had an estimated 1:1 ratio of 
omega-6 to omega-3 fatty acids in their diet.1  The current Western diet is estimated to be 
between 10 to 20 omega-6 to 1 omega-3.1, 62  Since the mid to late twentieth century, 
there has been a shift from animal-based oils to vegetable-based oils in order to lower 
cholesterol.  The modern agricultural business has contributed to the increase in omega-6 
fatty acids by changing the feed of livestock.1  Although it increases production, the high 
omega-6 content in the grain fed to the animals decreases the omega-3 and lowers the 
overall PUFA composition when compared to wild animals of the same species.1  The 
omega-6 to omega-3 ratio in the diet is also different based on populations and locations.  
The rates in the United States and the United Kingdom and northern Europe are 
calculated to be 15.00:1 and 16.74:1, respectively.1  The ratio in Japan is currently 
4.00:1.1  In India, there exists a difference based on rural (5 to 6.1:1) and urban (38-50:1) 
populations.1  The concern is how this change has affected the health of Westernized 
humans.  To examine the effects, the metabolism of the fatty acids must be discussed. 
3. Metabolism of Fatty Acids 
 The essential fatty acids are the PUFA of linoleic acid and alpha-linolenic acid 
that serve as the beginning compounds in the metabolism of fatty acids. Linoleic acid, the 
starting compound for the omega-6 (n-6) series, is converted to GLA by Δ6 desaturase.60, 
64  GLA is expanded into dihomo-γ-linolenic acid through the elongase enzyme.  The 
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latter can be converted into a series of prostaglandins referred to as the 1 series or into 
AA via Δ5 desaturase.60, 64  AA can further metabolize through a series of enzymes of 
cyclo-oxygenase and lipoxygenase into the 2 series of prostaglandins of TXA2, PGE2, 
and PGI2 or 4 series leukotrienes of LTB4, LTC4, and LTE4.60, 64   
 The n-6 synthesis path is considered to promote platelet aggregation and is 
considered to lead to pro-inflammatory molecules.60, 64  The omega-3 (n-3) synthesis, 
however, leads to prostanoids and leukotrienes that are considered to be anti-
inflammatory.60, 64  Due to the negative effects, inhibitors for the omega-6 pathway have 
been developed, including the inhibition of phospholipase A, which is the enzyme that 
signals the release of AA.65  ALA, the n-3 synthesis series initial compound, is converted 
into EPA by Δ6 desaturase, chain elogation  and Δ5 desaturase.60, 64  DHA is formed from 
additional Δ6 desaturase enzyme.  EPA through a series of enzymes, cyclo-oxygenase and 
lipogenase, is converted in the n-3, anti-inflammatory eicosanoids of the 3 series 
prostanoids TXA3, PGE3, and PGI3 and 5 series leukotrienes LTB5, LTC5-LTE5.60, 64  The 
omega-6 and omega-3 metabolic series is detailed in Figure II-3.  It is important to note 
that humans lack the enzyme to convert LA into ALA.1  Each synthesis mechanism plays 
a role in the pathology of a number of conditions including cardiovascular disease which 
will be discussed in detail.   
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omega-6 omega-3
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C18:2 - Δ 9,12
linolenic acid
C18:3 - Δ 9,12,15
C18:3 - Δ 6,9,12 C18:4 - Δ 6, 9,12,15
C20:3 - Δ 8,11,14
arachidonic acid
C20:4 - Δ 5,8,11,14
C20:4 - Δ 8,11,14,17
EPA
C20:5 - Δ 5,8,11,14,17
Δ 6 desaturase
Δ 5 desaturase
DHA
C22:5 - Δ 4,7,10,13,16,19
chain elongations
and Δ 6 desaturase
chain elongation
cyclo-oxygenase
lipoxygenase
Omega-6 derived eicosanoids Omega-3 derived eicosanoids  
Figure II.3: Metabolic pathways for the essential fatty acids of linolenic acid and α-linolenic acid 64, 66 
 
 Due to the inability to convert LA into ALA, the omega-3 and omega-6 pathways 
compete for the same set of enzymes, elongase, Δ6 desaturase, and Δ5 desaturase, making 
the two pathways interact with each other for the same resources.  The generally accepted 
preference for the enzymes is omega-3, then omega-6, followed by omega-9.60  This 
order raises two important observations.  The first is that if cell walls have a high 
abundance of omega-9 in modern humans, then it is suggestive that there is a deficiency 
of the omega-3 and omega-6 compounds in the biological system since there should only 
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be small amounts of the omega-9 compounds based on this order.60  The rate limiting 
reaction is the conversion of ALA to EPA using Δ6 desaturase and the enzyme favors 
ALA over LA.67  Typically, however, in the modern diet there is a higher concentration 
of LA than ALA available.1, 67  With the increase in concentration, the conversion of LA 
with Δ6 desaturase becomes the favored reaction pathway resulting in an increase in the 
production of AA.67   
 A difference in gender affects the rate of conversion of ALA into EPA and DHA.  
In a comparison of males and females, the conversion of ALA into EPA and DHA is 
greater in women, possibly due to the presence of estrogen.67  The increased rate of 
conversion may be necessary especially in pregnant and lactating women to meet the 
needs of the developing fetus or child.67  The developing fetus during the final weeks of 
the last trimester requires 15-35 mg/week of DHA for brain development alone.68  The 
women’s conversion rate may be high to accommodate these needs.  In a recent study to 
test this hypothesis of gender difference, 36 subjects between the ages of 18 and 35 of 
mixed genders were used to determine the concentration of circulating omega-3 PUFA in 
plasma with no changes in their diets.69  The concentration of DHA in plasma 
phosphatidylcholine, triglycerides, and NEFA was higher in women which is in support 
of the hypothesis.69  In both genders, the location of adipose tissue deposits on the body 
can have an effect.  Upper-body adipose tissue deposits release free fatty acid into 
circulation faster than lower-body deposits and creates a high concentration of fatty acids 
available for processing.70  Women release free fatty acids faster than men but have an 
undetermined mechanism that prevents a higher concentration of free fatty acids or more 
oxidized fatty acids.70  Regardless of the gender differences, the overall efficiency rate 
 30
for human conversion of ALA into the longer chain fatty acids is lower than in other 
species.67  The conversions of ALA to EPA, EPA to the DHA precursor and the precursor 
to DHA are 0.2%, 0.13 % and 0.05% efficient, respectively.67  For this reason, in order to 
increase the amount of DHA and EPA, a dietary supplement of these fatty acids is usually 
used for metabolic and nutritional studies instead of a supplement of ALA.    
 A number of dietary and health factors affect the activity of both the Δ5 and Δ6 
desaturase enzymes.  Cholesterol, saturated fats, alcohol, and trans fatty acids are capable 
of decreasing the activity of these enzymes.60, 63  Protein deficiency, fasting, a glucose-
rich diet, and increasing age have been shown to lower the activity of Δ6 desaturase 
enzyme.60  In order to maintain normal activity, Δ6 desaturase needs to have the co-
factors of pyridoxine, zinc, and magnesium.60  Insulin, a reduced calorie diet, and a fat 
free diet can increase the Δ6 desaturase performance.60  In a study of mice, conjugated 
linoleic acid (CLA) was able to increase the activity and the messenger ribonucleic acid 
(mRNA) expression of Δ6 desaturase.71  In the mice that were fed a 1.5% diet of either 
CLA, LA, or a saturated fatty acid, palmitic acid, the mRNA expression of Δ6  and Δ5 
desaturase was higher in the mice fed the CLA diet than those receiving the other two.71  
Based on this result, the CLA may have a positive effect on the conversion of LA and 
ALA into the longer chain fatty acids. Health conditions, such as diabetes mellitus, 
hypertension, hyperlipidemia, and metabolic syndrome X, lower the activities of  Δ6  and 
Δ5 desaturase.60, 72 
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B. Relationship of Fatty Acids to Disease and Health Conditions 
1. Coronary Heart Disease 
 For over thirty years, the relationship of fatty acids in CHD, specifically the long 
chain PUFA, has been examined in a variety of studies ranging from animal to small 
nutritional to larger epidemiological studies.  The evidence from these studies offers 
support for the relationship, but some question its effectiveness in all populations and the 
extent of the benefits gained by altering the omega-3 or omega-6 fatty acids consumption 
in a diet.  
a. Epidemiological and Observational Studies 
 One of the first studies of dietary fatty acid intake and its effect on plasma lipids 
was based on an observation that Greenland Eskimos, who have a diet high in marine 
animals, had a very low occurrence of coronary atherosclerosis or CHD.  An initial study 
of this population showed that they had lower concentrations of cholesterol, triglycerides, 
and lipoproteins than a control population.73  Using gas chromatography, Dyerberg et al. 
showed that the esterified fatty acids in the Eskimo group had a lower percent total of 
linoleic acid and a higher percent total of EPA when compared to the control groups73  
Although the authors state that the difference in esterified fatty acid composition and the 
lower concentration of the serum lipids suggest a diet like the Greenland Eskimos may be 
linked to lower CHD risk factors, but it does not offer a definitive answer.73 
 Kromhout et al. completed a twenty year study of the men in a fishing town in the 
Netherlands.  Fish consumption, dietary, and health histories were collected in 1960, and 
then a follow-up of these 852 men was completed in 1980.74  The mortality rate from 
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CHD was more than 50% lower in the men who consumed at least 30 grams of fish per 
day, and an inverse relationship between fish dosage and 20-year mortality from CHD 
was determined.74  Ten years after this publication in 1985, a population control study 
was completed on patients who had one cardiac event; and a control group that contained 
primarily married men between the ages of 25 and 74 from the Seattle, Washington, 
area.75  Both the control and case study patients had blood specimens analyzed, and their 
spouses were asked to complete a questionnaire on their diets.75  One fatty fish meal per 
week was associated with a 50% reduction in the risk of having a primary cardiac event.75 
Using gas chromatographic analysis of the red blood cell membranes, they demonstrated 
an inverse relationship between the amount of n-3 PUFA and the risk of primary cardiac 
arrest.75   
 The U.S. Physicians’ Health Study is a large observational study involving 22,071 
US male physicians who were between the ages of 40 and 84 in 1982 with no incidences 
of myocardial infarction (MI), stroke, transient ischemic attack, or cancer.76, 77  The group 
was randomly assigned to receive aspirin, beta carotene, both drugs, or two placebos.  At 
the start of the study, each subject completed a questionnaire that assessed the factors for 
cardiovascular disease, diet, and exercise.76, 77  Follow-up questionnaires were completed 
twice during the first year and annually thereafter.76, 77  Analysis of the sudden cardiac 
deaths, which is death that results within one hour of the onset of symptoms, showed a 
decreased risk in subjects who had at least one serving of fish per week compared to the 
subjects who only consumed fish once a month.77  There was a reduction in overall 
mortality, but no decrease in risk for total MI, non-sudden cardiac death or total 
cardiovascular mortality.77  Baseline serum samples from the subjects who had 
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experienced sudden cardiac death were analyzed for serum levels of fatty acids using gas 
chromatography and then compared to control samples.76  The n-3 baseline concentration 
was inversely proportional to the risk of sudden death before and after other cardiac risks 
factors, and other fatty acid groups were adjusted in the model.76  By comparing the 
lowest quartile with the highest, there was an 81% lower risk of sudden death.76   
 In a similar study design like the U.S. Physicians’ Health Study, the Health 
Professionals’ Follow-Up Study is a cohort study with 45,722 male US health 
professionals who had no incidences of cardiovascular disease at the baseline in 1986.78  
The dietary intake of n-6 and n-3 PUFA was determined by questionnaires completed by 
the subjects at intervals over a 14 year period.78  The risk of sudden death was lowered 
with a higher intake of EPA and DHA (≥ 250 mg/day) and was independent of the n-6 
consumption.78  EPA and DHA consumption did not have an association with the risk of 
nonfatal MI or total CHD.78  Higher ALA intake was inversely associated with risk of 
nonfatal MI, regardless of high or low n-6 consumption; but, ALA and n-6 did not show 
any association with sudden death.78  Men with less than 100 mg/d of EPA and DHA had 
an interesting outcome. With each 1 g/d of ALA, there was a lowering of the risk of 
nonfatal MI and total CHD (58%, MI and 47% CHD).78 
 Most of the studies discussed above relied on the dietary intake for analysis of the 
relationship of the omega-3 fatty acids and CHD.  Nonesterified fatty acids (NEFA) or 
free fatty (FFA) acids are a possible risk marker that can be directly measured in the 
serum and is free of biases from the subject.  In the Paris Prospective Study, a high 
fasting NEFA was an independent risk factor for sudden cardiac death, but not for MI or 
overall cardiovascular mortality.79, 80  In the same study, the concentration of NEFA was 
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predictive of cancer mortality and was stronger in smoking and/or alcohol-related 
tumors.79  In contrast to the Paris study, the Ludwigshafen Risk and Cardiovascular 
Health Study concluded that the NEFA levels predicted all-cause and cardiovascular 
mortality in the subjects who had a coronary angiography at the start of the study.81  
These results were independent of other cardio risk factors including BMI, HDL-C, LDL-
C and triglyercides.81  These two studies involved less than 5,000 subjects, and the use of 
such small population samples limits these results.  Additional studies need to be 
completed to determine if NEFA can be considered for inclusion as a cardio risk factor. 
 Not all studies have been able to determine an inverse relationship between 
cardiac events and the intake of n-3 fatty acids.  The Health Professionals’ Follow-up 
Study showed no statistically significant relationship between the fish consumption and 
the risk of sudden death, nonfatal MI, and other CHD related events.82  The EURAMIC 
(EURopean multicenter case-control study on Antioxidants, Myocardial Infarction, and 
breast Cancer) study involves subjects from eight European countries and Israel.  Patients 
with their first MI (n=639) and controls (n=700) had subcutaneous adipose tissue samples 
collected and the fatty acid content was analyzed using gas chromatography.83  An 
inverse relationship between ALA percentage in the adipose tissue and the risk of an MI 
was evident, but the protective effect of DHA was not demonstrated.83  In the Seven 
Countries’ Study, an initial positive relationship was seen between fish consumption and 
25-year mortality from CHD;  but after adjusting for confounding effects of saturated 
fatty acids, antioxidants such as flavonoids, and smoking, the relationship was no longer 
statistically significant.84   
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 As mentioned in the metabolism of the fatty acids, women are able to convert 
ALA into EPA and DHA to yield higher concentrations than men.  Up to this point, the 
epidemiological studies have focused on the male sex.  The Nurses’ Health Study began 
in 1976 with 121,700 women between the ages of 30 and 55 who were nurses in 11 US 
states.85  Dietary information from 84,688 of these subjects who did not have 
cardiovascular disease or cancer was collected through questionnaires in 1980, 1984, 
1986, 1990, and 1994.85  After adjustments for cofactors including age and smoking, the 
omega-3 fish consumption was inversely proportional to the risk of CHD death and to a 
lesser extent CHD and nonfatal MI.85  In the same study, trans fatty acids were analyzed 
for their risk of CHD.  Mozaffarin et al. conducted a review of healthy women involved 
in the Nurses’ Health Study I and II.  Based on dietary intake of trans fatty acids and 
markers for systemic inflammation, there was a positive relationship between CLA and 
the inflammation biomarkers.63  A consumption related trend of lowering incidences of 
CHD with higher numbers of fish servings per week was shown in a review of the 
subjects in the Nurses’ Health Study who were diagnosed with type 2 diabetes with no 
history of CHD at the start of the study.86  In the twenty-year follow-up, the inverse 
relationship of lowering risk of CHD with PUFA and a positive relationship of trans fat 
with CHD was held with all cofactors’ adjustments made.  Oh et al. showed that younger 
women and women who are overweight (body mass index (BMI) > 25 kg/m2) had the 
most evident inverse relationship between fish consumption and risk of CHD.86  ALA 
dietary intake was linked to a reduced risk of sudden cardiac death, but not to nonfatal MI 
or other CHD cardiac events in the Nurses’ Health Study.87  When comparing the lowest 
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quintile of ALA consumption and the highest two, those in the highest had a 38 to 40 % 
reduction in risk of sudden cardiac death.87 
 Differences in the epidemiological studies may be due to variations in definitions 
of the cardiac end points such as sudden death, differences in the populations studied, and 
the difficulty of having subjects estimate their servings of fish.  Case-control studies have 
limitations including vulnerability to biases based on the subjects’ recall of his or her diet 
and in the selection process of focusing on one disease.  Cohort studies reduce this 
vulnerability, but they are limited in the classifications set at the baseline of the study, 
changes to diet in between follow-ups not being collected, and the loss of subjects during 
the extended study can limit the validity of the results of these studies.   
b. Diet Intervention Studies 
 Diet and Reinfarction Trial (DART) was the first controlled dietary intervention 
study able to link omega-3 fatty acid and a positive response in the secondary prevention 
of myocardial infarction (MI).  The study focused on 2033 men who had recovered from 
a MI.88  The men were randomly selected into groups in which one group was asked to 
increase their intake of fatty fish to at least two servings per week or were given a fish oil 
supplement if they could not eat fish.88  After a two year follow-up, the men advised to 
eat fish had a 29% (P<0.05) decrease in all-cause mortality, but no reduction in a second 
MI was seen.88  Also, subjects who consumed about 4 grams of fish per day lowered 
serum TG by 25 to 30% .88  Supporting evidence for this initial study was found in the 
Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico Prevenzione 
(GISSI- Prevenzione) study which was a randomized trial of 11,324 patients who had 
suffered a MI within three months.89  The groups consisting of 85% males were placed on 
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supplements of n-3 PUFA with 850 -882 mg of EPA and DHA daily, 300 mg/day of 
vitamin E (α-tocopherol), both types, or a placebo for 3.5 years.89  The relative all-
mortality risk decreased by 15% (P=0.023), and  a 45% (P=0.01) decrease in sudden 
cardiac death was seen.89   
 In support of the previous studies, a randomized study of the treatment for the 
prevention of a second MI was completed on an Asian male population in the Indian 
Experiment of Infarct Survival.  In an 18 hour period after an apparent MI, the patients 
were randomized into a fish oil (EPA, 1.08 g/day), mustard oil (ALA, 2.9 g/day), or 
placebo group.90  After a one-year follow-up, the fish oil group had significant reductions 
in complications after a MI and in total cardiac deaths when compared to the placebo.90  
The mustard oil group did not have a reduction in total cardiac deaths; however, it did 
show a reduction in complications seen after a MI such as cardiac arrhythmias and 
ventricular enlargements.90  Although this study is small in number, it suggests that a 
secondary prevention effort using fish oil or mustard oil should be started early after the 
initial symptoms of an MI.  Using the idea that initial treatment for secondary prevention 
must be started early, a Norwegian study examined the effect of a daily four gram dose of 
n-3 or corn oil.91  Each n-3 capsule contained 850-892 mg of EPA and DHA.91  The 
comparison between the groups yielded no benefit of the one type of oil over the other in 
the prevention of another cardiac event which included sudden cardiac death, second MI, 
or unstable angina for a one to two year period.91  This study may show that a population 
which already has a diet high in n-3 fatty acids may not benefit from an increase in these 
fatty acids after a cardiac episode.  Also, the comparison of n-3 fatty acids and the corn 
oil, which is rich in n-6 and n-9 fatty acids, may not be a controlled study.  A control with 
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an actual no oil placebo would have been a comparison similar to that seen in previous 
studies.  The study did, however, see an increase in HDL cholesterol and a lowering of 
TG concentrations which show that n-3 fatty acids may have a positive effect on these 
cardio risk factors.91  The Norwegian study is not the only one to not see a positive effect.  
A trial of 3,114 men with angina under the age of 70 was divided into random groups and 
provided with dietary advice to eat two servings of oily fish per week or to take 3g of oil 
as a substitute, eat four to five portions of fruits and vegetables per day, eat a combination 
of both, or advised to eat sensibly.92  The all-cause mortality reduction seen in other 
studies was not demonstrated here. The fruit and vegetable group had poor compliance 
but saw results.92  The men advised to eat fish saw no improvement and; in fact, the 
members of the group that took fish oil capsules had a higher risk of cardiac death 
(11.5% v 9%, P=0.2).92  The authors state that the lack of evidence to match other studies 
may be a reflection of the lack of compliance by the subjects or the adjustments for other 
risk factors being inappropriate.92   
 The measurement of serum lipids and statistics on the cardiac events after n-3 
fatty acids supplementation are not the only measures of the effects of these fatty acids on 
CHD.  A coronary angiogram is a specialized X-ray that uses an injected dye to view the 
blood vessels of the heart.  A trial of 223 patients who were clinically proven to have 
coronary artery disease were randomized into a control group that received a fatty acid 
tablet with a ratio similar to the European diet and a group that received a capsule with 
fish oil that was approximately 55% EPA and DHA.93  Besides the lowering of cardiac 
events, the patients on the fish oil supplement saw more regression of the coronary artery 
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disease on the angiogram than the placebo group.93  The authors also noted an increase 
compared to the controls in the LDL cholesterol concentration.93 
c. Omega-6 Fatty Acids 
 Omega-3 fatty acids have been the focus of the majority of studies completed on 
the role of fatty acids in CHD, but omega-6 fatty acids have been the center of attention 
in a few studies. Omega-6 fatty acids are essential; but like fat-soluble vitamins, a level 
must be maintained that is both biologically necessary and beneficial. The inhabitants of 
Israel can be considered a test population for the effects of omega-6 fatty acids.  The 
general Israeli diet is higher in LA than the diets in the United States and Europe.94  Israel 
has seen an increase in the cases of cardiovascular disease, hypertension, non-insulin 
dependent diabetes mellitus (NIDDM), and obesity.94  All of these diseases are linked to 
hyperinsulinemia and insulin resistance which can be induced by LA.94  The paradox of 
omega-6 fatty acids is that they have been shown to reduce the total cholesterol 
concentration and high-density lipoprotein cholesterol (HDL-C) which reduces the risk of 
CHD mortality; but at the same time, the measurement of the LDL oxidation 
susceptibility and risk of acute MI is increased, as seen in the Jerusalem Nutrition 
Study.94, 95  The hypothesis for omega-6 actions is that LA and the hydroperoxides of LA 
may reduce the activity of prostacyclins in the vascular wall and aid in platelet 
aggregation.94, 95   
 The adipose tissue and platelet concentration of fatty acids was determined by gas 
chromatography in 226 patients who were having a coronary angiogram due to coronary 
artery disease (CAD) or valvular heart disease.96  The linoleic acid percentage of the total 
fat in each type of sample was positively associated with myocardial score, which is the 
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measure of the location and severity of the coronary lesions on a scale of 0 (best) to 15 
(worst), in men.96  Platelet EPA in men and platelet DHA in women was inversely 
associated with the myocardial score.96  Recently, Laaksonen et al. completed a 15 year 
cohort study on 1551 middle-aged men which included an examination of their dietary 
intake and the measurement of the serum fatty acid concentration by gas 
chromatography.14  When the upper third was compared to the lower third of dietary 
consumption of LA and ALA, both lowered the risk of mortality by cardiovascular 
disease to 61 % less likely for LA and 30 to 42% less likely for ALA.14  The total serum 
concentration of the esterified PUFA was more strongly associated to the risk of CVD 
mortality than the measurement of the dietary PUFA intake, and no association of total 
fat intake was seen with CVD mortality.14  No association was also found between serum 
omega-3 fatty acid concentrations and CVD mortality.14  In a New Zealand 1997 
National Nutritional Study, the serum cholesteryl and fatty acid concentrations in 
cholesteryl esters, phospholipids, and triglycerides were determined.97  The myristic acid 
in all three lipid measurements was positively associated with total serum cholesterol, 
and the cholesteryl ester form of myristic acid was a stronger predictor of total 
cholesterol than TG or phospholipids.97  LA inversely correlated with the total serum 
cholesterol.97  This is one test that supports the use of fatty acids as a predictor of serum 
cholesterol; and since cholesterol is one of the primary risk factors of CHD, fatty acids 
may be an important predictor to include.  The role of CLA in CHD is not clear.  It has 
been determined that the role of CLA is isomer dependent and cis-9, trans-11 and trans-
10,cis-12 have different effects on lipids, but the complete effect on human health is not 
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clear.98  Testing on isolated isomers needs to be completed in order to determine the 
health advantages or disadvantages.  
d. Systematic Reviews 
 Since a large number of studies have been completed on omega-3 fatty acids, 
meta-analysis or systematic reviews of the trials have been published.  Harris et al.’s 
(1997) analysis reached the following conclusion on omega-3 consumption: total 
cholesterol is not affected, LDL-C and HDL-C rises slightly (5-10%, 1-3%, respectively), 
and TG is reduced by 25 to 30 %.99  ALA did not have the same effect.99  In a systematic 
review, the higher risk reduction in CHD mortality is seen in high-risk subjects who 
consume 40-60 g of fish daily.100  Little to no risk improvement is seen in already low-
risk subjects.100  Buther et al. completed a meta-analysis of 11 trials completed between 
1966 and 1999 and determined that both dietary and supplemental intake of omega-3 
fatty acids reduces total CHD mortality, mortality due to MI, and sudden death in patients 
with CHD.101  The two most recent systematic reviews of omega-3 studies offer 
conflicting results.  Hooper et al. examined 48 randomized controlled trials and 41 cohort 
studies that measured effects of omega-3 for 6 months or longer.15  No effect of omega-3 
fatty acids on total mortality, cardiovascular events, or cancer was statistically 
significant.15  There was also no separation of studies that looked at primary vs. 
secondary MI events.  Wang el al. examined both primary and secondary studies 
separately in their meta-analysis.   Fourteen randomized control trials examining 
secondary prevention yielded a strong reduction in all-cause mortality, MI, and cardiac 
and sudden death.102  Although weaker, a similar relationship was found in the 25 
primary prevention studies and no relationship of ALA to CHD endpoints was seen.102  A 
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number of issues plagued these studies including dose variations, differences in the types 
of fish or supplements consumed, variations in the inclusion criteria, and limited data on 
ALA and women.   
e. Fatty Acids and Simvastatin 
 Simvastatin, the major form of treatment for hyperlipidemia, can have an effect 
on the fatty acid metabolism and alter the serum fatty acid composition in subjects.  
Simvastatins inhibit the 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) 
reductase, a key enzyme in cholesterol synthesis, which makes it available to act in the 
fatty acid metabolic synthesis through malonyl-CoA or oxidation in the Krebs cycle by 
acetyl-CoA.103  As a result, a number of studies have begun to examine how simvastatin 
alters the fatty acid composition and how a combination therapy of statins with omega-3 
may benefit CHD patients.  Two separate studies on hypercholesterolemic patients 
examined fatty acid composition of serum by gas chromatography from patients who 
were on a 30 to 40 mg/d dose of statins and were monitored at 12 to 24 weeks after the 
initial dose.  In both cases, the total sum of the PUFA was decreased by 13 and 22%.16, 103 
In the first study, the relative percentages, but not the concentrations of LA and ALA 
decreased and AA and DHA increased.16  The second study demonstrated a similar 
decrease in LA and ALA and an increase in AA, but the study also showed an increase in 
GLA.103  The sum of EPA, DHA, and AA had a significant increase.103  Based on the 
metabolic pathway, these results suggest that the statins increase the activity of the Δ5 and 
Δ6 desaturases which leads to the production of more AA, EPA, and DHA.  Further 
studies have to be completed to demonstrate if this hypothesis is valid.  In an examination 
of free fatty acid metabolism changes with high-dose simvastatin in type 2 diabetics, 
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plasma palmitate, a saturated fatty acid, had not changed when compared to the normal 
controls.104   No other free fatty acids were monitored.  In a study of the combination of 
atorvastatin with omega-3 supplements, the subjects with the combined treatment had an 
increase in the HDL-C concentration and a decrease in systolic blood pressure when 
compared to the controls and subjects with only statin.105  Omacor, a concentrated 
omega-3 capsule that contains 44% EPA and 36% DHA, was given to patients with 
hypertriglyceridemia who were not being controlled by simvastatins.  The serum TG 
decreased by 20-30% and VLDL-C by 30-40% with no effective change in the LDL-C or 
HDL-C concentrations.106  The unchanged HDL-C serum concentrations may be due to 
the fish oil causing a decrease in the production and fractional catabolic rate of HDL apo 
A-1 and HDL apo A-II resulting in no significant change.107  Atorvastatin did not have an 
influence on either rate.107 
f. Mechanism of Action 
 The mechanisms of action, particularly the protective effects of the omega-3 fatty 
acids, are not clear.  Fatty acids incorporate into lipoproteins and cell membranes, where 
they affect membrane characteristics,  alter eicosanoid production, increase  the 
relaxation of the blood vessels, and induce dose dependent reductions in platelet 
aggregation, leukocyte activation, and plasma triglycerides, all of which might reduce the 
risk of coronary heart diease.83  The first mechanism and the one that influences other 
diseases besides CHD, is the anti-inflammatory effect.   The omega-6 fatty acids are 
known to produce eicosanoids that increase platelet aggregation and are pro-
inflammatory.60  With an increase in the omega-3 fatty acids, and given the fact that the 
common enzymes are preferential to them, the shift of the metabolism would be to the 
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omega-3 fatty acids which produce anti-inflammatory eicosanoids.60  A second 
mechanism is the inhibition of endothelial activation, which is the process of increasing 
the endothelial expression of leukocyte adhesion molecules in atherogenesis.108  The 
greater number of double bonds in n-3 fatty acids showed a greater inhibition of key 
factors in endothelial activation.108   The omega-3 function may include a reduction in 
adhesion molecule expression and platelet-derived growth factor.109  As seen in the 
DART trial, the third mechanism of lowering the CVD risk is by the lowering of the TG 
serum levels.88  Doses of 3 to 5 grams have been used in the treatment of 
hypertriglyceridemia.64  The exact mechanism of this function is unknown, but according 
to Chan et al., fish oil supplements lowered plasma TG concentrations by decreasing the 
VLDL apo-B production.107  The other potential mechanism reduces susceptibility of 
ventricular arrhythmia, is antithrombogenic and slightly hypotensive, and promotes nitric 
oxide-induced endothelial relaxation.60, 109   
g. Dosage and Adverse Effects 
 The American Heart Association (AHA) recommendation for the consumption of 
omega-3 fatty acids for the prevention of CHD is dependent on a person’s risk for CHD.  
AHA recommends that adults eat a least two servings of fish per week and/or ALA 
consumption through plant sources like walnuts, flaxseeds, and soybeans if no history of 
CHD exists.109  Patients with CHD are recommended to intake at least 1 gram of EPA 
and DHA per day either by fish or omega-3 fatty acid capsules.109  A higher dose of 2 to 
4 grams of EPA and DHA is recommended for patients who have 
hypertriglyceridemia.109  Most of the adverse affects of omega-3 fatty acids are dose 
dependent.  Omega-3 fatty acids can be an anticoagulant and affect bleeding time, so high 
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doses of fatty acids should be monitored by a physician.62, 109  As stated in the omega-3 
trials, an increase in LDL-C can occur.  Additional side effects can include fishy 
aftertaste and gastrointestinal problems.62  With oily fish consumption, one must be 
concerned with toxins in the fish.  Methylmercury, polychlorinated biphenyls, and 
dioxins can be found in fish such as shark, swordfish, king mackerel, and other large, 
predatory fish.62, 109  Some of these toxins may aggravate CHD and are not recommended 
for women who are pregnant or lactating and young children due to possible effects on 
development.62, 109  There are a number of options for other fish that have lower 
concentrations of these toxins but still have high concentrations of EPA and DHA that 
can be consumed to limit exposure. 
2. Diabetes and Metabolic Syndrome  
 Metabolic syndrome is a collection of related conditions that were determined to 
be from metabolic changes that can lead to the development of atherosclerotic 
cardiovascular disease and diabetes.  The idea of metabolic syndrome has been in the 
literature for years, but in the late nineties, a push to define the condition was started.  
Organizations such as the World Health Organization (WHO), European Group for the 
Study of Insulin Resistance, and the NCEP:ATP III all produced definitions of metabolic 
syndrome.  The syndrome definition according to the ATP III, for example, is that a 
patient who has metabolic syndrome will have three of the following:  waist 
circumference greater than 102 cm in men and 88 cm in women, serum triglycerides 
greater than or equal to 1.7 mmol/L, blood pressure greater than or equal to 130/85 
mmHg, HDL cholesterol less than 1.0 mmol/L in men and 1.3 mmol/L in women, and a 
serum glucose greater than or equal to 5.6 to 6.1. 2-4  All of the definitions agree on the 
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basic components, glucose intolerance, obesity, hypertension, and dyslipidemia, but not 
on the minimum criteria.2-4   In late 2005, two scientific statements from joint groups 
related to metabolic syndrome appeared from the American Diabetes Association (ADA) 
and the European Association for the Study of Diabetes (EASD) and the American Heart 
Association (AHA) and National Heart, Lung, and Blood Institute (NHLBI).2, 4  The 
claims made in the ADA/EASD statement focus on the lack of the syndrome existing 
purely and not having dual patients who are both diabetic and have metabolic syndrome.4  
Kahn et al. stated that the development of the syndrome is unclear, expressed doubt 
regarding its use as a marker for CVD risk, and questioned how the syndrome was any 
different than the individual factors that define it.4  The AHA/NHLBI statement 
supported the premise that the syndrome exists and set recommendation guidelines for 
the treatment of the condition.3  Despite the conflict over the criteria and the existence of 
the syndrome, the ending conclusion for both statements is that more research needs to be 
conducted.  In the AHA/NHLBI statement, it lists measures that are associated with the 
syndrome that need to be studied in greater detail; and free fatty acids are included due to 
their link to insulin resistance.2  
 Insulin resistance is one prevailing pathological path for the development of 
metabolic syndrome and dyslipidemias.2-8  An increase in the concentration of fatty acids 
in serum is a major contributor to the development of insulin resistance.  Fatty acids in 
serum can be from adipose tissue triglycerides or the product from lipoprotein lipase of 
lipoproteins rich in triglycerides.3  Insulin plays a role in both processes.  Once the excess 
fatty acid reaches insulin sensitive tissues such as muscles, they inhibit the glucose intake 
by inhibiting the insulin mediated pathway.3  In the liver, increased free fatty acids 
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increased the concentrations of glucose, triglycerides, very low density lipoproteins, and 
low density lipoproteins and decreased the release of high density lipoproteins.3  All of 
these markers are current measures for the definition of metabolic syndrome, except for 
the causes of these changes which are the concentrations of the free fatty acids.  It is 
interesting to note here that the waist circumference guideline in the defining criteria of 
metabolic syndrome is the accumulation of visceral fat.  As related to the development of 
insulin resistance, the larger amount of adipose tissue available allows for a great source 
of triglycerides that can be released as free fatty acids.  Garaulet et al. found that central 
obesity was positively related to the omega-6 PUFA and inversely related to both mono 
unsaturated fatty acids and polyunsaturated fatty acids.110   
 Recent studies have begun to look at the effects of a particular set of fatty acids, 
polyunsaturated fatty acids, and their possible ability to prevent the onset of insulin 
resistance; and, therefore, the prevention of metabolic syndrome and the other conditions 
that may develop.  Omega-3 fatty acids, particularly fish oil, and to a lesser extent 
omega-6 fatty acids have been linked to the prevention and the mediation of insulin 
resistance.5-8  Vessby et al. combined the results of a number of studies that examined the 
serum lipid fatty acid concentration of patients with conditions related to insulin 
resistance such as diabetes, obesity, and coronary heart disease.8  Vessby et al. 
determined that when compared to controls, the disorders showed a decrease in linoleic 
acid and an increase in dihomo-gamma linolenic acid.8  They also indicated an increase 
in Δ9 and Δ6 desaturases and a decrease in Δ5 desaturases activities which can be 
monitored through the use of long chain polyunsaturated fatty acid (LCPUFA) 
concentrations.8  More studies have associated the dietary intake of fish oil which is 
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primarily composed of omega-3 fatty acids with the prevention of the symptoms of 
insulin resistance.  EPA and DHA, omega-3 fatty acids found in fish oil, have been used 
in dietary studies and have lowered triglyceride and VLDL levels in serum which are 
related to both insulin resistance and coronary heart disease risk factors.5-7  One 
interesting study completed by Stene and Joner that focused on fish oil intake 
demonstrated that it lowered the risk of the development of type I diabetes mellitus 
through the consumption of cod liver oil during the first year of life.5, 9  There are also 
studies that fish oil can delay the onset of diabetes through slowing the progression of the 
disease through its anti-inflammatory, antithrombotic, and antiarrhythmic properties.   
3. Other Diseases 
 Fatty acids have a number of functions in biological systems that make them 
essential including controlling membrane characteristics by their structure, the production 
of eicosanoids, and other functions previously discussed.  Their nature leads them to 
involvement not only in CHD, but also in other diseases related to inflammation.  The 
mechanisms of breast, prostate, and other cancers in in vitro studies have been altered 
favorably, but epidemiological evidence has not come to the same conclusion in all 
cases.111  In a review by Terry et al., five of the twelve epidemiologic studies of breast 
cancer risk showed a significant inverse association with fish or marine fatty acids.111   
Prostate cancer research showed that 5 out of 11 studies in which the n-6 diet was higher 
and the n-3 intake was lower, found that marine fatty acid reduced the risk of prostate 
cancer.111  The possible mechanism of n-3 anticarcinogenic function include the 
prevention of AA converting to its eicosanoids which are known to be pro-inflammatory, 
changed cell growth and metabolism by influencing gene expression and signal 
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transduction, increasing or decreasing free radicals, and altering the metabolism of 
estrogen.112, 113  Rheumatoid arthritis, a disease related to inflammation, may be improved 
through an increase in omega-3 fatty acids in the diet.65, 114  The dietary intervention trials 
of omega-3 fatty acids have shown a reduction in the symptoms of rheumatoid arthritis in 
patients and, in some cases, the subjects are able to stop the use of non-steroidal anti-
inflammatory drugs (NSAIDs).115-117  The omega-3 fatty acid mechanism in this case is to 
inhibit the production of prostaglandin E2, which is a product of the cyclo-oxygenase 
(COX) enzyme that promotes inflammation and is also inhibited by NSAIDs.115-117   
 The effects of the omega-6 increase in the modern diet have also been suggested 
for the rise in mood disorders including depression, bipolar disorder, and postpartum 
depression.118  In a review by Parker et al., the increased consumption of fish was 
associated with a lower incidence of these types of mood disorders in a majority of the 
studies reported.118  The use of EPA and DHA for the treatment of major depressive 
disorder, bipolar disorder, and borderline personality disorder has been completed in 
eight studies where five showed an improvement in the scoring of the condition or, if on 
a mood stabilizing drug, a decrease in the side effects of the medication.118  EPA has also 
been linked to a decrease in the occurrence of osteoporosis in post-menopausal women 
by the suppression of osteoclast, which induces bone resorption,  and by the inhibition of 
its precursor’s cytokine formation.119  
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CHAPTER III  
 
 
Review of Cholesterol and Fatty Acid Quantification Methods 
 
I. Measurement of Cholesterol, Triglycerides, and Lipoproteins 
 A multitude of measurement methods have been used to determine the 
concentrations of cholesterol, triglycerides, and lipoprotein subfractions since each was 
linked to disease, especially CHD.  The CDC has established both the reference method 
and simpler, routine methods for each of these measurements.  The CDC, the NCEP, and 
other organizations have established these methods in clinical laboratories and have set 
guidelines to ensure standardization and reliable measurements at each individual lab.120-
122   
A. Cholesterol 
 A method developed by Abell et al.123 has become the basis for the CDC 
reference method for cholesterol.18  Procedurally, a 0.5 mL sample of serum is treated 
with 5.0 mL of alcoholic KOH which hydrolyzes the cholesteryl esters.18  After the 
cholesterol is extracted with 10 mL of hexane, a portion of the cholesterol solution is 
dried and exposed to the Liebermann-Burchard124, 125 reagent.  The L-B reagent was first 
published by Liebermann and then applied to cholesterol by Burchard.  The current 
version of the reagent is acetic acid, sulfuric acid, and acetic anhydride.  The reagent 
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reacts with cholesterol and the absorbance of the product is read at 620 nm.18  The 
proposed mechanism by Burke et al. starts with the protonation of the –OH group and a 
loss of water followed by successive protonation resulting in an exceedingly conjugated 
product which is pictured in Figure III.1.   
SO2OH
+ SO2
Proposed Product of Liebermann-Burchard
Proposed Product of Zak
HO
cholesterol
 
Figure III.1:  Proposed products of the Liebermann-Burchard  and Zak reagents by Burke 
et al. 126 
    
Under strict protocol and the use of pure cholesterol as a standard for calibration, the bias 
when compared to isotope dilution mass spectrometry is 1.6%.18  Isotope dilution mass 
spectrometry is the standard method of detection utilized by the National Institute of 
Standards and Technology.18  Cholesterol concentration is expressed as either mg/dL or 
mmol/L.   
 Additional color reactions similar to the L-B reaction have been developed and 
analyzed for their ability to determine the cholesterol concentration in serum samples. 
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Webster completed a review and comparison of three of these colorimetric reactions that 
work satisfactorily with cholesteryl esters. The Sperry-Webb reagent has a composition 
that includes glacial acetic acid, acetic anhydride, and sulfuric acid while the Trider color 
reagent utilizes dichloroethane, acetyl chloride, and sulfuric acid.19  The Zak reaction is 
much similar to the L-B reagent system with Fe3+ replacing the acetic anhydride in the 
acetic acid and sulfuric acid system which produces a colored product.127  The Zak 
reagent system was determined to be the best reagent due to its greater sensitivity and 
stability.128  Another color reagent adopted by Chugaev and Gastev used a  2:1 mixture of 
20% w/v ZnCl2 in glacial acetic acid combined with 98% acetyl chloride.129  The 
Chugaev and Gastev reagent was used to measure cholesterol with great accuracy by 
researchers Hanel and Dam.130 
 The enzymatic method is the primary clinical routine method for the measurement 
of cholesterol.  The reagent system is commercially available in standard manual kits and 
offers specialized automated instruments that can handle the method.  The general 
procedure is to mix the reagent with 3-10 μL of serum or plasma, incubate for a period of 
time, and then measure the absorbance.18  The general series of reactions are as follows:18 
 Cholesteryl ester + H2O ⎯⎯⎯⎯⎯⎯ →⎯ hydrolaseesterlcholestero  cholesterol + fatty acid     (3.1) 
 Cholesterol + O2 ⎯⎯⎯⎯⎯ →⎯ oxidasaelcholestero  cholest-4-en-3-one + H2O2        (3.2) 
 H2O2 + phenol + 4-aminoantipyrin ⎯⎯⎯ →⎯Peroxidase  quinoneimine dye + 2 H2O   (3.3) 
Interferences that may include high concentrations of bilirubin, ascorbic acid, compounds 
consuming H2O2,   and plant sterols, can occur when the method is utilized because the 
reaction is not selective to only cholesterol.18  The reaction is not affected though by 
hemolysis, uric acid, or bilirubin in concentrations below 5mg/dL. 18   With proper 
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calibration and laboratory controls, the accuracy is between 1 and 3% with a coefficient 
of variation of 1.5 to 2.5%.18  Additional methods such as thin layer chromatography, gas 
chromatography, mass spectrometry, and near infrared reflectance spectrometry have 
been developed, but only the standard reference colorimetric method and the routine 
enzymatic method are used by clinical laboratories.18 
B. Triglycerides 
 The reference method for triglycerides first involved the extraction of the 
compounds from serum or plasma.  Preprocessing includes a chloroform extraction that 
removes the water-soluble compounds of glucose and glycerol that interfere with the test 
and an application of silicic acid to remove the phospholipids.18  The isolated 
triglycerides undergo alkaline hydrolysis with KOH to produce unesterified fatty acids 
and glycerol.18  The free glycerol is oxidized to form formaldehyde that can react with 
chromotropic acid to produce a colored product that is measured at 570 nm.  The 
summary of the reaction is the following.18   
  triglycerides + KOH     fatty acids + glycerol  (3.4) 
  glycerol + periodate    formic acid + formaldehyde  (3.5) 
  formaldehyde + chromotropic acid   chromogen  (3.6) 
Like cholesterol, the measurement is expressed as mg/dL or mmol/L.    
 The enzymatic method for the routine analysis of triglycerides does not involve an 
extraction step.  Like cholesterol’s enzymatic method, the reagent kits and automated 
instruments are widely available for clinical use.  Although multiple options exist for TG 
determination by enzymes, the first step is to separate the fatty acids from the glycerol 
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backbone using lipase to catalyze the reaction.18  The following is the common reaction 
path.18 
 Triglycerides + 3 H2O ⎯⎯ →⎯Lipase  glycerol + 3 fatty acids    (3.7)  
 glycerol + ATP ⎯⎯⎯ →⎯ aseGlycerokin  glycerophosphate + ADP    (3.8)  
 Glycerophosphate + O2 ⎯⎯⎯⎯⎯⎯ →⎯ oxidasesphateGlyceropho  dihydroacetone + H2O2 (3.9) 
 H2O2 + phenol + 4-aminoantipyrin ⎯⎯⎯ →⎯Peoxidase quinoneimine dye + 2 H2O  (3.10) 
Additional options include spectrophotometric measurement of the NADH produced in a 
reaction of glycerophosphate with nicotinamide adenine dinucleotide (NAD) or 
measurement of the production of adenosine diphosphate (ADP) in Equation 3.8 by 
measuring the resulting loss of NADH.  Enzymatic TG methods are linear to 700 mg/dL 
and have a coefficient of variation between 2 and 3 % in automated systems.18  
Correction for endogenous glycerol is needed in cases of hyperglycerolemia, a rare 
disorder that results from a deficiency of glycerokinase, where the concentration of 
glycerol in serum is 50 to 100 times greater than the normal range of 1 mg/dL.18  The 
concentration of the glycerol is determined by completing reactions 3.5 through 3.7 on 
the serum which will be the concentration of the endogenous glycerol.18  This value is 
then subtracted from the TG values to determine the actual concentration of TG in the 
sample.18 
C. Lipoprotein Subfractions 
 The CDC primary reference method for the determination of lipoprotein fractions 
is based on ultracentrifugation of the serum sample.  One method is sequential 
differential ultracentrifugation which requires repeated ultracentrifugation steps that raise 
the solvent density to extract each lipoprotein fraction. Therefore, the densities of the 
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KBr solutions are changed dependent on the specific lipoprotein subfraction targeted. To 
float VLDL and chylomicron, the necessary density is 1.006 g/mL; for IDL 1.019 g/mol; 
for LDL 1.063 g/mL, and for HDL 1.21 g/mL. VLDL, IDL, HDL and LDL sub-fractions 
can be isolated using the vertical spin density gradient ultracentrifugation that was 
described by Chung et al.131-133  Based on their method, the plasma will have to be 
adjusted to a density that is equal to or greater than HDL, which is the densest particle 
that will be separated (1.21 g/mL), through the use of potassium bromide, KBr. 131-133  
The density-adjusted plasma will be layered under NaCl and centrifuged under conditions 
appropriate for the type of rotor and the sample size used.131-133   The benefit of the 
Chung et al. method over the standard density gradient method using swingout rotors is 
that the separation occurs in a short time period which limits the possibility of having 
native oxidation of the lipoproteins and limits the time the particles are exposed to high g 
forces and salt concentrations.131-133  Although effective in separating the fractions, the 
methods are time consuming and are usually limited to the specialized lipid medical or 
research clinics.   
 The CDC reference method for high-density lipoprotein cholesterol is a 
combination of ultracentrifugation and polyanion precipitation to prepare the HDL for 
quantification of the cholesterol by the reference method previously discussed. 18  
Through ultracentrifugation, VLDL lipoproteins and any chylomicrons are removed from 
the top layer after 18 h at 105,000 x g.18  The apo B-100 containing lipoproteins of the 
remaining IDL, LDL, Lp(a), and HDL in the infranatant are removed by precipitation 
with heparin sulfate and MnCl2 followed by centrifugation.  The remaining HDL 
particles are measured for cholesterol using the standard reference method.   VLDL-C is 
 56
equal to the total cholesterol minus the concentration of the total infranatant cholesterol.  
LDL-C is the total infranatant cholesterol minus HDL-C.  These estimations are possible 
and reasonable in normal subjects due to the concentration of IDL and Lp(a) being 2-3 
mg/dL of the TC value.18  An indirect measurement for the determination of LDL-C is 
the Friedewald Equation which is  
    [LDL-C] = [TC]-[HDL-C] – [TG]/5   (3.11) 
where the [TG]/5 is based on the average ratio of TG to cholesterol in VLDL particles.18  
This equation is not accurate in cases where TG concentrations are greater than 400 
mg/dL which is a problem in lipid clinics who have patients who can have TG levels in 
the thousands.18  The only option in these cases is to complete the ultracentrifugation and 
precipitation procedure described above referred to as the beta-quantification method.   
 Additional methods for lipoprotein analysis have been developed.  Precipitation 
methods that isolate one or more fractions from the others in the sample have been 
successful.  One such example was described in the beta-quantification method.  
POLYMEDCO developed a method that complexes the precipitant with magnetic 
particles which can be removed by magnetic disk instead of a centrifugation step.18  
Chromatographic separation of the lipoproteins either by high performance liquid 
chromatography (HPLC) or agarose column chromatography has been successful in the 
separation of VLDL, LDL, HDL2, and HDL3.  Like ultracentrifugation, the process is 
time consuming and expensive and limited to specialized laboratories.  Immunochemical 
assays have been developed and are successful in the quantification of the fractions due 
to the difference in proteins on the particles.  The last method used for the separation of 
lipoprotein particles is gel electrophoresis.  The net charge on the surface of the 
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lipoprotein particle from the amino acid side chains and the phosopholipids and the size 
of the particles allow for separation.  HDL travels the farthest on the gel followed by 
Lp(a), VLDL, LDL, and chylomicrons.  The pattern of the sample on the gel can separate 
patients into normal, Type III hyperlipoproteinemia, hypertriglyceridemia, and other 
dyslipidemic states.55, 56 
II. Polyunsaturated Fatty Acid Methods 
 For serum PUFA analyses there currently is no standard reference method.  The 
current methods for determination of the PUFA are through thin layer chromatography 
(TLC), gas chromatography (GC), and high performance chromatography.  New methods 
in mass spectrometry and nuclear magnetic resonance as part of the advancing field of 
lipidomics will be discussed.   
A. Extraction Methods 
 The first step in the analysis of PUFA is the separation of the fatty acids from the 
serum or other biological sample.  Since serum and other biological samples are complex 
mixtures, the extraction step is necessary in order to remove proteins, sugars, and other 
molecules that can interfere with the chromatographic techniques.  The extraction 
methods can be divided into liquid-liquid extractions and solid-phase extraction. 
 Liquid-liquid extractions are the primary methods used for the separation of the 
fatty acids.  The liquid-liquid extractions will have an organic/hydrophobic solvent which 
will dissolve the lipids and an aqueous/hydrophilic solvent for the non-lipid components.  
The solvent chosen is dependent on the form of lipid that is being extracted.  Neutral 
lipids like cholesterol and triglycerides can be extracted using non-polar organic solvents 
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such as hexane.134  Phospholipids, an example of a polar, complex lipid, require the use 
of a polar organic solvent such as methanol or ethanol.134  The first extraction of the fatty 
acids from serum using liquid-liquid extraction was developed by Folch et al. in the 
1950s.23  Folch et al. used 10 mL of chloroform-methanol solution 2:1 (v/v) for every 1 
mL of serum or the solution can be adjusted for use with biological tissues.23 The sample 
was mixed, centrifuged at 2500 x g for 10 min at 20 °C, and the aqueous phase collected 
for fatty acid analysis.23  Additional extraction solvent combinations include hexane, 
hexane-methanol, hexane-isopropanol, and ether.24  In a comparison of solvents for lipid 
extraction, the most popular solvent, 2:1 chloroform-methanol (v/v), was only able to 
extract 90% of the triglycerides, which can alter the percentage of PUFA detected, and 
99% of the cholesterol.24  Hexane-isopropanol removed 53% of the TG and 94% of the 
cholesterol, and ether and hexane only were very poor in extracting the TG with only 2% 
of the original TG recovered.24  A detergent extraction system first designed by Bordier 
was also tested.  Modest results of 73% TG recovery were demonstrated.24  An important 
note to make is that the chloroform-methanol and hexane-isopropanol solvent pairings 
also precipitated high concentrations of proteins where the ether, detergent system, and 
hexane only test did not.24  The key choice for the liquid-liquid extraction is dependent on 
the fatty acids that need to be extracted.  For example, fatty acid methyl esters (FAME) 
are non polar and can be extracted with non-polar organic solvents such as hexane.26 A 
Morrison and Smith procedure is two volume extraction with pentane and one volume of 
water which obtained a 97-99% recovery of FAMEs.26   
 Solid-phase extraction will use a solid phase and a liquid phase to separate the 
sample.  Phospholipids can be extracted with this method.  The solid phase is composed 
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of silica modified with cyanopropyl-, aminoproply- or dihydroxypropoxypropyl groups 
which become the absorbent material.134  Organic solvents dissolve the phospholipids and 
remove them from the column.  In comparison with liquid-liquid extraction, solid-phase 
is rapid, reliable, and requires a smaller sample size; however, most methods still use 
liquid-liquid because larger sample sizes are available.  
 Once extraction has occurred, samples must be watched for degradation by 
oxygen, light, and solvents.  All samples should be stored at -70 °C and stored under 
nitrogen or argon if samples will not be analyzed for an extended period of time.  An 
anti-oxidant can be added, but care must be taken to choose one that will not interfere 
with any analysis.   
 Preparation of the methyl esters of the fatty acids in TG, phospholipids, free fatty 
acids, and other forms must occur before analysis.  Acid-catalyzed transesterification 
includes methanolic, hydrochloric, and sulfuric acid, and boron trifluoride in methanol as 
possible reagents.26  All of these reagents require heating, and the one that is most often 
used is the boron trifluoride-methanol reagent. The boron reagent though has a limited 
shelf life, and an overconcentrated solution can cause a loss of PUFA.  Additional 
reagents such as acetyl chloride and aluminum chloride have also been used.26  Base-
catalyzed transesterification is also possible through the use of sodium methoxide and 
potassium hydroxide in methanol which have an advantage over the acidic catalysts in 
that the reactions can occur at ambient temperatures and proceed rapidly.26  The 
disadvantage is that it does not esterify free fatty acids and the conditions must be 
anhydrous.26  These methods methylate non-esterified fatty acids (NEFAs) and 
transesterify lipid-esterified fatty acids in samples. 
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 A method for the methylation of NEFAs without transesterification of esterified 
lipids can be completed through the use of a procedure designed by LePage and Roy.  To 
obtain compounds with lower boiling points for use in analysis, the LCPUFA must be 
converted into methyl esters.  The sample is placed in a Teflon-lined capped tube and 
dissolved/suspended in 4.0 mL of methanol-benzene 4:1 (v/v), prior to which an internal 
standard of 50 to 300 μg of tridecanoic acid is added for the purpose of quantification.20 
While stirring, 200 μL of acetyl chloride is slowly added over one minute.  The reaction 
tube is heated at 100ºC for one hour and, after cooling, 5.0 mL of 6% K2CO3 solution is 
added to stop the reaction.20  The tubes must be centrifuged, and the benzene layer is 
available for use in various analysis techniques. 
B. Chromatographic methods 
 Thin-layer chromatography (TLC), gas chromatography (GC), and high 
performance liquid chromatography (HPLC) with various detectors such as ultraviolet-
visible (UV-VIS), fluorescence, and evaporative light scattering detection have each been 
applied to the analysis of PUFA.  Combination techniques such as liquid-
chromatography-mass spectrometry (LC-MS) and gas chromatography – mass 
spectrometry (GC-MS) have expanded the capabilities of these methods.  This expansion 
has led to advancements in the study of lipidomics. 
 Thin-layer chromatography (TLC) consists of a plate coated with silica gel or 
alumina and a mobile phase of an organic solvent such as chloroform, methanol, water, 
or combinations of these.  The fatty acid will migrate on the stationary phase (the plate) 
while being carried by the mobile phase.  The distance traveled is based on the fatty 
acid’s affinity for the mobile phase.  Identification of the fatty acid occurs based on the 
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retardation factor (Rf) which is the ratio of the distance traveled by the analyte to the 
distance traveled by the solvent.  By comparing unknown samples with standards, a fatty 
acid can be identified.  The analyte locations on the plate are visualized through the 
application of a reagent that makes the spot visible through UV detection or other 
methods.  TLC provides a quick separation of the fatty acids, but the technique does 
destroy the fatty acids and is not very reproducible.  It is best used as a test before 
running a sample through a more complex chromatographic method. 
 Gas chromatography is the method most applied to fatty acid analysis.  GC is 
used for the separation of volatile organic compounds.  FAME is the form of fatty acid 
that is easily analyzed with this method.  All forms of the fatty acid must be converted to 
FAME in order to be analyzed with this method.  The stationary phase is a capillary, non-
polar column with a carrier gas of hydrogen.  The use of a non-polar column will separate 
FAME based on boiling point which will result in the MUFA and PUFA eluting first 
followed by the saturated components.  Quantification of the samples requires peak 
integrations. Scale calibrations require the addition of an internal reference, such as 
methyl docosatrienoate, to the sample.16  The relative amount of each fatty acid is 
determined by dividing individual peak areas by the sum of all the fatty acid peaks.16   
 GC has become the primary analytical method for the detection of fatty acids so 
research work using slight variations of the method is extensive.  Flame ionization (FID) 
and mass spectrometry (MS) are the two major forms of detection for GC.  The resolving 
of peaks is comparable in both, but MS has the benefit of allowing for the verification of 
peak identity by its mass spectrum.  Using GC/MS and extraction and esterification or 
direct transesterification methods described previously, the intraassay CVs ranged 
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between 2.5 and 13.2% with interassay CVs ranging from 4.6 to 22.9%.21  After spiking 
serum samples, the recovery ranged from 76 to 106%.21  The quantification of the analyte 
is based on the calibration of the closest standard.  The linearity and reproducibility had a  
coefficient of variation of 9.8% and r2 > 0.923.21  The concentration range for adults in a 
study of control subjects is provided in Table III-1. 
Table III-1: Concentration ranges of serum polyunsaturated fatty acids 
FATTY ACID 
RANGE OF CONCENTRATION 
FOR AN ADULT 
(> 17 YEARS) 21, 
μMOL/L 
α-Linolenic Acid, C18:3, ω3 50-130 
Eicosapentaenoic Acid, C20:5, ω3 14-100 
Docosahexanoic Acid, C22:6, ω3 30-250 
Docosapentaenoic, C22:5, ω3 20-210 
Total ω3 (mM) 0.2-0.5 
  
γ-Linolenic Acid, C18:3, ω6 16-150 
Arachidonic Acid, C20:4, ω6 520-1490 
Linoleic Acid, C18:2, ω6 2270-3850 
Homo-γ-linolenic, C20:3, ω6 50-250 
Docosapentaenoic, C22:5, ω6 10-70 
Docosatetraenoic, C22:4, ω6 10-80 
Total ω6 (mM) 3.0-5.4 
  
Palmitoleic, C16:1, ω7 110-1130 
Vaccenic, C18:1,ω7 280-740 
7-Hexadecenoic, C16:1, ω9 25-105 
Oleic Acid, C18:1, ω9 650-3500 
Mead, C20:3,ω9 7-30 
Tetracosanoic, C24:1, ω9 60-100 
Total polyunsaturated (mM) 3.2-5.8 
 
In a comparison of GC/MS with GC/FID completed on the same serum samples, the 
GC/FID results indicated a higher concentration of linoleic acid than GC/MS.21  GC/FID 
results were expressed as relative percentages of the total fatty acids, which is common in 
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a number of studies, whereas GC/MS results were expressed as actual concentrations.  
Langerstedt et al. make the point that the relative concentrations can provide incorrect 
results in cases where high levels of nonessential fatty acids can falsely lead to a 
decreased percentage of the essential fatty acids that are being examined.21  Results and 
outcomes based on a percentage of the total have to be questioned until absolute 
concentrations are determined.21  Numerous additional studies have examined serum fatty 
acids, either as free fatty acids or as esters, using GC with its various forms of 
detection.16, 22, 76, 103, 106, 135-137  With the same sample preparation and GC 
instrumentation, tissue samples, including adipose tissue, have allowed for the analysis of 
various fatty acids that are stored in the body.83, 110   
 Although successful, especially, in comparing relative percentage change in fatty 
acids for clinical studies, GC’s disadvantages include the derivatization steps which can 
alter the structure of the fatty acid or create side-products that can overlap with the 
analytes needed.26  Short chain FAME can be eluted quickly and missed.138  Also, the 
procedures are quite labor intensive; and it is difficult to obtain meaningful 
concentrations when using only a limited number of standards. These limitations 
strengthen the case for the development of a simple and direct method that does not 
require separation and reacts directly with the polyunsaturated fatty acids. 
 Where GC uses a gas as its mobile phase, HPLC uses a liquid one and a solid or 
liquid coated solid in its stationary phase. The analytes are absorbed on the stationary 
phase to varying degrees resulting in separation based on its affinity to the solid or liquid-
coated solid.  HPLC is advantageous over GC due to speed, resolution, sensitivity, 
specificity, sample protection, and its lower temperature operation which reduces the risk 
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of isomerization of the fatty acids.134  The method, however, is used for the separation of 
the lipid class due to overlapping peaks that are improved with the use of the reverse-
phase method and different detectors.   
 Fatty acids do not contain any chromophores that allow them to be directly 
detected by UV-VIS or fluorescence.  As a result, the detection occurs through flame 
ionization detection (FID), electrochemical detection, or chemiluminscence detection.  
FID, as in GC, has high sensitivity and is primarily used for the analysis of serum 
samples without additional sample preparation other than the extraction and methylation 
of the fatty acids.138  Electrochemical detection can be done without tagging the fatty 
acids; however, the addition of the tagging reagent can increase the sensitivity.138   HPLC 
with electrochemical detection was used to determine the free fatty acids in plasma with 
no tagging agent.   The resolution of eight examined fatty acids, saturated and 
unsaturated, was completed in 10 minutes on the column with a resolution only low 
(0.12) between palmitoleic acid and linoleic acid.139  The relative standard deviation was 
less than 1.5 in mixtures of the standards and less than 5% in serum samples spiked with 
known concentrations of the standard fatty acids.139   Derivation of the fatty acids is 
necessary for detection by UV-VIS, fluorescence, and chemiluminscence.  A number of 
agents can be used including benzyl, p-nitrobenzl, phenacyl, p-bromophenacyl and 
others.138  HPLC with UV detection was completed for the determination of long chain 
fatty acids in plasma and lipoproteins.  After saponification of the sample, 2-
nitrophenylhydrazine was added for the derivatization prior to the extraction of the fatty 
acids from the sample.140  The coefficients of variation range between 3 and 31%.140  
Recovery of a standard solution of fatty acids ranged between 95 and 110%.140  LA is the 
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most abundant long-chain fatty acid followed by palmitic acid with LDL and HDL 
compositions of fatty acids appearing to reflect the composition of plasma.140  It is 
important to note the derivatization reaction can be affected by the amount of reagent, the 
reaction temperature, and the incubation time so care must be taken to ensure strong 
attachment and for the prevention of side chains.138  Cis- trans- isomers of the fatty acids 
can be detected through silver ion chromatography with a silver loaded HPLC column.138  
The separation is based on the formation of weak charge transfer complexes between the 
silver ions and double bonds.138  HPLC with these various forms of detection have been 
used for the fatty acid analysis of animal and other human biological samples, products of 
the oxidation of lipids, foods, plant extracts, and oils.138, 140-142 
 Alternative methods including combining mass spectrometry with GC and LC, 
LC-MS/MS, multidimensional mass spectrometry, and nuclear magnetic resonance are 
all advanced techniques that are used to examine fatty acids and their metabolites in the 
growing field of lipidomics.  Through the use of multidimensional mass spectrometry, 
new classes of phospholipases and new roles for lipids in cerebral function have been 
discovered.143  A technique of reverse phase LC-MS/MS surveyed with precursor ion 
scanning and succeeding product ion scanning was able to increase the detection limits of 
phospholipid metabolites by 5 to 20 fold allowing for even minor components of studies 
to be detected.143 
 The last method of fatty acid analysis is the determination of free fatty acids by an 
enzymatic method.  Shimizu et al. first developed the enzymatic method in 1979 and 
colorized it in 1989.  It is dependent on the activation of free acids by acyl-CoA 
synthetase.  The reaction of the extracted serum fatty acids involved are the following.144 
 66
 FFA + CoA + ATP ⎯⎯⎯⎯⎯ →⎯ − synthetaseCoAacyl   acyl-CoA + AMP + PPi  (3.12) 
 AMP  + ATP ⎯⎯⎯ →⎯myokinase  2ADP      (3.13) 
 2 ADP + 2 phosphoenolpyruvate ⎯⎯⎯⎯ →⎯ kinasepyruvate  2 ATP + 2 pyruvate (3.14) 
 2 pyruvate + 2 NADH ⎯⎯⎯⎯⎯ →⎯ asedehydrogenlactate 2 lactate + 2 NAD+   (3.15) 
The reaction was then coupled using acyl-coA oxidase from yeast to react with the acyl-
CoA generated by the fatty acids.144   One product of the reaction, hydrogen peroxide, 
can be further reacted to produce red quinine dye.144  A microfluorometric method using 
these reactions allowed for direct analysis of the serum’s free fatty acids with no 
extraction step which led to improved sensitivity and lower cost.145   This method of 
determination of the free fatty acids is widely available in kits from multiple suppliers.   
III.  Purdie Assay Development 
 The Purdie Assay was developed based upon a reaction by Chugaev (Tshugaev) 
and Gastev.  The Chugaev and Gastev reaction uses a 2:1 mixture of 20% w/v ZnCl2 in 
glacial acetic acid combined with 98% acetyl chloride.129  The Chugaev and Gastev 
reagent was used to measure cholesterol with great accuracy by Hanel and Dam.130  The 
reagent was also used for the determination of dolichol, any number of long-chain 
unsaturated isoprene groups with a terminal alcohol group, and dolichyl derivatives.146  
The major goal of the original project was the determination of the cholesterol in each of 
the lipoprotein fractions without a separation step.  As mentioned previously, the 
determination of LDL-C, HLD-C, and the other fractions required either a precipitation 
of some of the fractions or a sequential ultracentrifugation process.  A direct method was 
attempted when it was determined that the Chugaev color product of cholesterol was 
active using circular dichroism (CD).  Two milliliters of the Chugaev reagent were added 
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to 50 μL of serum.  After 8 min of incubation at 67 °C, the solution was cooled to room 
temperature and 1 mL of chloroform was added before CD analysis from 625-325 nm. 28, 
147, 148  The CD detection exhibited good linearity for the correlations between TC 
measurements and determinations of both HDL-C and (VLDL+LDL)-C.28, 147, 148  The 
separation of VLDL-C and LDL-C was not possible. 
 Refinement of the reagent system and a switch to visible absorption spectroscopy 
improved upon the previous results.  The modified reagent was changed to a higher 
concentration of ZnCl2 which contained 980 g of acetyl chloride and 350 g of ZnCl2.149  
The increased concentration heightened the intensity of the signal allowing the sample 
size to be reduced.150  The resulting spectra were assumed to be the product of cholesterol 
and its esters with the reagent.  Using a simple algorithm and calibrations, the 
concentration of each of the subfractions of cholesterol was determined and compared to 
the standard enzymatic test.  The correlation between the spectrophotometric and 
enzymatic measurements for TC and LDL-C were strong with low coefficients of 
variances.149, 150  The correlation for both VLDL-C and HDL-C was not as strong.149, 150  
The correlation between TC and the LDL-C values do validate the spectroscopic method, 
but further work on including IDL-C in the mathematical model could have improved the 
results.150  Two patents resulted from this work.151, 152 
 During this period, the reagent system was also being modified and examined for 
any possible interference.  Zinc chloride, zinc acetate, zinc perchlorate salts, and 
perchloric acid with acetyl chloride all produce colors of various intensities.150  Acetic 
acid was found to inhibit the reaction requiring a longer incubation time to achieve the 
final color.150  Hemoglobin was the only protein that caused interference with the 
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spectrum, and it only occurred at high concentrations.150  This is important to note 
because venous blood collection can rupture red blood cells releasing hemoglobin into 
the serum sample.150    
 Further refinement of the reagents’ system led to 1 mL of 98% acetyl chloride, 40 
μL of 70% perchloric acid and 10 μL of sample.29  In the case of serum where 
precipitation of the proteins occurred, a 3 minute period in a centrifuge at 3400 rpm was 
required before decanting the solution into a glass cuvette.  The spectrum was recorded at 
15 min over 350 – 750 nm.29 Upon examination of additional uses of the Purdie Assay, it 
was determined that cholesterol and its esters, unsaturated fatty acids, triglycerides, and 
phospholipids with unsaturated fatty acids attached reacted with the Purdie reagent and 
produced absorbance and fluorescence spectra.29  This work showed that the absorbance 
spectra was not only cholesterol, but also included other compounds in serum that reacted 
with the reagent.  Methyl ester forms of myristic acid (C14:0), palmitic acid (C16:0), 
stearic acid (C18:0), oleic acid (C18:19), LA acid, linolelaidic acid (C18:29,12), ALN and 
GLN (C18:39.12.15), AA, EPA, and DHA were a few tested.29, 31, 32  Saturated fatty acids 
did not react with the Purdie reagent system. Oleic acid had a minimal absorbance.  Food 
oils including olive oil, safflower seed oil, and fish oil were also tested.29, 31, 32  The 
remaining fatty acids had unique absorbance patterns based on the number of double 
bonds present.  Slight differences between LA and linolelaidic and ALN and GLN 
existed.  Due to this ability, the Purdie assay could serve as a quality control test reagent 
for standard reference materials and natural oils.32  Sterols including beta-sitosterol, 
stigmasterol, and Vitamin D were shown to produce a colored product.29    Cholesteryl 
esters were determined to be the sum of the cholesterol spectra and the PUFA that was 
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attached.  Synthetic serum samples and synthetic dyslipidemic samples were prepared to 
model these conditions and correlations between the synthetic mixtures and human serum 
samples were positive.29  Slight variations between the two spectra existed, but the 
overall fit was good for an initial attempt to mimic dyslipidemic disease states.   
 Using the 25:1 mixture of acetyl chloride and 70% perchloric acid, the ability for 
reaction to occur with steroids opens the door for a second quality control assay.33  The 
Purdie reagent has selectivity for acylation of the α- over the β- position at the C-17 
which would allow for differentiation of anabolic steroids.33  It was also determined that 
if multiple reactants are present, the resulting spectrum is the addition of each of the 
components, assuming no interferences are present.33  The selectivity of the reaction was 
completed by an examination of the steroids, PUFA, and terpenes that were able to react 
with the Purdie assay.  It was determined that the reaction is selective to –CH2-C=C- and 
can distinguish isomers like conjugated linoleic acid from linoleic acid.31 
 Once it was established that the reagent system was reacting with the cholesterol 
and the PUFA in the serum, the quantification of these components was attempted using 
multiple linear regression (MLR) techniques.  Using K-matrix methods and the molar 
extinction coefficients for cholesterol and each PUFA, prepared mixtures were 
analyzed.31  Cholesterol, LA and CLA at high concentrations were determined.31  Large 
errors were associated with the LNA, AA, EPA and DHA.31  Multiple reasons are 
possible for this including experimental error, low signal to noise ratio for the lower 
concentrations of these four PUFA, and analysis errors related to the algorithm chosen.  
The analysis was useful in a dietary intervention study on one male, obese subject who 
was placed on a low fat diet.  The sum of the PUFA determined by MLR and the 
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enzymatic TG concentrations over the 4 month study followed the same qualitative 
pattern.31  This suggests that the Purdie assay could offer a qualitative monitoring assay 
and with further attempts with additional mathematical algorithms, complete 
determination of all components can turn it into a quantitative assay.   
 The Purdie assay and its pattern differences seen in samples of serum from 
dyslipidemia patients were tested in an exploratory clinical trial.  Ninety-six subjects with 
normal , Type I, familial hypercholesterolemia (FH), Type III, and diabetic conditions 
had their serum samples analyzed with the Purdie assay.30  Using principal component 
analysis (PCA) and clustering, pattern recognition techniques allowed for an 81.3% 
assignment of each spectrum into a group of the same conditions.30  It is important to 
note here that some of these patients were already on lipid lowering drugs which can 
place the spectra into a different group or cluster resulting in a lower fitting accuracy.30  
More information on treated and untreated patients may lead to a higher rate of clustering 
accuracy.    
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CHAPTER IV  
 
 
EXPERIMENTAL METHODS 
 
 The determination of the concentration of analytes present in a solution involves 
multiple steps.  The first is the reaction of the sample with the Purdie Assay.  
Adjustments must be made depending on the sample type which can include serum, a 
prepared mixture sample that is in chloroform, or a food sample.   After obtaining the 
spectra, the analyses both quantitative and qualitative can be completed.  Each method 
explored for these types of analysis will be explained. 
A.  Reaction with Purdie Assay 
 As discussed in Chapter 2, the Purdie Assay has been well developed over the last 
few years; and, therefore, the methods associated with the assay are well established.  
The procedures followed for this study are discussed by the sample type and the inclusion 
or exclusion of water added to the reaction system.  The water effect will be discussed in 
the following chapter. 
1. Serum Samples 
 A 10 μL sample of serum is added to a 13 x 100 mm borosilicate disposable test 
tube.  One milliliter of pure acetyl chloride (Arcos) is added to the test tube.  A 40 μL of 
perchloric acid (70% ACS reagent grade, GFS) is added to the side of the test tube and 
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slowly introduced to the acetyl chloride/sample solution.  The process must be slow and 
controlled to prevent excessive splashing that can occur if the solution is added too 
quickly.  The reaction time is started as soon as the perchloric acid is added.  The solution 
is mixed by hand for twenty seconds to allow for the release of the small amount of 
hydrochloric acid gas from the reaction test tube.  The test tube is covered with a Teflon 
cap and placed into a centrifuge for 3 minutes at 3400 RPM.  After centrifugation, the 
precipitated proteins are separated, and the liquid is transferred to a 10 mm pathlength 
optical glass cuvette with Teflon stopper for the remaining time.  Absorbance spectra are 
taken at 15 minutes using a HP 8452A Hewlett Packard spectrophotometer.  A 5 second 
integration time and a 2 nm resolution were used to collect the spectra over the range of 
350-800 nm.  The blank for each reaction was pure acetyl chloride.  The reagent mixture 
of acetyl chloride with perchloric acid does produce a slight color at 15 minutes.  Due to 
the possibility of variability and small absorbance value, the combination of acetyl 
chloride and perchloric acid was not used as the blank.  Spectra of the colored species 
generated from the mixture of the two reagents were obtained and used in the quantitative 
analysis of the spectra.  Additionally, the procedure was altered for the examination of 
the kinetics of the reaction.  After the centrifugation and separation of the sample, the 
spectrophotometer was set to collect spectra every minute for 20 minutes using the 
onboard software.   
2.  Prepared Mixtures, With and Without Water  
 Throughout the course of the study, it was realized that the water content of the 
perchloric acid and serum in the reaction solution has an effect on the reaction.  Mixtures 
were prepared from standards of cholesterol and the methyl esters of the fatty acids in a 
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chloroform solution.  Centrifugation was unnecessary since no proteins were added.  Data 
collection remains the same as for serum.  The inclusion of water involves the addition of 
10 μL of distilled water as the first step, followed by the acetyl chloride, the chloroform 
mixture sample, and finally the perchloric acid.  The remaining steps of the assay 
remained the same as serum in order to maintain constancy during the 15 minute reaction 
period.  As stated with the serum, collection of the spectra every minute for 20 minutes 
can be completed using the software of the spectrophotometer for examination of the 
kinetics.   
3.  Other Mixtures  
 New samples that contain the analytes of interest are constantly being considered 
for use with the Purdie Assay.  With each new analyte, consideration must be given to the 
composition of the sample and any possible interference that might cause alterations in 
the analysis.  In samples such as food oils including sunflower, safflower, and fish that 
have been analyzed with the Purdie Assay, the procedure was the same as the prepared 
mixture discussed previously.  Procedures with and without water added to the reaction 
were completed for analysis in attempted quantitative methods.  Any sample that does not 
have water or proteins present can be analyzed using the established prepared sample 
procedure.  If proteins are present, such as in animal blood and milk samples, the 
procedure will have to include the decanting step that is discussed with the established 
serum method.  The Purdie Assay can be adapted further as more samples are considered 
as demonstrated with the various mixtures examined to date.  
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B.  Samples 
 Methyl linoleate, methyl linolenate, methyl arachidonate, methyl 
eicosapentaenoate, methyl docosahexaenoate, methyl conjugated linoleate, and free 
cholesterol were all used to prepare mixtures.  All of the standards were 90 to 99 % pure 
based on gas chromatographic analysis and were all purchased from Sigma-Aldrich.  
Stock solutions for each of the analytes with a maximum total concentration of 0.02 M 
and 0.04 M were prepared.  The stock solutions were used to prepare mixtures to limit the 
majority spectral response to ranges between 0.2 and 0.9 absorbance units.  The mixtures 
prepared for each quantitative analysis method varied and will be discussed with each of 
the methods. 
 Serum samples for this work were provided by staff and volunteers at the 
Oklahoma State University Wellness Center (OSUWC) and from the Lipidology 
Laboratory and Clinic at the University of Cape Town Medical School (UCT), South 
Africa.  The anonymous samples from OSUWC were from volunteers who were already 
requesting a lipid profile and had given consent, Appendix I.  No attempt was made to 
solicit samples nor was any extensive medical information derived from the samples 
except for the cholesterol concentration which was determined by an outside chemical lab 
using the enzymatic test.  The subjects fasted for at least 12 hours prior to the collection 
of the sample.  A venous blood sample was collected into a Vacutainer™ red and grey 
capped separation tube.  After inversion of the tube five times to mix the blood and the 
components of the collection tube, the sample was centrifuged at 3400 RPM for 15 
minutes.  The collection tube contains a clotting activator which takes approximately 30 
minutes to activate and a floating gel that separates the red cells from the serum during 
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the centrifugation step.  The serum, which was the top layer in the tube, was then 
transferred to a 10 mL glass vial with a screw cap.  The Purdie Assay was completed on 
the sample within three days of receiving the sample.  Samples were stored in a 
refrigerator at 2-4 °C.  Samples were allowed to return to room temperature prior to 
analyses.  OSUWC samples, about 20 in number, were from patients with normal to 
elevated cholesterol levels. 
 UCT samples were collected from patients who were admitted to the Cape Town 
Clinic under the direction of Professor A. David Marais for the identification and 
treatment of lipid disorders.  All samples were collected and separated by the staff of the 
clinic using the same containers and procedures as the OSUWC samples.  Permission to 
work with the samples was obtained through the UCT Lipid Clinic, Appendix II.  Once 
separated, a portion of the serum was placed into microcentrifuge tubes instead of the 10 
mL glass vials.  The remaining portion of the serum was used for other methods in the 
Lipidology Laboratory.  The 619 samples collected were analyzed over a three month 
period.  The cholesterol values and a diagnosis of the lipid disorder, where possible, were 
determined by the UCT Laboratory.   
C. Quantitative and Qualitative Analysis and Multivariate Modeling of the Spectra   
 The objective in this section was to measure molar concentrations for the seven 
major serum lipids from a single absorbance spectrum. Separations are not involved. 
Although a challenging problem, it is to our advantage that indications are that individual 
spectra are additive. The determination of the concentration of an analyte first involves 
defining a model or approach that can involve calibration with standard solutions 
followed by a prediction of the concentrations of each component in the sample.  The 
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defining of the model and subsequent calibration are needed to determine the relationship 
between the concentration of the analyte and the resulting response, i.e. the spectral 
absorbance.  If the relationship can be clearly defined, then the prediction of unknown 
samples can occur.  The key is to find an approach that best defines the relationship 
between the concentrations and the absorbance.   
In the following sections, four approaches will be described that were used for the 
calibration and validation of the total multi-component assay. The ultimate verification 
will be to show the validity of the additivity assumption.  
1.  Multivariate Approaches 
 In order to explain the multivariate analysis methods that will be employed, the 
spectrographic problem must be clearly defined. According to Beer’s Law, absorption by 
a single component at a single wavelength is defined by the following equation: 
  a = ε d c       (4.1) 
where a is the absorbance, ε is the absorption coefficient, d is the cell thickness and c is 
the molar concentration of the sample solution. For the same cell thickness for all of the 
samples, Beer’s law can be restated as 
  a = k c       (4.2) 
where k  is the reduced absorption coefficient. If multiple components, m, are in the 
system, the expression expands to: 
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where ai is the absorbance at wavelength i; kij is the absorption coefficient of the j 
component at wavelength i and cj is the concentration of the jth component. When p 
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wavelengths from the spectra are used, matrix notation can be used to arrive at the 
following equation: 
  A = Kc       (4.4) 
where A is a p x 1 vector that is the resultant spectra, K is a p x m matrix of the 
normalized molar absorptivities, and c is a m x 1 vector of the concentrations of the m 
components. By determining the matrix c , the concentrations for all six PUFAs and 
cholesterol will be obtained.  
a. Direct Calibration 
 The direct method is based on measuring pure component spectra to obtain the 
molar absorptivities which requires standards of each of the analytes to be available for 
analysis. There are two key requirements. First, there must not be any interactions 
between the different components or between components and the solvent.153 Second, no 
known matrix constituents can interfere with the resultant spectrum.153 In the context of 
the current problem, all of the components are available in pure form, and their molar 
absorptivities can be obtained to complete the matrix K.  During initial experiments, no 
matrix effects or other interactions were encountered. Using this method, the unknown 
concentration vector can be determined by: 
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where co is the vector of the predicted concentrations, K is the matrix of the 
absorptivities, and ao is the vector of the sample spectrum.153 Equation (4.5) applies when 
the number of wavelengths used in the analysis is greater than the number of 
components.  Relative error can be low as long as the two requirements are true, and 
multiple wavelengths are used.    
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 To determine the components of the K matrix for each of the analytes, molar 
absorptivities were determined.  Multiple linear regressions were completed for every 2 
nm wavelengths between 350 nm and 800 nm for each analyte to determine the molar 
absorptivity for each of the seven analytes of this study.  The concentration ranges for the 
chloroform solution containing the methyl esters of LA, ALA, AA, EPA, and DHA 
ranged from 0.0025 M to 0.02 M with 10 to 20 concentrations chosen in equal increments 
over this range for the calibration curve.  Cholesterol and CLA had ranges from 0.001 to 
0.01 M.  The difference in the concentration ranges were required in order to maintain the 
absorbance falls within the range of 0.2 to 0.9 absorbance units.  Molar absorptivities for 
each analyte with and without water were determined.   
b. Indirect and Inverse Calibration 
 In these procedures, calibration absorptivities are determined using mixtures. The 
methods will allow for any interactions that exist between components or between 
components and the solvent to be accounted for in the answer. These methods are divided 
into two parts; calibration and analysis. To calibrate, a set of spectra for samples of 
mixtures with known concentrations of the components are measured. K-matrix approach 
uses a matrix of the known concentrations and a matrix of the respective absorbancies. 
The matrix K can be solved using the general least square solution equation: 
  AcccK TT 1)( −=   (4.6) 
where c is the matrix of the known concentrations, A is the matrix of the spectra of the 
samples, and K is the matrix solution to the molar absorptivities of the components.153 
The K matrix is then used in the analysis step to determine the concentrations of the  
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components in the unknown sample using the equation: 
  1)( −= TToo KKKac  (4.7) 
where co is the vector of the concentrations of the unknown sample, and ao is the 
spectrum of the unknown sample.153 The advantage of this approach is that the K matrix 
generated is representative of real absorptivities. Disadvantages are that every component 
that absorbs must be known, and the method relies on the inversion of two matrices 
which becomes a problem if the components have similar absorption spectra, in which 
case, a singular matrix may occur.  
 The inverse calibration method is based on the model 
  APC =    (4.8) 
where C is the matrix of the concentrations, A is the matrix of the absorbance, and P is a 
matrix of the calibration coefficients.153  The matrix P is determined by  
  CAAAP TT 1)( −=   (4.9) 
by using ordinary least squares analysis.153  Using a sample spectrum, ao, and multiplying 
it by the generated P matrix, the unknown concentrations in the sample spectra can be 
determined.  Unlike the matrix K in the K-approach which are absorptivities related to 
the analytes, the components of the P-matrix do not have any physical meaning.153  P-
matrix approach does have the advantage of involving only one matrix inversion.153 
c. Principal Component Analysis 
  Principal Component Analysis (PCA) is an unsupervised pattern recognition 
method which takes high dimensional data and projects it to a lower dimensional space.  
The method is considered unsupervised because no prior knowledge of the classification 
is included in the calculation.  The goal of PCA is to use the matrix of the original set of 
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data, X, and approximate it by producing two smaller matrices called the score, T, and 
the loadings, L.  In terms of a matrix equation,  
  TTLX =    (4.10) 
where X is defined as n row of objects and p columns of features; T is represented by n 
rows with d columns of principal components, LT is the transpose matrix of L and is 
defined by d columns and p rows153.  To determine the principal components, the 
nonlinear iterative partial least squares (NIPALS) algorithm was used.  NIPALS 
determines the principal components based on the maximum variance criterion which 
requires that each component describes the maximum amount of variance that the first 
did not model with its vector.  As a result, the first principal component models the most 
variance followed by the remainder.  Each principal component will be orthogonal to all 
the others.  The number of principal components required for the system being examined 
was determined by percentage of explained variance, eigenvalue-one criterion, and/or 
cross-validation.  PCA can be completed on the correlation or covariance matrix 
generated from the data.  The correlation matrix is used when the variables have large 
differences in the variance or the units of measure are different.  The data is then 
standardized first before proceeding with PCA.  The principal components can be 
combined with multiple linear regression to obtain the predicted concentration values in 
the principal component regression method.154  This method was examined, but partial 
least squares regression has advantages.  PCA for this study was primarily used for the 
generation of the principal components which can be used in cluster analysis for pattern 
recognition and as a possible input for neural networking.  All principal component 
analysis was completed using SAS Institute’s statistical software, JMP155.  
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d. Partial Least Squares (PLS) Regression 
 Partial Least Squares (PLS) regression methods are widely used in all fields 
including chemistry. PLS was developed in the late sixties in the field of economics by 
H. Wold and was later applied to chemical analysis by  S. Wold, and H. Martens.154, 156  
The model parameters in PLS have been shown to be more robust to changes in 
calibration samples than the previous standard methods of multiple linear regression and 
principal component regression.154    In previous methods, the concentration matrix was 
determined by decomposing the A and C matrix separately.  In the case of PLS, the 
decomposition of the absorbance matrix A, which is the X matrix in the general theory, 
and the concentration matrix C, which is the Y matrix in the general theory,  are 
estimated simultaneously.154   PLS’s approach is similar to PCA and is based on the 
NIPALS algorithm with the exception that both the X and Y matrices will be 
decomposed into latent variables instead of just the X matrix in PCA.154  The initial 
formula is based on the equation 
  XBY =    (4.11) 
where Y is the concentration matrix, X is the absorbance matrix, and B is the relationship 
between the two.  The new variables are called X-scores and serve as predictors of both 
X and Y.156  The X-scores that are the elements of matrix T are linear combinations of 
the original variables in matrix X with calculated weights W for form 
  XWT =    (4.12) 
which allows X to now be defined as 
  HTPX T +=    (4.13) 
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where T are the scores of X, the elements of P are the loadings, and the errors are 
represented by the matrix H.156  The X-scores must be determined so that, when 
multiplied by the loadings, they provide a good summary of X and maintain small 
residuals in equation 4.13.  A corresponding procedure is completed for the Y matrix.  
The Y-scores that are the elements of matrix U are linear combinations of the original 
variable Y with calculated weights Q for form 
  YQU = .156     (4.14) 
which allows Y to now be defined as 
  GUQY T +=    (4.15) 
where U are the scores of C, the elements of Q are the loadings, and the errors are 
represented by the matrix G.156  The X-scores must also be good predictors of Y to  
yield 
 FTQY T +=     (4.16) 
which can be written by including Eq. 4.12 to 
 FXBFXWQY T +=+=   (4.17) 
which is a multiple regression model.156  The PLS-regression coefficients can be related 
to the matrix X resulting in B written as  
 TT QWPWB 1)( −=    (4.18) 
where the relation has been written to directly relate with X.156  The final equation, which 
is the same as multiple linear regression, can be expressed as  
 EXBY +=     (4.19) 
where Y is the concentration of the analytes, X is the absorbance matrix, B is the matrix 
of the PLS regression coefficients b, and E is the matrix of the residuals.  The advantage 
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of this method over others is that the directly related decompositions of the two matrices 
creates an algorithm that is robust to calibration changes.153  Two types of this approach 
have been developed.  When each analyte is calibrated and predicted one at a time, the 
method is referred to as PLS1.  When two or more components are calibrated and 
predicted simultaneously, then the PLS2 algorithm must be used.  A comparison between 
both PLS1 and PLS2 was completed for this study.  All PLS analysis was completed 
using The Unscrambler software package.157 
 As with any of the methods discussed to this point, the results will only be as 
good as the data that is supplied to the algorithm.  Mean centering of the spectral data is 
necessary for reduction in the errors and is a common pre-processing step in the use of 
PLS.  The optimum number of principal components for PLS was determined by cross-
validation 156.  The cross-validation method will remove one or a group of samples prior 
to the model being calibrated.  The left out points are used to determine the prediction 
residuals which allow the samples to both determine and test the model.  The calibration 
is repeated again with different samples removed until all of the residuals have been 
computed for each sample.  The root mean square error of calibration (RMSEC) and root 
mean square error of validation (RMSEV) are calculated for each model.  The general 
equation is  
  
N
yy
RMSE
N
i
ii∑
=
−
= 1
2
^
)(
 (4.20) 
where y and y’ are the predicted and actual concentrations and N is the number of 
samples.  The model with the minimum values for RMSEC and RMSEV and the lowest 
 84
number of factors is the model with the optimum number of PCs.  A plot of the RMSEV 
against the number of PCs in the model can indicate the appropriate model.  
 One critical aspect is the wavelength selection.  When PLS and other methods 
were originally introduced, they were considered to be full spectrum methods that would 
determine the concentrations regardless of the region of spectra used.158  It has since been 
proven both experimentally and theoretically that the selection of wavelengths can 
significantly reduce the prediction errors of the models.158-163   Wavelengths can be 
selected using a PLS based method developed by Frenich et al.164  A large coefficient b 
may be an indication of a wavelength that should be included, but it can be a wavelength 
with a small absolute value and a high variance.164  In order to use the b coefficients, the 
X variables can be weighted with the inverse of the standard deviation to standardize the 
X variable space.164  The new form of the PLS equation is 
 JBXY wds += tan     (4.21) 
where Xstand are the standardized absorbencies, Bw are the weighted PLS coefficients and 
J is the matrix of the resulting residuals.164  A large coefficient of the resulting Bw matrix 
indicates an important wavelength that should be considered in the wavelength selection 
process.164  After selecting a set of wavelengths with high bw-coefficients, the PLS model 
with original data is completed; and the RMSEV for the optimum number of PLS factors 
is calculated.164  The process is repeated again with fewer selected wavelengths.164  The 
lowest point on a plot of the RMSEV against the number of selected wavelengths will 
determine the optimum number of wavelengths with high bw-coefficients to use for the 
PLS model.  Frenich et al. used this method of wavelength selection using PLS1 on two 
multicomponent mixture problems and were successful in lowering the prediction 
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error.164  To determine the wavelength included for each component, they divided the 
high bw-coefficients into five sets based on numerical ranges.164  Kassim and Simoneit 
altered this method for PLS2 and used a stepwise elimination method to remove the 
lowest bw-coefficients until the lowest prediction error was found for the optimum model 
of PLS.  A combination of the stepwise elimination method and the numerical criteria 
were used in this study to examine the effect of wavelength selection on this set of 
analytes.  Wavelength selection should not be applied blindly, and the method used must 
consider spectrally important regions.162   
 Variations of the PLS method have been developed based on the need for the 
analysis of various systems.  The orthogonal PLS (O-PLS) method was recently 
developed to handle systematic variations such as baseline, drift, and scatter effects, and 
impurities that can be present in the spectral matrix.165, 166  N-way PLS models have been 
developed to extend PLS to include N variables of objects or samples.  The normal PLS 
is two way with the columns as variables and the rows as samples.  In three-way PLS, the 
matrix becomes a box with a third variable added such as time, change in pH, or another 
factor.  For example, the three-way PLS was used to study the element concentrations of 
the water and sediment of the rivers Saale and Elbe.  Although it was difficult due to the 
large variability of the system chosen, the three-way PLS was able to improve the 
prediction of the suspended matter concentrations compared to the two-way PLS 
model.167  Although the data collected in this study are not conducive to three-way PLS, 
it is a method that may be of interest if samples from the same patients are collected over 
time in any future studies.  Comparisons of PLS methods with PCR and artificial neural 
networks on the same system have been completed, and the artificial neural networks 
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have been shown to have a lower root mean square error of prediction which 
demonstrates that multiple methods should be considered when determining quantitative 
results to select the best method for the current system.168 
e. Generalized Standard Addition Method (GSAM) 
 One of the classical methods for the quantitative detection of analytes is an 
standard addition method (SAM).  SAM is based on adding known concentrations of 
analyte to an unknown sample in order to determine optimally the concentration of the 
analyte in the original sample.  The known concentrations are added to the sample, the 
response is recorded, and a plot of the response vs. the known added analyte 
concentrations can determine the unknown concentrations, assuming the system is linear. 
SAM requires that the chosen response be linear over the entire concentration range. It is 
zero when no analyte is present, and no other components of the system interfere with the 
response chosen.169  If any of these conditions can not be met, then SAM can not be used.  
In the case of a multicomponent mixture where multiple analytes are of interest, the 
generalized standard addition method was developed by Saxberg and Kowalski to handle 
the matrix effects and other drawbacks seen in SAM.169  GSAM has been successfully 
applied to spectrophotometry170, inductively coupled plasma spectrometry171-173, and 
anodic stripping voltammetry174, 175 
  For the project at hand, all seven analytes have absorbances that are overlapping 
in the region of 350 nm to 550 nm.  No unique wavelength exists for each of the analytes; 
therefore, SAM is not a possible option.  GSAM, an analysis that simultaneously 
performs the calibration and prediction using multiple wavelengths, is a possible method.  
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The lack of a pure blank serum without any of the analytes being studied can be 
accommodated by GSAM.   
 In matrix notation, the relationship between the absorbance and the analyte 
concentrations in GSAM is  
  R = CK = ΔCK + CoK = ΔR + Ro   (4.22) 
where R is the matrix of the measured spectra of the unknown mixture plus the added 
analyte concentrations at multiple wavelengths, C is the concentration matrix with both 
the added analyte concentration, ΔC, and the unknown analyte concentration, Co, K is the 
matrix of the absorptivities for each component at each wavelength, ΔR is the matrix of 
the spectra of added analyte, and Ro is the measured spectra of the unknown mixture.169   
Since the addition of the analyte will alter the volume, the corrections for the response R 
in equation 4.19 becomes 
  ΔQ=ΔNK     (4.23) 
where ΔQ is matrix of the volume corrected response changes, and ΔN is the quantity of 
the additions in moles, micrograms, or another absolute quantity.176  In the 
overdetermined system where more additions than analytes are used, the resulting least 
squares solution for K is  
  K=(NTΔN)-1ΔNTΔQ     (4.24) 
assuming that (NTΔN)-1 exists.176  The final equation that is used to determine the 
concentration in the unknown analytes is  
  no = (KKT)-1Kqo    (4.25) 
where n0 is the vector of the initial concentrations, and qo is the vector of the volume 
corrected response for the initial unknown sample.176  Each addition can be a single 
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analyte, or it is possible to make multiple additions of analytes at the same time which are 
referred to as multiple standard additions.169    The linear model of GSAM as described 
above is for systems where the components of the K matrix are assumed to be constant 
over the entire range of concentrations. This is the case in the current study; however, 
GSAM can be changed to include additional terms in the quadratic and cubic forms of the 
model.169  A prior two-dimensional method of GSAM to handle both the 
chromatographic and mass spectrometric data from GC-MS and other combined 
instruments had already been developed and applied.177 
 The uncertainty of the estimation of K is based on the condition number of the K 
and ΔN matrices.  The equations have been defined as  
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where || || is the norm of the vector or matrix; cond is the condition number; and δ is the 
matrix of the small changes between the modeled and actual values of the respective 
matrices and vectors.176, 178-180  Equation 4.27 is dependent on having fully selective 
sensors that do not have any or very low interferences with each other.176, 178-180  Ideally, 
the condition number of the K matrix would be 1 which would allow for no amplification 
of error.176, 178-180  Although it is difficult to define all wavelengths of the current system 
of this study that do not contain interferences with other analytes, careful wavelength 
selection can aid  in lowering the condition number of K and reduce, therefore, the 
amplification of the error.  Although the condition number of the K matrix may be high 
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due to the similarity of the spectra of the six PUFA’s, it has been shown that low 
uncertainties can still be obtained for the analyte concentration as long as there is 
goodness of fit.176, 178  Kalivas states that the condition number of K is the upper limit of 
the error.178  Equation 4.26 is dependent on the experimental design of the additions used 
in the formation of the ΔN matrix.  This portion of the error is controlled by the 
experiment and should be designed to minimize the condition number of the matrix since 
it is not always possible to minimize the condition number of the K matrix due to the 
analytes being examined.176, 178-180  The effect of experimental design on this matrix was 
examined during this study.  D-optimal181 and four component mixture designs182 were 
considered and used in the development of the GSAM additions using The 
Unscrambler157  and the JMP155 software packages.  In a study of the volume and matrix 
effects for GSAM, it was determined that the volume-corrected responses can increase 
the errors in the determined concentrations resulting in the conclusion that it is best to 
maintain a constant volume to minimize the variance in the analyte predictions.183  To 
reduce this error, a constant volume for the initial sample and each addition was 
maintained.  Each addition for the GSAM study was 10 μL to the mixture plus the 
reagents’ total volume of 1.05 mL.  To maintain a constant volume, 10 μL of chloroform 
was added to the initial unknown sample concentration. GSAM was used for the analysis 
of both prepared mixtures with four components and serum samples. 
f. Artificial Neural Networks (ANN) 
 ANN have become an important tool in a wide variety of research fields.  Inspired 
by the information processing of neurons found in biological nervous systems, ANN can 
be trained to find solutions, expose pattern recognitions, and classify data. The basic 
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method of operation of ANN is defined by the way the individual elements, inputs, 
neurons, and output are connected and by the strength of the connections which are called 
weights.  The weights are determined by training which follow specified learning rules 
until the network is able to complete the desired problem.  This process is similar to the 
learning process the biological system undergoes when it is exposed to a new task.  New 
connections or modifications to existing connections are made during this process.  
Although ANN are not as complex as biological systems, they have been used to solve a 
number of problems.  Productive results have been seen in applications ranging from 
autopilot enhancements in aerospace, to speech recognition, and even financial models in 
real estate.184  ANN have been used for the classification and identification of 
pharmaceutical and illegal drugs such as heroin using both HPLC and GC data as 
input.185, 186  An ANN was developed to aid in the diagnosis of malignant breast nodules 
from digital mammographic and ultrasonographic images.187  Besides pattern recognition, 
ANN have been used for the quantification of mixtures including amino acids, organic 
dyes, and the oil pollutants in water samples using UV spectra, fluorescence spectra, and 
combinations of both as input parameters for the ANN.188-190  Due to the power of ANN, 
it will be used for a pattern recognition set and for the quantitative determination of the 
seven components.    
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Figure IV.1: Example of a basic neural network design 
 
A basic network design adapted from Hagan et al. is shown in Figure IV.1.184  The 
network is divided into three layers comprised of input, hidden layers, and output.  In the 
context of the current problem, the input parameters will be numerical descriptors of the 
spectra.  The parameters could have included the absorbance at specified wavelengths for 
each parameter and characteristics of the spectra including average slopes of the curves 
and the area under the curves, etc.  In the current study, selective wavelengths and 
principal components were considered.  Each of the parameters in the input layer is 
connected to neurons in the hidden layer.  The term hidden is applied due to the fact that 
inputs and outputs from these layers are not seen in the analysis of the method.   The 
hidden layers can consist of one or more layers.  The hidden layer includes a weight 
matrix (W), a summation step (Σ), a bias vector b, a transfer function f, and an output 
vector a.184  The number of hidden layers and the number of neurons in each layer is 
flexible and is determined by examination of the errors in the results.  Connections 
between input layer and the hidden layer are described by the weight matrix W.  The 
input parameter matrix, p, is multiplied by the weight to form Wp, and a bias is added.  
Each neuron of the hidden layer has a bias bi, a summation step, a transfer function f, and 
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an output ai.  The bias is summed with the weighted input parameters to form the net 
input n, which is the following equation in matrix form:184  
n = Wp + b    (4.28). 
The result of the summation step n is placed into the transfer function which produces the 
output vector of the hidden layer,  
a = f (Wp +b)               (4.29) 
that leads to the input components of the next layer.184  The next layer can be an 
additional hidden layer or can be the final output of the NN.  Possible options for the 
transfer function, f, can include both linear and non-linear functions including 
symmetrical hard limit, log-sigmoid, hyperbolic tangent sigmoid, and other.184   
 The input of the network and its architecture can be defined by the problem and 
adjusted to improve the fit of the network.  The number of inputs used in a network must 
fully define the problem at hand.  The input vector in this study consisted of either 
selected wavelengths or principal components that were used to describe the spectra for 
each mixture or serum.  The wavelength range from 350 – 550 nm was considered, but 
the excessive wavelengths proved to increase the prediction errors.  The number of 
hidden layers and number of neurons of each layer define the network architecture which 
can be altered to find the network that produces the lowest error of prediction.  ANN is 
defined by the number of inputs and the number of neurons in each layer.  For example, a 
15-30-4 network has 15 input parameters, 30 neurons in the hidden layer, and 4 outputs.  
Although problems are complex, the goal of ANN is to find a simple network that meets 
the low error of prediction standards for a clinical assay.  If the system has too few or too 
many neurons or layers, the details of the function or problem are not being described.184   
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 A key factor in developing a useful network is the training of the network.  Both 
the weights and the bias are determined during this process.  Given a set of data, three 
groups are randomly formed.  Ten percent are the validation set, 10% are placed in the 
testing set, and 80% are placed in the training set.  Each set of data is scaled to have a 
range that matches the ranges of the transfer functions used in the NN.  A number of 
learning algorithms are available in the software programs.  The Levenberg-Marquardt 
Backprogagation training algorithm was the gradient-based optimization used in this 
study.  The algorithm is designed to minimize the mean square error between the outputs 
supplied in the training set and the ones generated by the network.184 To monitor the 
selection of the number of neurons, a method called “early stopping” was used.184  The 
process is used to prevent the over fitting of the training data. The process requires a 
validation set of input and output from the training set to be monitored during training.  
The errors produced by the validation set will serve as a control on the process.  As 
training is started, the error will be decreased.  The error will reach a low and begin to 
rise again if overfitting has begun.  At that point, the training is completed, and the 
program is stopped.   Monitoring the complexity of the network was completed during 
the training process through the use of Bayesian regularization.  Bayesian regularization 
and other similar methods add a penalty term to the performance index of the network 
which is the sum of the squared weights.184  If this term of the index is too small, the 
network is overfitted.  If the term is too large, important parts of the details of the 
absorbance/concentration relationship may be missed. The final step is the error analysis 
of the testing set to determine the accuracy of the NN for prediction.  The root mean 
squared error of prediction (RMSEP), in Equation 4.20 will be used.  The prediction set 
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consisted of prepared mixtures that were not included in the training, validation, or test 
sets used in the development of the network.   
 ANN do not have the ability to extrapolate.  The range of input parameters used in 
the training set is the only range that it will be able to analyze accurately.  In the case of 
serum and prepared mixture analysis, the perceptible highest and lowest concentrations of 
each component must be included.  In order to get the widest concentration range, 
possible concentrations from patients with untreated and treated dyslipidemias were 
included in the training of the NN.  For example, a patient with Type I dyslipidemia has 
an elevated concentration of triglyceride, part of which is PUFA, and a normal level of 
cholesterol.  These vastly different concentrations and spectra had to be considered in the 
design of the training set.  For the four component non-water samples, no experimental 
design was used.  All generated mixtures for that were completed for analysis with other 
chemometric methods. This resulted in 1500 spectra that were divided into the training, 
validation, and test sets.   
 The water added network was prepared differently.  The seven component 
training set was partially designed using full factorial designs with limitations in place to 
ensure the resulting spectra would remain inside the 0.2 to 1.0 absorbance range across 
all wavelengths.  The resulting matrix of concentrations used to prepare the mixtures is 
listed in Appendix III.  Each of the 130 mixtures was prepared and analyzed at least twice 
with the Purdie assay.  Added to the mixtures were single solutions of each of the seven 
analytes used to calculate the molar absorptivities of the analytes.  A total of 665 spectra 
were used for the training, validation and testing of the NN.  The prediction set contained 
16 mixtures that were used for error analysis. 
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 All ANN calculations were completed using the Neural Network Toolbox, version 
4.0 included as part of the software package MATLAB R12.191  Multiple architectures 
were attempted and trained since the design must be altered for each data set examined.  
An example of an ANN architecture used is the three component analysis. We have 
found that an input of 66 wavelengths in the range of 350 to 480 nm provided the most 
acceptable network for the determination of the concentrations of three analytes.  
Through extensive examination of NN architectures, a two-layer network (66-32-3) with 
66 inputs, 32 neurons in the hidden layer, and 3 neurons in the output layer was 
determined to be the best.  The transfer functions chosen were the hyperbolic tangent 
sigmoid function  
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for the hidden layer and  
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for the output layer a linear function.184  The scaling factor used on the input and output 
data for use with the range -1 to +1 to match the use of the hyperbolic tangent sigmoid 
function was 
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where A is the absorbance, As is the scaled absorbance, and Amin and Amax are the 
minimum and maximum absorbance values of the absorbances.  Equation 4.32 was 
applied for each input wavelength individually.  Equation 4.32 was also applied to the 
concentration matrix to scale the input and output data to the range of -1 to 1 to fit the 
selected transfer function.   
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2. Pattern Recognition  
 Using PCA discussed previously, the resulting principal components were plotted 
versus each other to produce a two and three dimensional representation of the data to 
determine if any patterns or clustering was occurring.  PCA was completed for both 
prepared mixtures and treated and untreated serum samples.  If a pattern was seen, then 
hierarchical cluster analysis was used to group the data points using the JMP software 
package.155  In cluster analysis, the process will start with one piece of data and combines 
groups based on distances from each other in the principal component space.153  The 
distances can be determined using a number of different methods including weighted 
average and Ward’s method.  Non-hierarchical cluster analysis, which is less frequently 
used, differs in that it starts with the data divided into groups; and the groups are altered 
to meet certain conditions such as minimization of the distance and other criteria.153  The 
cluster analysis in this study was hierarchical with Ward’s method used for the distances.   
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CHAPTER V  
 
 
EFFECTS OF WATER ON THE MOLAR SPECTRA 
 
 The experimental results for this study have been divided into three parts.  The 
first is the effect of water on the molar absorptivities.  Previous studies have published 
the molar absorptivities of each of the fatty acids, with no water added to the assay 
method.29, 31, 32  Since water is approximately 97% of serum, it was tested to see the effect 
of this amount of water on the reagent system.192  This simple test revealed significant 
changes in the molar absorptivities.   
 As previous work had established, the only major compounds that can react with 
the reagent system are the PUFA and cholesterol.  It should be noted that prior work 
examined saturated fatty acids, steroids, and other pharmaceutical drugs that contained 
the –CH=CH-CH2-reagent selective group. 29-33   Saturated fats did not produce colored 
products. 29-33   The steroids and other pharmaceutical drugs do react, but their 
concentration at therapeutic levels in serum would be much too low compared to the 
PUFA and cholesterol to significantly alter the spectral pattern. 29-33   Therefore, the focus 
of the analysis is limited to those compounds that will provide the largest contributions to 
a serum spectrum.    
 Initially, all calibration attempts with standards of the PUFA and cholesterol were 
completed with no water added to the reaction as in previous research. After initial 
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attempts to use the resulting molar absorptivities to fit sample serum spectra, it was 
determined that the molar absorptivities were too large and had different patterns that, 
although close, did not fit the serum completely.  After considering the reaction system 
and all possible sources of error, it was determined that the only difference between the 
serum reactions and the prepared mixture reactions was the additional water and protein 
found in serum.  During the reaction with a serum sample, the proteins are precipitated 
from the reagent solution and do not alter the spectral pattern.  Serum normally has a 
water to solid percentage ratio of 93:7 where the solids are the proteins and lipids.192  
With the sample size of serum being 10 μL, approximately 9.7 μL of water is added to 
the reagents when serum is analyzed.  The initial test of the water effect was to spike 
serum.  Increments of 5, 10, 20 and 30 μL were added to the reaction.  The resulting 15 
minute spectrum for each addition is shown in Figure V.1.  The general trend is a 
decrease in absorbance with the region of 380 to 460 nm being affected most.   Other 
spectral regions also diminished in height as more water was added.  Although dilution of 
the mixture is occurring, the changes in the pattern and height are too significant to be 
fully accounted for by this factor.  Follow up tests of adding water to the standards 
yielded different spectra for each of the analytes. 
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Figure V.1: Overlaid spectra for 10 μL of serum with 5, 10, 20, and 30 μL of water added to the 
reagent solution prior to reaction. 
I. Cholesterol 
 Cholesterol molar absorbance spectra with and without water have some 
differences, but only a slight decrease in its maximum peak at 520 nm.  A comparison of 
the molar spectra with and without water is in Figure V.2.  Cholesterol is defined by three 
major peaks occurring at 362 nm, 420 nm, and 520 nm.  The 520 nm peak is unique to 
cholesterol when compared to the other analytes and, as a result, was considered for a 
single wavelength determination of the cholesterol concentration until a truer 
measurement of the underlying PUFA was completed.  The effect of water on the 520 nm 
absorbance results is an 8% decrease when 10 μL of water is added.  The 362 and the 420 
nm peaks have a decrease in absorbance of 33% and 55%, respectively.  With only an 8% 
difference at the 520 nm peak, it offers some explanation as to why cholesterol 
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calibrations without water differed by less than a 10% error when compared to the 
enzymatic test.  It was not until the PUFA were included in the models that the problem 
became apparent. 
Figure V.2: Overlaid molar absorptivities of cholesterol with and without 10 μL added to the reagent 
mix.  Cholesterol – NW is the cholesterol standard without water in the reagent mixture.  Cholesterol 
is the cholesterol standard with water. 
II. Linoleic and Conjugated Linoleic Acid 
 Spectra for linoleic acid (LA) and conjugated linoleic acid (CLA) originally 
differed in the magnitudes of molar absorptivities and in spectral patterns.  The two 
maxima in the spectra of LA and CLA both occur at 372 and 426 nm, Figure V.3 and 
Figure V.4.  The percent drop in absorbance at 372 nm for LA was a 55% decrease 
compared to an 11 % decrease for CLA when water was added.  The percent difference at 
426 nm, when water was present in the reagent, was a 24% decrease for LA and an 
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increase of 22% for CLA.  The best numerical indicator for the spectral difference 
between these two isomers is the ratio of the absorbances of the 372 nm peak to the 426 
nm peak.  Without the presence of water, the ratio was 2.3 for LA and 1.6 for CLA.  With 
water, the ratios are lowered to 1.7 for LA and 1.1 for CLA.  This ratio difference 
between the spectra supports the argument that the concentrations of these compounds in 
mixtures and serum can be separated.  The two factors that influence that statement are 
the differences in the magnitude of the molar absorbance and the ratio differences 
between the two peaks demonstrating the pattern differences.  The absorbance increase at 
428 nm for CLA is very significant to their discrimination since it is the only band to 
increase in intensity in water. 
 
 
 
 
 
 
 
 
 
 
Figure V.3: Overlaid molar absorbance spectra for LA with and without the 10 μL of water.  
Linoleic Acid Methyl Ester – NW is the PUFA standard without water in the reagent mixture. 
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Figure V.4:  Overlaid molar absorbance spectra for CLA with and without the 10 μL of water.  
Conjugated Linoleic Acid Methyl Ester – NW is the PUFA standard without water in the reagent 
mixture. 
 
 CLA and LA were both run in the kinetic mode of the diode –array instrument to 
investigate the effect of water on the development of the absorbance.  Spectra were 
recorded every minute for a 20 minute time period for each analyte, with and without 
water.   Resulting spectral overlays for a 0.02 M solution of LA are shown in Figure V.5.  
Figure V.6 displays the corresponding plots for a 0.01 M solution of CLA.  Figure V.7 A 
and B are plots of absorbance versus time in minutes at 372 nm in Figure V.6(A) and 426 
nm in Figure V.6(B) for all four kinetic experiments. The significant difference can be 
seen at the 426 nm peak for the LA solutions.  In the non-water reaction, the 426 nm peak 
reaches an obvious maximum at 11 minutes then begins to decline.  In the water reaction, 
the peak continues to increase in absorbance until the end of the 20 minutes.  Only a 
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small variation exists in the 372 nm peak when comparing the water and non-water 
sample.  The non-water reaction rate is fast during the first six minutes of the reaction 
compared to the rate for the water sample.  This observation suggests that the water 
hinders the reaction resulting in the decreased absorbance.   
 The plots in Figure V.7 also demonstrate differences in the kinetics of CLA and 
LA.  Each component has a different rate of reaction, and these differences could 
possibly be exploited for analyses. The reaction of the standards and the mixtures could 
be monitored over the reaction time of 3 to 20 minutes to yield more information about 
the sample to help the analysis.  The first three minutes of the reaction, however, are lost 
during serum analysis due to the required spin time to remove the proteins from solution.  
Monitoring the reaction over the entire period may be a useful project to consider in the 
future.  The data collected on one sample would be increased from one spectrum to 
multiple spectra and includes time as a variable.  The added information and a proper 
chemometric method may be able to improve upon the errors in the quantitative results 
for the determination of the analyte concentrations.   
 In summary, CLA and LA have a large molar absorptivity difference.  The molar 
absorbance magnitude of CLA is 5.2 times higher than LA in the presence of water.  
There is also a difference in the pattern that can be determined by examining the ratio of 
the peaks of 362 nm and 420 nm.  The ratio for CLA is 1.7 where LA is 1.1.  The 
differences in magnitude and the spectral patterns allow for the possibility of separation 
in the deconvoluting methods to determine the concentration of each component. 
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Figure V.5: Spectral ensembles that compare the kinetics of LA (A) absorbance spectra after each 
minute of the reaction of 10 μL of 0.02 M LA standard in chloroform solution with only the reagents 
added over a 20 minute time period. (B) Absorbance spectra for each minute of the reaction of 10 μL 
of 0.02 M LA standard in chloroform solution with 10 μL water added to the reagents of the assay.  
The legend applies for both figures. 
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Figure V.6: Spectral ensembles that compare the kinetics of CLA (A) Absorbance spectra for each 
minute of the reaction of 10 μL of 0.01 M CLA standard in chloroform solution with only the 
reagents added over a 20 minute time period. (B) Absorbance spectra for each minute of the reaction 
of 10 μL of 0.01 M CLA standard in chloroform solution with 10 μL water added to the reagents of 
the assay. 
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Figure V.7: (A) Absorbance v. time for the peak at 372 nm for the reagents with and without water 
for CLA and LA.  NW means no water was added to the reaction.  (B) Absorbance v. time for the 
peak at 426 nm for the reagents with and without water for CLA and LA. 
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 The two double bonds in LA allow for an investigation of the assay’s ability to 
discriminate between all cis- and all-trans by virtue of a spectral difference.  The trans, 
trans isomer also called linolelaidic acid can be compared to the cis, cis LA isomer, 
linoleic acid.  Standard forms of the methyl esters of LA and linolelaidic acids were 
obtained and the molar absorptivities of each, with water present, were determined using 
the methods already described. Their molar absorptivities are compared in Figure V.8 
that also includes the structures of each of the analytes.  The spectra show strong 
similarities in the magnitude and overall pattern.  The percent difference at the 372 nm 
peak is 17% with LA being higher than linolelaidic acid.  The 426 nm peak is reversed 
with the linolelaidic acid absorbance being 2% higher than the LA molar absorbance.  
The ratio between the 372nm: 426 nm molar absorbance is 1.7 for LA and 1.4 for 
linolelaidic acid which might be within the error limits.  The similarities in the molar 
absorptivity and the ratio of the two major peaks lead to the conclusion that the assay is 
unable to discriminate between the cis,cis and trans, trans isomers of LA.  Tests of this 
conclusion will have to be reexamined as part of the development of the chemometric 
methods discussed in the next section of this chapter. 
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Figure V.8: Molar absorbance spectra for LA and linolelaidic acid methyl ester which were 
completed with water included in the reaction.  The chemical structures for each are displayed below 
the figure. 
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III. α- and γ- Linolenic Acid 
 ALA and GLA are two structural isomers of the PUFA that contain three double 
bonds in their structure.  ALA, an omega-3 fatty acid with double bonds on the 9, 12 and 
15 carbons, was examined with and without water added to the reaction.  The spectral 
difference is shown in the graph of the molar absorptivities in Figure V.9.  The ratio of 
the two maximum peaks, 372 nm to 426 nm, is 1.0 without water and 0.97 with water.  
The percentage of the difference between the molar absorptivities is 56% for 372 and 
51% for 426 nm with the water spectra being higher in both cases.    
 The GLA is an omega-6 fatty acid with double bonds on the 6, 9, and 12 carbons.  
Because of cost constraints, it was only examined with the addition of water.  A second 
fatty acid methyl ester with three double bonds in a longer carbon chain was examined as 
an alternative under the same conditions,  cis-11,14,17- eicosatrienoic acid methyl ester 
that has a 20 carbon chain with three double bonds located in it.  ALA and GLA have an 
18 long carbon chain.  Prior to this part of the study, it was unclear if the Purdie assay 
could discriminate among a series of PUFA with the same number of double bonds, e.g. 
GLA, ALA, and cis-11,14,17- eicosatrienoic acid.  The comparison of the molar spectra 
for the similar fatty acids is shown in Figure V.10.  Chemical structures for each are 
shown in Figure V.11.  There is a difference of only 5% between ALA and cis-11,14,17- 
eicosatrienoic acid (ETA) at each of the major peaks.  ETA has a maximum peak ratio of 
0.97 which is the same as the ratio of the peaks in ALA with water.  The longer carbon 
chain does not appear to alter the molar spectrum.  Based on this result, all of the PUFA 
containing three bonds will be expected to produce a similar molar absorptivity.  GLA 
has a different peak ratio of 0.90 and a percent difference of 0.85% for 372 nm and 8.7% 
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for 426 nm when compared to ALA.  With the difference in the peak ratios, a trial of 
chemometric methods will have to be completed to determine if this difference in pattern 
is sufficient to lead to a separation of the concentration of GLA from ALA in complex 
mixtures.  With the highly overlapping molar spectra and only small variations between 
all three spectra, the conclusion that the color development and resulting spectral pattern 
are dependent on the number of double bonds present can be supported.     
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Figure V.9: Comparison of ALA methyl ester under the changed reaction conditions where 10 μL of 
water was added. 
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Figure V.10:  Molar absorbance spectrum for the fatty acids with three double bonds in the carbon 
chain.  The similarity in the spectra results from the Purdie reagent producing spectra that are the 
same for the same number of double bonds present in the compound. 
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Figure V.11: Chemical structures for each of the PUFA containing three double bonds. 
 
IV. Arachidonic Acid  
 Additional support for the Purdie reagent producing spectra that are determined 
by the number of double bonds and not the compound nor the length of the carbon chain 
is provided by examining AA and cis-7,10,13,16-docosatetraenoic acid methyl ester 
(DTA).  Each of these PUFA contains four double bonds.  First, AA was examined under 
the water and no water reaction conditions, and the molar absorbance spectrum for both 
is in Figure V.12.  AA has two major peaks at 376 nm and 424 nm.  The percent 
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differences between the spectra are 41% for 376 nm and 50% for 424 nm, with the water 
reaction being lower.  The ratio between the 376 nm and 424 nm peak remained the 
same, so water did not have an effect on the spectral pattern. It just reduced the 
absorbance.    
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Figure V.12: Comparison of AA methyl ester under the changed reaction conditions where 10 μL of 
water was added and no water (NW) added. 
 
The molar spectra comparison of AA with DTA with water is shown in Figure V.13 with 
the chemical structures included in Figure V.14.  The resulting spectra show similar 
patterns in the region of 350 to 460, and then the DTA has an elevated absorbance 
through 650 nm.  It is unclear if this is a true depiction of the molar spectra for DTA or if 
it is the result of an error that occurred the day that the data was collected.  Limited 
supply of this standard has inhibited reproduction of the experiments.  The presence of 
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the change from 460 to 650 nm is a concern, especially, at the 520 nm region since it is 
the major absorbance peak for cholesterol.  The similarities in the 350 to 460 nm region, 
where all of the other PUFA absorb, are almost a duplicate of each other.  Based on these 
regional differences and the results from the PUFA with three double bonds, the 
statement that the Purdie assay will produce a unique spectral response that is dependent 
on the number of double bonds present is supported.     
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure V.13: Molar absorbance spectrums for the fatty acids with four double bonds in the carbon 
chain.  The similarity in the spectra results from the Purdie reagent producing spectra that are 
identical to those with the same number of double bonds present in the compound. 
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O
O
cis-7,10,13,16-docosatetraenoic acid methyl ester  
Figure V.14: Chemical structures for AA and cis-7,10,13,16-docosatentraenoic acid methyl ester 
 
V. EPA and DHA 
 The final two PUFA that are included in this study were EPA and DHA, Figure 
V.15,  reveals the effect of water on the reaction of the Purdie reagent with EPA, and 
Figure V.16 contains the molar spectrum from the reactions with DHA.  The chemical 
structures for each PUFA are in Figure V.17.   EPA, with five double bonds, and DHA, 
with six double bonds, have a major absorbance peak at 376 nm and a shoulder before a 
steep descent at 444 nm.   EPA had a percent molar absorbance difference of 36% and 
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43% for each wavelength when water was added to the reaction system.  DHA had a 60% 
decrease in percent difference in molar absorbance at 376 nm and 67% at 444 nm.  Both 
EPA and DHA have a ratio of 376 nm absorbance: 444 nm absorbance of 1.4 without 
water and 1.6 with water.  As previously reported1-3 and confirmed with the water added 
reaction, EPA and DHA have similar patterns and only differ in the magnitude of the 
molar absorptivity.  A plot of the molar absorptivities of each component versus the other 
is provided in Figure V.18.  The plot is linear with no looping in the pattern which 
suggests that the patterns are the same.  Chemometric methods will have to be tested to 
determine if separation of the individual concentrations can be achieved.  If it is not 
possible, the combination of all of the spectra may be necessary.  Since they are both 
omega-3 fatty acids, the combination will not be as disconcerting as combining any of the 
other analytes. 
 
 
 
 
  
 
 
 
 
Figure V.15: Molar absorbance spectra for EPA methyl ester with and without (NW) 10 μL of water 
added to the reaction 
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Figure V.16:  Molar absorbance spectra for DHA methyl ester with and without (NW) 10 μL of 
water added to the reaction 
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Figure V.17: Chemical structures for EPA and DHA methyl esters 
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Figure V.18: Molar absorbance of DHA v. molar absorbance of EPA.  The equation of the line is y = 
0.839x + 30.8 with an R2=0.999. 
 
 In summary, the addition of water to the reaction to simulate its possible influence 
on serum analyzed with the Purdie Assay produced a significant effect on the magnitude 
of the molar absorptions.  All seven major analytes had a reduction in the molar 
absorptivity values, with the exception of CLA at 428nm, and experienced changes to 
their spectral pattern.  Through examination of the kinetics of two of the analytes, LA and 
CLA, it was determined that water slowed the rate of the reaction which resulted in a 
lower absorbance for the 15 minute spectra.  Through the early stage analysis of analytes 
with the same number of double bonds as part of the chain, the spectral patterns appear to 
be nearly identical in pattern and absorbance.  This results in the conclusion that the 
Purdie reagent produces a unique spectral pattern for each PUFA with the same number 
of double bonds in the chain.  The exception to this statement is CLA, the conjugated 
isomer of linoleic acid.  CLA has a molar absorbance 5.2 times that of LA with a 
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difference in the ratio of its major absorbance peaks.  As the number of double bonds in 
the carbon chain increases to five and six, the spectral pattern becomes essentially 
identical except for an increase in its magnitude.  Spectra for EPA and DHA illustrate this 
problem.  It is an issue that will have to be addressed in the quantitative analysis.   
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CHAPTER VI  
 
 
CHEMOMETRIC METHODS APPLIED TO ASSAY 
 
 Multiple attempts to simultaneously determine the concentration of the seven 
major analytes in serum by using prepared mixtures as the model system is the second 
part of the results’ section.  Results will be examined both with and without the water 
addition using a variety of methods including PLS, ANN, and GSAM.  The final section 
is focused on the possibility of clustering being applied as a method to determine disease 
states based on different spectral patterns.  Prepared mixtures and a limited set of data 
generated on serum samples from the Cape Town laboratory will also be discussed.  The 
quantitative and qualitative analyses together describe the basic abilities of the Purdie 
assay. 
I. Description of Data 
 As seen in the examinations of the molar absorbance spectra, the data for 
quantitative analysis are divided between two sets.  A third set of data from the UCT 
Lipid lab was used for the qualitative analysis to be discussed in section III of this 
chapter.  The mixture analysis combined with the calibrations for experiments without 
water resulted in a set of 1471 spectra.  After initial analysis, outliers determined by 
examining influence and residual variance plots were removed to reduce the number to 
1410.  This set of data was divided into training, prediction, and test sets as needed for 
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analysis with the multiple multivariate methods.  Figure VI.1 consists of the minimum 
and maximum spectra for this set of samples.  Table VI-1 contains the concentration 
ranges for each of the four components examined with the non-water reagent system.  
The minimum concentrations are the non-zero minimums.  The units of μM are used to 
represent the concentration in the assay reaction.  
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Figure VI.1: Spectra representing the minimum and maximum spectra for the data set completed 
without water.  The minimum spectrum is for a low concentration of LA.  The dashed line spectrum 
is a mixture of ALA and AA.  The light gray spectrum is a mixture of cholesterol, LA, and ALA.   
 
Table VI-1: Concentration range of data set without water 
 Cholesterol
Linoleic 
Acid α-Linolenic Acid 
Arachidonic 
Acid 
Min. Concentration 
(μM) 9.41 15.4 15.9 19.0 
Max. Concentration 
(μM) 151 196 201 201 
Average  
(μM) 80.1 106 109 110 
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 The second data set was for water samples.  This set was designed using full 
factor design with limits in place to maintain the total absorbance under 1.0 absorbance 
units.  The molar concentrations of the solution used are given in Appendix III.  Table 
VI.2 lists the minimum and maximum concentrations in μM.  The spectra in Figure VI.2 
are the minimum and maximum spectra of the entire data set of 667 mixture spectra.  
Eight outliers were removed, and the remaining spectra were divided as needed for each 
method.  A set of prediction spectra were completed independently and were used to 
determine the root mean standard error of prediction (RMSEP) for each of the methods.  
The concentrations of these mixtures are within the ranges in Table VI-2. 
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Figure VI.2: Spectra show the limits of the minimum and maximum spectra for the data set 
completed with water added.  The minimum spectrum is for a low concentration of LA only.  The 
dashed line spectrum is a mixture of cholesterol, ALA, AA, EPA, DHA, and CLA.  The light gray 
spectrum is a high concentration sample of cholesterol only. 
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Table VI-2: Concentration range of the mixture spectra completed with water. 
 Cholesterol 
Linoleic 
Acid 
α-
Linolenic 
Acid 
Arachidonic 
Acid EPA DHA Conjugated
Min. 
Concentration 
(μM) 10.8 19.7 19.4 17.8 18.2 20.8 9.87 
Max. 
Concentration 
(μM) 77.8 197 204 214 182 214 99.2 
Average (μM) 44.3 109 111 116 100 117 54.5 
 
II. Multivariate Approaches 
A. Direct and Indirect Calibration Methods 
 The standard method of analysis for multivariate systems has been the multiple 
linear regression analysis.  In cases where there are more input responses to describe the 
spectra than analyte concentrations, the system is overdetermined and least squares 
analysis must be used.   As described in the methods section, the basic equation is 
C=(KTK)-1 KT A, where C is the concentrations of the unknown solution, K is the matrix 
of the molar extinction coefficients, and A is the absorbencies for the spectra of the 
unknown solution.  The key is defining the matrix K.   
 In the first method, the K matrix was defined using molar extinction coefficients 
that were determined by calibrating each standard with multiple dilutions to find the 
calibration lines (slope and intercept) for each wavelength of the spectra.  This method is 
a direct calibration method.  Figure VI.3 is an example calibration line for LA at 372 nm.  
The equation of the line had a slope of 3500 with an intercept of –0.0174 and an R2= 
0.994.  This process was repeated for each of the analytes, and the resulting K matrix was 
formed and then used to examine prepared mixtures. Full spectral molar absorptivities 
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used for this analysis are summarized in Figure VI.4.  DHA and EPA were combined as 
one in this set of calibrations. 
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Figure VI.3: Absorbance v. concentration for LA at 362 nm.  This is an example of the calibration 
lines determined for each wavelength examined for each component. 
 
 
 
 
 
 
 
 
 
 
Figure VI.4: Molar absorbance spectra resulting from the calibration of the standard solutions 
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 The resulting concentrations for prepared mixtures did not result in low percent 
errors.  In attempts where all six analytes and 101 wavelength variables formed in the K 
matrix, the resulting concentration matrix could not determine which components were 
zero.  Since the solutions had known components, the K matrix was altered to include 
only the molar absorptivities of the analytes in the mixture.  For example, if the solution 
contained only cholesterol and LA, then the K matrix was reduced to data for only two 
analytes.  Four representative solutions are displayed in Table VI-3.   
Table VI-3: Resulting concentrations from the component dependent K matrix results with percent 
errors 
Mixture 1       
  Experimental Matrix Percent Error 
  Concentration (μM) Concentration (μM)  (%) 
Cholesterol 64.4 48.3 -2.15 
Linoleic 65.4 56.2 -9.59 
Linolenic 64.1 70.4 5.28 
       
Mixture 2      
  Experimental Matrix Percent Error 
  Concentration (μM) Concentration (μM)  (%) 
Cholesterol 80.5 79.6 -1.11 
Linoleic 32.7 24.7 -24.7 
Linolenic 48.1 42.1 -12.5 
Arachidonic 31.6 41.5 31.4 
       
Mixture 12      
  Experimental Matrix Percent Error 
  Concentration (μM) Concentration (μM)  (%) 
Cholesterol 32.2 36.2 12.3 
Linoleic 32.7 30.4 -7.23 
Linolenic 32.1 35.4 10.3 
Arachidonic 31.6 28.0 -11.4 
EPA/DHA 75.1 98.8 31.5 
       
Mixture 14      
  Experimental Matrix Percent Error 
 Concentration (μM) Concentration (μM)  (%) 
Cholesterol 48.3 48.3 0.08 
Linoleic 49.1 56.2 14.6 
Linolenic 48.1 70.4 46.3 
Conjugated Linoleic 49.6 51.3 3.26 
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 This attempt is obviously not a suitable solution to the problem of finding a 
method for the quantification of the unknown spectra resulting from the Purdie assay.  
The first problem is that in an unknown solution, the components are uncertain; therefore, 
the K matrix cannot be defined.  The other problem is that while the percent errors are 
low for the three component mixtures of cholesterol, linoleic, and linolenic, the percent 
error also increased as the number of analytes increased. It is interesting to note that 
cholesterol is low in all of the mixtures attempted.  Cholesterol has the one unique 
absorbance peak at 520 nm.  All components contribute to the total absorbencies in the 
range 350 to 480 nm.  As the number of the PUFA variables in this region is increased, 
the error increases.  An alternative method had to be found that can analyze overlapping 
peaks.  Figure VI.5 is mixture 1 comparing the results of the least squares solution, the 
experimental results, and the addition of the known concentrations times each of the 
molar absorptivities.  There is an obvious difference in the experimental spectra and the 
matrix and addition spectrum.  Either there is an error in the calibration, or the matrix 
method is not best method to solve the problem.  Additional attempts at calibrations with 
water have been completed, but a similar problem with the percent error increasing with 
the number of analytes was observed.   
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Figure VI.5: Comparison of the least squares solution with the experimental and simple addition 
spectrum 
 
 A second method was attempted that used both the classical least squares method 
and a non-negative least squares algorithm to solve the over determined system.  Using 
all 101 wavelengths from 350 to 550 nm, the RMSEP for twenty of the mixtures were 
analyzed using both methods.  Table VI-4 compares the two results.  The non-negative 
least square solution approach reduced the RMSEP for four of the PUFA and increased 
RMSEP for cholesterol and ALA.  The non-negative solution was able to predict more of 
the cases where the components were not present in the mixture compared to the direct 
calibration.  The RMSEP in both cases are too large to lead to any useful prediction 
model using the directly calibrated K matrix.  The ratio of the RMSEP to the mean 
concentration of each analyte expressed as a percentage reaffirms this statement.  Ideally, 
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the percentage would be under 10%, which is not the case in any of the analytes 
determined in this calculation. 
Table VI-4: Direct calibration results comparing classical least squares to a non-negative least 
squares solution 
 
Direct 
Calibration 
(RMSEP, μM) 
Ratio 
RMSEP:Mean 
Concentration, 
% 
Direct Calibration  
(non-negative)  
(RMSEP, μM) 
Ratio 
RMSEP:Mean 
Concentration, 
% 
Cholesterol 2.02 3.90 43.7 84.6 
Linoleic 
Acid 115 226 51.4 101 
Linolenic 
Acid 29.1 59.7 62.1 128 
Arachidonic 
Acid 56.0 130 41.1 95.5 
EPA/DHA 29.0 44.2 18.7 28.4 
Conjugated 68.8 133 37.7 72.0 
 
 The indirect K-matrix and P-matrix calibrations’ methods were done on the same 
set of data as the direct calibration method.  The dilution mixtures used in the calibrations 
of the non-water samples were used to determine both the K matrix and P matrix in the 
respective methods.  The resulting columns in the K matrix from the K-matrix method 
are the molar absorptive spectra for each of the analytes.  DHA and EPA were 
determined separately by the method.  The resulting spectra from using all of the 
wavelengths are in Figure VI.6. 
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Figure VI.6: Molar absorptivity spectra determined by the K matrix indirect calibration method 
 
The resulting matrix was then used to determine the concentration of the same twenty 
analytes used in the direct calibration method.  The P-matrix indirect calibration was also 
completed, but one of the drawbacks of the method is that the P matrix has no physical 
meaning.  The components are not the molar absorptivities of the analytes.  The RMSEP 
and the relative error compared to the mean of the concentrations for the K-matrix are in 
Table VI-5.  The P-Matrix result had a ratio of RMSEP to mean concentration over a 
thousand percent.  This is the result of poorly designing the concentration matrix.  It will 
be repeated with a designed matrix to obtain the comparison between both methods. 
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Table VI-5: Indirect calibration results comparing K-matrix method 
 
K-matrix, RMSEP 
(μM) 
RMSEP:Mean 
Concentraion, % 
Cholesterol 18.7 36.1 
Linoleic Acid 36.2 70.9 
Linolenic Acid 9.91 20.3 
Arachidonic Acid 18.1 42.1 
EPA 39.5 88.8 
DHA 36.8 71.3 
Conjugated 24.0 45.7 
 
Neither method is able to determine the concentrations.  The K-matrix approach has 
provided the best determination of all of the components except for EPA and DHA. The 
P-matrix approach cannot even approach an answer that is close to the known 
concentrations of the mixtures.  The direct and indirection calibrations methods cannot 
handle the highly overlapping spectra that are present.  The last attempt to improve the 
error of prediction is to introduce different strategies for wavelength selection and 
mixture design on the results. 
 Mixture design for the water samples, as stated previously, was a limited full 
factorial design to maintain a proper absorbance.  Both the direct and indirect methods 
were completed on the spectra.  The K matrix for the direct calibration method was 
composed of the molar spectra for each analyte discussed in Chapter V.  The resulting 
molar spectra from the K-matrix approach using only the mixtures from the full factorial 
design are shown in Figure VI.7.   
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Figure VI.7: Molar absorptivities from the components of the K matrix from the water samples 
 
Overall the spectral patterns compared with the spectra from the calibrations, except for a 
magnitude shift for all spectra.  An average increase in the molar absorption is 11%.  The 
RMSEP for all four methods are in Table VI-6.   
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Table VI-6: Comparison of direct and indirect calibration methods utilizing a full factorial design for 
the mixtures 
 
K Matrix, 
 
P Matrix, 
101 variables 101 variables 
Mean RMEP RMSEP: RMEP RMSEP: 
Conc. (μM) Mean, (μM) Mean, % 
 (μM)  %   
Cholesterol 22.7 4.67 20.6 1.41 6.16 
Linoleic 
Acid 44.3 6.32 14.3 46.1 104 
Linolenic 
Acid 39.1 1.96 5.03 16.9 43.2 
Arachidonic 
Acid 39.0 6.83 17.5 46.5 123 
EPA 26.8 15.5 58.0 30.6 114 
DHA 38.7 10.6 27.5 21.3 55.1 
Conjugated 
Linoleic 
Acid 22.9 1.84 8.04 7.59 33.2 
      
Direct Calibration, Direct Calibration, 
 Classical Least Squares Non-negative 
Mean RMEP RMSEP: RMEP RMSEP: 
Conc. (μM) Mean, (μM) Mean, 
 (μM)  %  % 
Cholesterol 22.7 4.15 18.2 4.38 19.3 
Linoleic 
Acid 44.3 28.7 64.7 28.7 64.8 
Linolenic 
Acid 39.1 16.0 40.9 9.37 24.0 
Arachidonic 
Acid 39.0 23.1 59.2 11.3 29.0 
EPA 26.8 43.3 162 92.5 346 
DHA 38.7 25.8 66.8 82.2 213 
Conjugated 
Linoleic 
Acid 22.9 4.48 19.6 3.49 15.3 
 
 
 
 
 133
 The results are a significant improvement over the findings from the previous 
attempt using spectra that were not produced from a mixture design. Water added to the 
reagent system is a variation, as well, since it increased the difference in a number of the 
analyte’s spectra.   Despite the improvement, the errors are still too significant to use 
these methods for analysis of serum or other systems.  A part of this difference may be 
the result of the K-matrix approach requiring two matrix inversions.  Since the spectra of 
the analytes are similar, the inversion may result in an almost singular matrix which 
cannot be used for the final determination of the concentrations.153  One solution to 
improve on the K matrix method is to reduce the number of wavelengths used in the 
calculation.  
  Wavelength selection can be used to reduce the effects of overlapping spectra.  
The difficulty in this system is including all of the PUFA.  Each of the PUFA absorb in 
the same region.  Table VI-7 displays the six groups of wavelengths chosen to examine 
the effects.  The combination of 75 and 21 were determined from criteria examining the 
standardization of PLS2 results.  The procedure will be discussed in the next section on 
PLS methods.   
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Table VI-7: Selected wavelengths chosen to examine the effects of wavelength selection on the 
determination of the concentrations of analytes 
Number of Wavelengths Selected Wavelengths 
101 350 – 550 nm, every 2 nm 
75 350, 352, 354,356,358,360,362,364,366,368, 
380, 382,384,386,388,390,392,394,398,400, 
402,414,416,418,420,424,426,428,430,432 
434,436,438,440,442,444,446,448,450,452 
454,456,458,460,462,464,466,468,470 
472,474,480,482,496,500,502,504,506,508,514 
516,518,520,522,524,526,528,530,532,534 
536,538,540,542,544 
69 350-480, 518, 520, 522 
66 350-480 
33 360-378, 388-394, 400, 412, 418, 420, 422, 
242, 426, 428, 430, 440, 442, 444, 480, 482, 
484, 518, 520, 522 
21 350, 360,362,366,380,382,390,392,426,440, 
444,446,462,464,470,496,528,530,534,536,538
 
 
Each of the wavelength groups was attempted using all of the components, cholesterol 
and the six PUFA.  A table comparing the number of variables with the RMSEP and the 
ratio of REMSEP to the mean concentration is included in Table VI-8.   
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Table VI-8: Effect of five wavelength selection groups on K Matrix results 
 K  Matrix, 75 K Matrix, 69 K Matrix, 66 
Mean RMSEP RMSEP: RMSEP RMSEP: RMSEP RMSEP: 
Conc (μM) Mean, (μM) Mean, (μM) Mean, 
 (μM)  %  %  % 
Chol 22.7 1.40 6.18 1.18 5.20 1.23 5.41 
LA 44.3 50.9 246 47.0 106 47.8 108 
ALA 39.1 17.0 65.4 6.87 17.6 6.67 17.1 
AA 39.0 49.0 278 39.0 99.9 40.3 103 
EPA 26.8 30.7 574 34.6 129 24.4 91.0 
DHA 38.7 21.7 93.3 33.1 85.6 22.5 58.2 
CLA 22.9 8.43 69.0 8.99 39.3 9.12 39.8 
        
 K Matrix, 33 Kmatrix, 21 
Mean RMSEP RMSEP: RMSEP RMSEP:
Conc (μM) Mean, (μM) Mean, 
 (μM)  %  % 
Chol 22.7 2.93 12.9 2.14 9.43 
LA 44.3 9.16 20.7 69.5 157 
ALA 39.1 24.5 62.6 2.80 7.17 
AA 39.0 76.4 196 63.6 163 
EPA 26.8 216 809 85.5 319 
DHA 38.7 177 457 61.3 158 
CLA 22.9 2.63 11.5 13.2 57.7 
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 Little to no improvement was seen with any of the wavelength groupings.  The 
highest number of variables included in the matrix resulted in similar RMSEP as was 
seen for the use of all 101 variables.  As the number of variables decrease, the RMSEP 
and the ratio increased significantly for all the analytes, including cholesterol.  
Cholesterol is the one analyte that should be able to be determined because of the unique 
520 nm peak.  If cholesterol is not determined within a reasonable error, then the method, 
in general, will not be a possibility for the quantification of this assay.  Using all 101 
wavelengths for the K matrix method is the best approach based on these results.   
 Given the fact that EPA and DHA are so similar and LA and CLA have 
overlapping spectral patterns with different magnitudes, an attempt was made to examine 
the K matrix method with only cholesterol, LA, ALA, and AA.  Using only the mixtures 
with these components from the designed mixture matrix, the resulting molar absorptivity 
spectra (Figure VI.8) place the focus on the similarities in the ALA and AA spectra.  In 
Table VI-9, the RMSEP has been reduced compared to the seven component K matrix 
results, but the similarity in the ALA and AA spectra result in a high RMSEP for these 
two compounds.  Having a more robust method than indirect or direct calibration that is 
capable of handling the severely overlapping spectra is required.   
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Figure VI.8: Molar absorptivity spectra that are the components of the K matrix from the K matrix 
approach using four components 
 
Table VI-9: Errors on prediction for K matrix approach using only four components 
 
Mean 
Concentration 
(μM) 
RMSEP 
(μM) 
RMSEP:Mean, 
% 
Cholesterol 26.2 5.57 21.2 
Linoleic 53.1 24.2 45.5 
Linolenic 63.3 47.9 75.7 
Arachidonic 65.4 51.2 78.2 
 
B.  Partial Least Squares (PLS) Approach 
 Multivariate calibration methods, PLS1 and PLS2, were applied to the spectral 
data from both the water and non-water data sets to examine different aspects of the 
problem.  As with the previous methods, the RMSEP was determined for each analyte.  
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The non-water set was used to examine the differences in PLS1 and PLS2 on the 
prediction errors.  The water samples were used to examine the effect of wavelength 
selection and the number of components on the calibration of the PLS model.   
 The RMSEP for PLS1 and PLS2 calibrations for four components are presented 
in Table VI-10.  PLS2 is only slightly better than PLS1 for each analyte.  This may be the 
case because the interference of the compounds in the spectra is taken into account in 
PLS2 and not in PLS1.  PLS1 determines the concentration of one analyte at a time; 
whereas, in the PLS2 all of the concentrations are determined simultaneously.  The 
higher RMSEP are obtained for LA, ALA, and AA while cholesterol is low.  LA, ALA, 
and AA have absorbance peaks that completely overlap; whereas, cholesterol has regions 
that do not, which causes the higher RMSEP in the overlapping analytes. 
 
Table VI-10: Comparison of the RMSEP for PLS1 and PLS2 
 
 
   
 
 
 
 
 
 Expanding PLS to include all seven components was done using PLS2 on the set 
of water samples.  The error comparisons of the two models are presented in TableVI-11.  
The combination of EPA and DHA reduced the error for these components and 
PLS1 
Mean Conc. 
(μM) 
RMSEP 
(μM) 
RMSEP:mean conc., 
% 
Cholesterol 62.5 6.15 9.85 
LA 88.6 64.0 72.2 
ALA 93.5 61.3 65.6 
AA 122 34.4 28.2 
    
PLS2 
Mean Conc. 
(μM) 
RMSEP 
(μM) 
RMSEP:mean conc., 
% 
Cholesterol 62.5 4.02 6.43 
LA 88.6 63.7 71.9 
ALA 93.5 61.7 66.0 
AA 122 33.0 27.1 
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demonstrated a slight decrease with the other components.  Combining DHA and EPA 
into one component helps to reduce the error and may be considered for use, but the 
RMSEP will need to be reduced considerably. 
Table VI-11: Change in errors seen when DHA and EPA are combined for PLS2 analysis 
PLS2 with 7 analytes 
 
Percent 
Error 
Maximum Percent 
Error 
RMSEP 
(μM) Ratio, % 
Cholesterol 9.18 14.6 1.82 7.21 
Linoleic 15.4 38.3 7.95 18.0 
Linolenic 6.82 18.7 2.71 7.06 
Arachidonic 12.0 35.3 6.66 17.2 
EPA 59.7 94.3 18.2 64.7 
DHA 6.89 55.4 10.6 45.7 
Conjugated 6.89 15.3 18.2 9.11 
     
PLS2 with 6 components 
 
Percent 
Error 
Maximum Percent 
Error 
RMSEP 
(μM) Ratio, % 
Cholesterol 9.44 17.4 1.87 7.41 
Linoleic 14.6 37.8 8.03 18.2 
Linolenic 5.66 18.3 2.35 6.12 
Arachidonic 10.4 27.4 6.57 17.0 
EPA+DHA 17.9 43.5 12.0 25.9 
Conjugated 7.64 18.6 2.10 17.0 
 
 A cross-validation method was used to determine the number of PLS1 and PLS2 
components to use in the final model.  This method performs the calibration on the data 
set minus one sample and predicts the concentration of the sample that was not included.  
Each of the samples is left out during the algorithm. Their concentrations are predicted 
and then compared to the actual concentrations.  The RMSEC was determined for various 
numbers of components to calculate the optimum number to include in the model.  An 
example of the RMSEC for various numbers of components for the PLS2 calibrations 
with the water samples is located in Figure VI.9.  The minimum RMSEC for the PLS2 
model pictured is 10PC using all 101 wavelengths.  For the PLS1 models, cholesterol 
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required 2 PCs, LA required 5 PCs, and ALA and AA required 10 PCs.  The RMSEC for 
the PLS2 for the non-water samples required 9 PCs.  All plots show a rapid decrease in 
the RMSEC for CLA and cholesterol.  The remaining fatty acids require more 
components to reduce the RMSEC.  The difference in behavior is due to the similarities 
of the spectra of the PUFA. 
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Figure VI.9: RMSEC as a function of the number of PLS2 components for each of the analytes with 
DHA and EPA combined. 
 
 Wavelength selection can be determined by examining the bw-coefficients from a 
PLS model using standardized data.  The bw-coefficients that are negative are variables 
that have a high influence from the other analytes.  The PLS2 model with the water 
samples was used with the standardized model due to similar RMSEP seen when 
 141
comparing PLS1 with PLS2.  The bw-coefficients for each of the analytes using 10 PC 
which had the lowest root mean square error of calibration (RMSEC) are in Figure VI.10. 
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Figure VI.10: bw – coefficients from a PLS2 analysis for each of the analytes 
 
 Two groups of wavelengths were determined based on the following criteria.  A 
75 variable collection included wavelengths that had three of the six components with 
positive bw-coefficients.  A 21 variable collection consisted of wavelengths that had four 
of the six components with positive bw coefficients.  A 33 variable collection of 
wavelengths that included the maximum wavelengths for each analyte with some added 
on either side of the peak maxima in case of shifts in the peaks.  The last two wavelength 
groups studied were the wavelengths in the region of 350-480 nm with and without the 
520 nm peak of cholesterol included.  Each wavelength grouping was analyzed with 
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PLS2 using the mean centered data and cross validation method for the determination of 
the number of PCs used for each model.  Each model was then used to predict the 
concentrations of each analyte.  The RMSEP versus the number of variables are reported 
in Figure VI.11.  
Figure VI.11: RMSEP compared for each analyte at various numbers of wavelength variables 
 
The 21 wavelengths chosen had the lowest RMSEP for all of the analytes.  The PLS 
method is dependent on having the most wavelengths with the least influence from other 
analytes.  The selected regions from 350 to 480 nm and the 33 variables selected based 
on maximum peaks of the molar spectra produced the highest RMSEP.  
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Table VI-12: The error analysis of the results on the prediction set from the water analysis and 
wavelength selection using 21 wavelengths 
 
Error analysis for the PLS2 model with 21 variables still has a high ratio of RMSEP to 
the mean concentration for each of the analytes which are shown in Table VI-12.  All 
variables need to be reduced to below 10%.   
C. GSAM Approach 
 The reaction system, unlike other analytical systems, does not have a blank that 
can be used in the analysis.  Serum is a complex system and a serum without any 
cholesterol and all of the fatty acid removed can not be obtained.  One chemometric 
method that can accommodate for this deficiency and, possibly, improve the error 
analysis is GSAM.  GSAM is based on adding multiple unknown amounts of analytes to 
the mixture to determine the concentration of the initial mixture.  The error associated 
with this method is based on the matrix of the addition and the resulting matrix of molar 
absoptivities.  Due to the overlapping spectra of the analytes, there is a limited 
opportunity to lower the error in that matrix.  The concentration of the addition can be 
controlled by mixture design.  Extreme vertices and D-optimal design were used to define 
the mixture matrix. 
 
Percent 
Error, 
% 
Maximum 
Percent 
Error, 
% 
Mean 
Concentration,
μM 
RMSEP, 
μM 
RMSEP:Mean 
Concentration,
% 
Cholesterol 7.26 12.0 25.2 3.17 12.6 
Linoleic 21.1 46.4 44.2 10.8 24.4 
Linolenic 4.12 10.9 38.4 2.42 6.30 
Arachidonic 31.1 54.4 38.6 11.0 28.3 
EPA+DHA 26.9 63.7 46.5 13.8 29.7 
Conjugated 6.30 13.7 22.8 2.55 11.2 
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 Extreme vertices design used the matrix of mixtures in Table VI-13 for the 
additions to the prepared mixtures.  The concentrations listed are the concentrations of 
the prepared mixtures prior to dilution.  Mixtures with and without water additions were 
prepared.  Table VI-14 displays a comparison between the two methods.  The condition 
number for the concentration matrix was 7.09, and the condition number of the K matrix 
was 82.1 for all 101 wavelengths.  When GSAM was attempted with wavelengths from 
350 to 450 nm, the condition number of the K matrix was 40.3.  GSAM theory 
determines that in cases of interferences, which are the overlapping spectra in this case, 
the condition number of the K matrix is the upper bound of the uncertainties which are 
amplified under these conditions.178  The ideal condition number of the K matrix is 1.  
Although the K matrix from both of the selected wavelength regions is high, Kalivas has 
shown that the prediction capability of GSAM may not be altered, which is seen in this 
set of data.178   
 The samples with water had the lowest RMSEP when compared with the direct 
and indirect calibration methods.  The variation seen in the spectra for the water samples 
may aid in improving the error.  The other difference between the two sets of data is the 
small improvements on the method that occurred during the experimental time.  As the 
operator gained more experience with the method, the manual components of the reaction 
were made more uniform.  Slight variation in the addition of the perchloric acid to the 
acetyl chloride and the vigor of the hand shaking will each have an effect on the sample.  
If an instrument is developed for the assay, these will be eliminated. 
 Figure VI.12 provides an example of a prepared mixture with each addition.  The 
spectrum that is the lowest is the original sample.  Figure VI.13 is a comparison of the 
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GSAM predicted spectra with the experimental value for one of the samples completed 
with water.  It is clear that the fit of the two spectra is an overlay, except in the high 
cholesterol peak.  One error that cannot be eliminated is related to the GSAM 
recommendation that the additions be at least double the amount in the initial sample.  If 
completed, the absorbance will be over the limit of 1.0 absorbance for serum.  The 
prepared mixtures were designed to match the concentration seen in a normal serum 
sample.  The cholesterol in the water samples is close to having a ratio of RMSEP to the 
mean concentration of 10%, which suggests the method and design of addition can have a 
low occurrence of error.  More tests on concentrations that are higher in cholesterol and 
new designs of the additions to fit future samples will have to be examined.  
Table VI-13: GSAM addition mixtures for examining four components.  An extreme vertices design 
was applied for the additions to the prepared mixtures. 
Added Mixture 
Cholesterol 
(M) 
LA 
(M) 
ALA 
(M) 
AA 
(M) 
1 0.004 0 0 0 
2 0 0.02 0 0 
3 0 0 0.02 0 
4 0 0 0 0.02 
5 0.002 0.01 0 0 
6 0.002 0 0.01 0 
7 0.002 0 0 0.01 
8 0 0.01 0.01 0 
9 0 0.01 0 0.01 
10 0 0 0.01 0.01 
11 0.001 0.0075 0.0075 0 
12 0.001 0.0075 0 0.0075 
13 0.001 0 0.0075 0.0075 
14 0 0.075 0.0075 0.0075 
15 0.001 0.005 0.005 0.0075 
16 0.002 0.01 0.005 0.0075 
 
 
 
  
 146
Table VI-14: GSAM combined results for samples with and without water 
Samples without water (n=8) 
 Mean Conc. (μM) RMSEP (μM) RMSEP:mean conc., % 
Cholesterol 51.8 11.4 22.0 
LA 54.9 11.5 21.0 
ALA 14.2 24.1 170 
AA 13.2 22.9 174 
    
Samples with water (n=10) 
 Mean Conc. (μM) RMSEP (μM) RMSEP:mean conc., % 
Cholesterol 51.4 6.29 12.3 
LA 53.8 6.04 11.2 
ALA 14.2 8.27 58.2 
AA 17.6 2.65 15.0 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
350 400 450 500 550 600 650
Wavelength (nm)
A
bs
or
ba
nc
e
 
Figure VI.12: Prepared mixtures with the additions added for the GSAM approach for one example 
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Figure VI.13: GSAM predicted spectra with the experimental spectra.  The dashed line is the GSAM 
predicted spectra.  The solid line is the experimental spectra for the prepared mixture. 
 
 An additional mixture design matrix was completed using D-optimal design.  
The ratios of the concentrations are in Table VI-15.  The condition number of the 
concentrations prepared is 3.38, which is lower than the extreme vertices trial.  The lower 
condition number results in a lower error according to the theory of GSAM.  The results 
for the matrix, Table VI-16, are an improvement over the RMSEP seen in the extreme 
vertices trial.  Mixture design is important in GSAM.  It can reduce the errors in the 
prediction of the concentrations, as demonstrated, and aid in reducing the number of 
mixtures that must be added to fully describe the analytes. 
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Table VI-15: D-optimal design for the additions used in a GSAM attempt. The condition number is 
3.3834 for the concentration matrix based on the prepared samples. 
 
Cholesterol
(M) 
LA 
(M) 
ALA 
(M) 
AA 
(M) 
Addition 1 0.25 0.25 0.25 0 
Addition 2 0.25 0 0 0.25 
Addition 3 0.25 0.25 0 0 
Addition 4 0.25 0 0 0 
Addition 5 0 0 0 0.25 
Addition 6 0 0 0.25 0 
Addition 7 0.125 0.125 0.125 0.125 
Addition 8 0 0.25 0 0 
Addition 9 0 0.25 0 0.25 
Addition 10 0.25 0 0.25 0 
Addition 11 0 0 0 0 
Addition 12 0 0.25 0.25 0 
Addition 13 0.125 0.125 0.125 0.125 
Addition 14 0.125 0.125 0.125 0.125 
 
  
Table VI-16:  GSAM results using D-Optimal design on three prepared mixtures 
 
Mean Conc., 
(μM) 
RMSEP, 
(μM) 
RMSEP: 
Mean Conc, 
% 
Cholesterol 36.6 1.67 4.57 
LA 85.9 8.51 9.91 
ALA 96.5 22.8 23.6 
AA 63.5 22.0 34.6 
 
 The GSAM approach for four components was attempted with serum samples.  
The concentration results for the cholesterol and the three PUFA are listed in Table VI-17 
with examples of the predicted and experimental spectra in Figure VI.14.  The cholesterol 
for the serum was determined with the standard enzymatic method.  Unfortunately, the 
PUFA could not be determined for comparison.  The RMSEP for the cholesterol is 10.7 
mg/dL.  The ratio of the RMSEP to the mean concentration of cholesterol is 5.83%.  
Determining the values with all four components while keeping the cholesterol error low 
is a starting point for the analysis of serum.  GSAM requires that all analytes and 
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interference must be fully described in the addition used.  Since serum contains a number 
of other analytes, such as EPA, DHA and CLA, that were not included, the values of the 
PUFA may be inaccurate.  Due to the time consuming process of analyzing serum using 
GSAM and the number of additions needed to describe all seven analytes, GSAM is not 
appropriate for a clinical laboratory that needs to examine hundreds of samples in a week.  
If the process can be automated, it may be considered.   
 
Table VI-17: GSAM four component analysis of serum samples.  RMSEP for the cholesterol is 
10.6451 mg/dL.  The ratio of the RMSEP to the mean concentration of cholesterol is 5.83%. 
 
 
Cholesterol, GSAM 
pred. (mg/dL) 
Cholesterol, 
Enzymatic 
(mg/dL) 
Percent Error 
% 
Sample 1 204 187 -8.88 
Sample 2 207 188 -10.3 
Sample 3 188 189 0.54 
Sample 4 193 189 -2.28 
Sample 5 174 163 -6.78 
Sample 6 175 173 -1.13 
Sample 7 188 189 0.33 
 
 LA (μg/mL) ALA (μg/mL) AA (μg/mL) 
Sample 1 291 1250 53.3 
Sample 2 619 794 81.4 
Sample 3 943 370 621 
Sample 4 458 867 199 
Sample 5 504 697 84.2 
Sample 6 907 178 581 
Sample 7 403 745 81.0 
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Figure VI.14: Comparison of the GSAM predicted spectra with the experimental spectra for two of 
the seven samples examined. 
D. Neural Networks 
 The data sets without water have been analyzed using ANN with three and four 
components.  The expansion to the additional analytes is in progress.  A collection of 
1410 spectra was used for the training.  The data set was randomly divided into a training 
set (80%), a validation set (10%), and a test set (10%).  The architecture of the network 
changes with each analyte and must be determined by examining the RMSEP resulting 
from each network attempted.  The transfer function for the first hidden layer was chosen 
to be a sigmoid function with the output transfer function being linear.  These two 
functions have been used previously in determining the concentrations in other 
spectrometric studies.188, 189, 193 The number of neurons in the output layer equals the 
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number of concentrations that is being determined by the network.  The number of 
neurons in the first hidden layer is the variable that must be determined.  A network is 
trained using a number of neurons, and then the RMSEP is determined for that network 
for all of the components.  A plot of the RMSEP compared to the number of neurons in 
the hidden layer for the three component analysis is in Figure VI.15.  The number of 
neurons for each analyte was the lowest for 32 neurons in the layer with the wavelengths 
of 350 – 480 nm resulting in 66 inputs for the network.  A plot of the ratio of the RMSEP 
to the mean concentration of the predicted set is in Figure VI.16.  The reduction in the 
RMSEP corresponds with a reduction in this ratio and in the average percent error for the 
prediction set. Any fewer than 15 nodes results in an increase in the RMSEP, and 
increasing the number of neurons over 40 results in an increase in the RMSEP suggesting 
overfitting.  The balance between not defining and overfitting the system is needed and is 
accomplished with the use of 32 neurons in the layer.  The overall network architecture 
was 66-32-3.  The error analysis is listed in Table VI-18 for this network.  The required 
number of epochs ranged from 76 to 223 for the training of each of the networks.  
Limiting the number of inputs to 25 selected wavelengths based on absorbance did not 
demonstrate a significant reduction in the RMSEP, which is shown in Table VI-19.     
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Figure VI.15: RMSEP versus the number of nodes in the hidden layer for the development of the 
three analyte network 
 
Table VI-18: RMSEP, mean concentration, and the ratio expressed as a percentage for the three 
component network. 
 RMSEP, (μM) 
Mean 
Concentration,
(μM) 
Ratio 
RMSEP:Mean 
Conc., % 
Cholesterol 1.19 49.2 8.44 
LA 2.95 105 8.03 
ALA 4.50 110 7.36 
 
Table VI-19:  Prediction error analysis for networks using 25 selected wavelengths 
Number of 
Neurons 
RMSEP, 
Cholesterol 
(μM) 
Ratio, 
Cholesterol
RMSEP, 
Linoleic, 
(μM) 
Ratio, 
Linoleic
RMSEP, 
Linolenic, 
(μM) 
Ratio,  
Linolenic 
20 2.63 4.06 2.99 3.24 2.86 6.49 
32 3.14 4.85 3.04 3.29 4.44 10.1 
50 2.17 3.35 4.92 5.34 2.86 6.47 
100 6.45 9.95 6.10 6.61 3.66 8.28 
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Figure VI.16: Ratio of the RMSEP to the mean concentration versus the number of neurons in the 
hidden layer 
 
 A number of methods and attempts to improve each with wavelength selection, 
mixture design, and alterations to the reagent procedure have been presented.  To 
summarize the results, a final comparison between GSAM, PLS, and ANN with four 
component samples completed with no water are compared.  The ANN architecture for 
the four component network was 66-40-4 as determined by examining the RMSEP.  The 
mixtures determined for each method were included in the predictions of all three 
methods.  The combined results are in Table VI-20. 
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Table VI-20: Summary table for four component analysis with GSAM, PLS2, and ANN 
GSAM 
 
Mean Conc. 
(μM) 
RMSEP 
(μM) 
RMSEP:mean conc., 
% 
Cholesterol 62.2 4.82 7.75 
LA 69.8 5.63 8.06 
ALA 31.3 6.45 20.6 
AA 28.0 2.34 8.37 
PLS2 
 
Mean Conc. 
(μM) 
RMSEP 
(μM) 
RMSEP:mean conc., 
% 
Cholesterol 62.2 5.17 8.31 
LA 69.8 6.89 9.86 
ALA 31.3 1.65 5.29 
AA 28.0 5.99 21.4 
ANN 
 
Mean Conc. 
(μM) 
RMSEP 
(μM) 
RMSEP:mean conc., 
% 
Cholesterol 62.2 3.34 5.37 
LA 69.8 3.79 5.43 
ALA 31.3 2.57 8.23 
AA 28.0 3.45 12.4 
 
 Based on the water samples, the ANN approach has the lowest RMSEP for all of 
the samples.  Mixture design and wavelength selections each contributed to the reduction 
of the errors seen with GSAM and PLS2 methods.  ANN has a lower RMSEP.  The high 
RMSEP for ALA and AA in GSAM and PLS2, respectively, may be due to the 
similarities in the spectra for the two analytes.  The error is reduced or at least distributed 
among both analytes in the case of ANN.  The ANN networks expanding to all seven 
components and with water added to the reaction are in the process of being trained.  
Once completed, the network will be used to analyze serum since the added water will 
simulate the same conditions of the serum reactions. 
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E. Pattern Recognition  
 Corresponding spectral patterns of the samples can be used for pattern recognition 
analysis.  The water sample selections that were created using full factorial design and 
the prediction set were analyzed using hierarchical cluster analysis with Ward sampling 
on the principal components.  The resulting plot of PC 2 versus PC 1 and the resulting 
clusters with 0.95 confidence density ellipses are present in Figure VI.17.      
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Figure VI.17: Principal component 1 v. principal component 2 for the prepared mixtures that were 
completed with water.  Nine clusters were determined. 
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 The clusters divide the samples into the respective analytes and mixtures.  Cluster 
1 is the blank with no analytes.  Some of the very low concentrations of linoleic acid are 
included.   Clusters 2, 3, and 6 are mixtures of all the components.  Cluster 4 and 7 are 
composed of AA, EPA, and DHA.  The lack of separation of these components is the 
result of the similarities of the spectra for each of these components, especially at lower 
concentrations.  Cluster 7 also contains the ALA samples.  They are not divided into any 
other cluster.  Cluster 5 is composed of all the cholesterol samples.  The final two 
clusters, 8 and 9, are the CLA with the division being the changes in concentrations.  The 
separation suggests that the pattern can be used to examine the patterns generated from 
different mixtures. 
 A set of data collected by the UCT on samples from patients was analyzed using 
similar methods.  After the cluster analysis, the collaborators in Cape Town determined 
the clusters are the result of the dyslipidemic state of the patients. 
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Figure VI.18: PC1 v. PC2 of the untreated serum samples. 
 
 The general trend that is seen in Figure VI.18, to this point, is that from top to 
bottom one goes from the Type V (top) through to the Type IIs in clusters 3,4, and 5 and 
end with control patients being distributed in 8 and 9.  Cluster 1 contains the Type V 
patient pattern.  Cluster 2 is Type III and Type IV (2 of each).  Separation will improve 
with an increase in the sample size of these types and with the inclusion of the fatty acid 
profiles.  Cluster 3 is a Type IIa pattern with a majority considered to be FH (8/14) and 
FCH (4/14).  Cluster 4 is a combination of Type IIa, IIb with controls with cholesterol 
values over 220 mg/dL.  Cluster 5 is a combination of  IIa, IIb and some patients on 
various stages of statin treatments.  Cluster 6 is a combination of controls with 
cholesterol over 200 mg/dL.   Cluster 7 is a cluster of samples with cholesterol between 
193 and 240 mg/dL, statin treated patients, controls, diet induced hypercholesterolemia, 
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and people under altered diet treatment for hypercholesterolemia.  Cluster 8 and 9 are 
clusters of controls and some statin treatment patients.  The one sample in cluster 10 is a 
sample of a type V patient in cluster 1 that was run with half the required volume of 
serum due to the extremely high absorbance of the entire spectra.  Although the 
collaborators were able to complete an initial analysis of the clusters, all of the following 
groups are subject to change as the fatty acid profile is increased and as more information 
about the medical history is gathered.  Further collection of data and patients’ histories 
including diet, treatments, and other health conditions will have to be collected to 
determine if this pattern recognition can be used as a screening tool for dyslipidemias in a 
clinical setting. 
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CHAPTER VII  
 
 
CONCLUSION 
 
 The goal of this research project was to develop a simple, direct alternative 
method for the determination of the polyunsaturated fatty acids in addition to cholesterol 
in serum and, possibly, other samples that contain these analytes.  Initial attempts by the 
Purdie laboratory to determine the concentrations were improved through the use of 
chemometric techniques and additional knowledge about the reaction conditions.  This 
study was able to determine the concentration of four of the seven components believed 
to be reacting with the assay in serum.  Additionally, the spectral patterns from a 
collection of serum spectra from a collaborating laboratory demonstrated a possible 
diagnostic test for dyslipidemias which offers support for an expanded study. 
  PUFA are a focus in both nutritional sciences and medical studies in the 
evaluation of risk factors for cardiovascular diseases, dyslipidemias, metabolic syndrome, 
and other diseases.  The studies have disclosed that unsaturated fatty acids can offer 
health benefits which include reducing cardiovascular death rates, lowering current 
cardio risk factors such as LDL cholesterol, and promoting positive effects for patients 
suffering from cancer, arthritis, and mental disorders .  With potential connections to 
these diseases, analytic methods have been developed to determine the concentrations of 
the PUFA in serum.  The current common method of detection is GC with FID or MS 
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detection, which includes a step of extraction and transformation of the PUFA to methyl 
esters to complete the detection.  To improve on the analytic method of detection for 
PUFA for quick and easy use in medical and nutritional research, a colorimetric reaction 
developed in the Purdie laboratory was utilized to develop a quantitative 
spectrophotometric assay. 
 The addition of water to the reaction to simulate a possible effect with serum 
analyzed with the Purdie Assay had a significant effect on the magnitude of the molar 
absorptions.  All seven major analytes had a reduction in the molar absorptivity values 
and experienced changes to their spectral pattern.  Through examination of the kinetics of 
two of the analytes, LA and CLA, it was determined that water slowed the rate of the 
reaction which resulted in a lower absorbance for the 15 minute spectra.  Through the 
analysis of analytes with the same number of double bonds as part of the chain, the 
spectral patterns are nearly identical in pattern and absorbance.  This results in the 
conclusion that the Purdie reagent produces a unique spectral pattern for each PUFA with 
the same number of double bonds in the chain.  The exception to this statement is CLA, 
the conjugated isomer of linoleic acid.  CLA has a molar absorbance 5.2 times that of LA 
with a difference in the ratio of its major absorbance peaks.  As the number of double 
bonds in the carbon chain increase to five and six, the spectral pattern becomes identical 
with an increase in its magnitude as seen with EPA and DHA.   
 A number of multivariate analysis methods were examined for the determination 
of the concentrations of individual components of prepared mixtures and, ultimately, 
serum based on the spectra resulting from the Purdie assay.  Direct and indirect 
calibration methods had low percentage errors for binary, tertiary, and quaternary 
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mixtures containing cholesterol, LA, ALA, and AA.  As CLA and the similar 
components of EPA and DHA were added, the percentage error rose.  Despite attempts to 
improve the analysis through wavelength selection, mixture design, and the addition of 
water to the assay, the methods were not able to handle the separation of all seven 
components. PLS, GSAM, and ANN were used to analyze the same set of prepared 
mixtures of cholesterol, LA, ALA, and AA.  The ANN outperformed the other methods 
with a ratio of RMSEP to the mean concentrations of 5.37 to 12.4% for the four 
components without the presence of water.  GSAM was utilized to examine serum and 
was able to determine cholesterol with a 1-10 % error compared to the enzymatic test 
results completed at an independent laboratory.  A new training set with the presence of 
water in the reaction is currently being established, and the resulting spectra will be used 
to analyze ANN determination of serum samples.  Since water has such a major effect on 
the spectra, in order for ANN to possibly determine serum, the entire training set of 
spectra must match conditions. 
 The final multivariate analysis technique to examine the qualitative patterns of the 
spectra was completed using PCA with cluster analysis.  A cluster diagram created from 
PCA data derived from untreated patients’ serum spectra had nine clusters which suggest 
separation based on dyslipidemias.  Prepared mixtures also yielded separation based on 
the components present and the concentration ranges of each of the components.  Both 
cluster analyses suggest that the spectrum itself can offer a benefit as a possible screening 
tool for dylipidemias; and, if combined with the quantitative data for PUFA and other 
cardiac risk factors, may be functional in risk prediction models.  Further studies with an 
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in depth analysis of medical histories must be completed before any final conclusion 
about the clustering can be established. 
 The Purdie assay can quantitatively determine the concentration of cholesterol, 
LA, ALA, and AA in prepared mixtures through the use of multivariate analysis methods 
with ANN yielding the lowest percentage errors and coefficient of variation.  The 
addition of the three remaining PUFA and expanding the ANN to include the effects of 
water for all components is a continuing project.  Once completed, the assay will be a 
useful clinical assay for a wide variety of research projects including further studies on 
the clustering and possible pattern recognition methods for the screening of 
dyslipidemias.       
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APPENDIX I 
Copy of Oklahoma State University Wellness Center blood testing consent form. 
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APPENDIX II 
Letter of Permission from the University of Cape Town Lipidology Clinic.    
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APPENDIX III 
Table of 130 mixtures from a full factorial design with limitation to maintain an 
absorbance between 0.2 and 1.0 absorbance units. 
 
 
Cholesterol 
(M) 
Linoleic 
(M) 
Linolenic
(M) 
Arachidonic
(M) 
EPA 
(M) 
DHA 
(M) 
Conjugated
(M) 
Mixture1 0 0 0 0 0 0 0
Mixture2 0.008 0 0 0 0 0 0
Mixture3 0 0.02 0 0 0 0 0
Mixture4 0.008 0.02 0 0 0 0 0
Mixture5 0 0 0.02 0 0 0 0
Mixture6 0.008 0 0.02 0 0 0 0
Mixture7 0 0.02 0.02 0 0 0 0
Mixture8 0.008 0.02 0.02 0 0 0 0
Mixture9 0 0 0 0.02 0 0 0
Mixture10 0.007 0 0 0.01 0 0 0
Mixture11 0 0.02 0 0.02 0 0 0
Mixture12 0.007 0.01 0 0.01 0 0 0
Mixture13 0 0 0.02 0.02 0 0 0
Mixture14 0.007 0 0.01 0.01 0 0 0
Mixture15 0 0.01 0.01 0.01 0 0 0
Mixture16 0.007 0.01 0.01 0.01 0 0 0
Mixture17 0 0 0 0 0.02 0 0
Mixture18 0.007 0 0 0 0.01 0 0
Mixture19 0 0.02 0 0 0.02 0 0
Mixture20 0.007 0.01 0 0 0.01 0 0
Mixture21 0 0 0.02 0 0.02 0 0
Mixture22 0.007 0 0.01 0 0.01 0 0
Mixture23 0 0.01 0.01 0 0.01 0 0
Mixture24 0.007 0.01 0.01 0 0.01 0 0
Mixture25 0 0 0 0.02 0.02 0 0
Mixture26 0.007 0 0 0.01 0.01 0 0
Mixture27 0 0.01 0 0.01 0.01 0 0
Mixture28 0.007 0.01 0 0.01 0.01 0 0
Mixture29 0 0 0.01 0.01 0.01 0 0
Mixture30 0.007 0 0.01 0.01 0.01 0 0
Mixture31 0 0.01 0.01 0.01 0.01 0 0
Mixture32 0.007 0.01 0.01 0.01 0.01 0 0
Mixture33 0 0 0 0 0 0.01 0
Mixture34 0.007 0 0 0 0 0.01 0
Mixture35 0 0.02 0 0 0 0.02 0
Mixture36 0.007 0.01 0 0 0 0.01 0
Mixture37 0 0 0.01 0 0 0.01 0
Mixture38 0.007 0 0.01 0 0 0.01 0
Mixture39 0 0.01 0.01 0 0 0.01 0
Mixture40 0.007 0.01 0.01 0 0 0.01 0
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Cholesterol 
(M) 
Linoleic 
(M) 
Linolenic
(M) 
Arachidonic
(M) 
EPA 
(M) 
DHA 
(M) 
Conjugated
(M) 
Mixture41 0 0 0 0.02 0 0.02 0
Mixture42 0.007 0 0 0.01 0 0.01 0
Mixture43 0 0.01 0 0.01 0 0.01 0
Mixture44 0.007 0.01 0 0.01 0 0.01 0
Mixture45 0 0 0.01 0.01 0 0.01 0
Mixture46 0.007 0 0.01 0.01 0 0.01 0
Mixture47 0 0.01 0.01 0.01 0 0.01 0
Mixture48 0.007 0.01 0.01 0.01 0 0.01 0
Mixture49 0 0 0 0 0.02 0.02 0
Mixture50 0.007 0 0 0 0.01 0.01 0
Mixture51 0 0.01 0 0 0.01 0.01 0
Mixture52 0.007 0.01 0 0 0.01 0.01 0
Mixture53 0 0 0.01 0 0.01 0.01 0
Mixture54 0.007 0 0.01 0 0.01 0.01 0
Mixture55 0 0.01 0.01 0 0.01 0.01 0
Mixture56 0.007 0.01 0.01 0 0.01 0.01 0
Mixture57 0 0 0 0.01 0.01 0.01 0
Mixture58 0.007 0 0 0.01 0.01 0.01 0
Mixture59 0 0.01 0 0.01 0.01 0.01 0
Mixture60 0.007 0.01 0 0.01 0.01 0.01 0
Mixture61 0 0 0.01 0.01 0.01 0.01 0
Mixture62 0.007 0 0.01 0.01 0.01 0.01 0
Mixture63 0 0.005 0.005 0.005 0.005 0.005 0
Mixture64 0.006 0.005 0.005 0.005 0.005 0.005 0
Mixture65 0 0 0 0 0 0 0.008
Mixture66 0.007 0 0 0 0 0 0.006
Mixture67 0 0.01 0 0 0 0 0.006
Mixture68 0.007 0.01 0 0 0 0 0.006
Mixture69 0 0 0.01 0 0 0 0.006
Mixture70 0.007 0 0.01 0 0 0 0.006
Mixture71 0 0.01 0.01 0 0 0 0.006
Mixture72 0.006 0.005 0.005 0 0 0 0.004
Mixture73 0 0 0 0.01 0 0 0.006
Mixture74 0.007 0 0 0.01 0 0 0.006
Mixture75 0 0.01 0 0.01 0 0 0.006
Mixture76 0.006 0.005 0 0.005 0 0 0.004
Mixture77 0 0 0.01 0.01 0 0 0.006
Mixture78 0.006 0 0.005 0.005 0 0 0.004
Mixture79 0 0.005 0.005 0.005 0 0 0.004
Mixture80 0.006 0.005 0.005 0.005 0 0 0.004
Mixture81 0 0 0 0 0.01 0 0.006
Mixture82 0.007 0 0 0 0.01 0 0.006
Mixture83 0 0.005 0 0 0.005 0 0.004
Mixture84 0.006 0.005 0 0 0.005 0 0.004
Mixture85 0 0 0.005 0 0.005 0 0.004
Mixture86 0.006 0 0.005 0 0.005 0 0.004
Mixture87 0 0.005 0.005 0 0.005 0 0.004
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Cholesterol 
(M) 
Linoleic 
(M) 
Linolenic
(M) 
Arachidonic
(M) 
EPA 
(M) 
DHA 
(M) 
Conjugated
(M) 
Mixture88 0.006 0.005 0.005 0 0.005 0 0.004
Mixture89 0 0 0 0.005 0.005 0 0.004
Mixture90 0.006 0 0 0.005 0.005 0 0.004
Mixture91 0 0.005 0 0.005 0.005 0 0.004
Mixture92 0.006 0.005 0 0.005 0.005 0 0.004
Mixture93 0 0 0.005 0.005 0.005 0 0.004
Mixture94 0.006 0 0.005 0.005 0.005 0 0.004
Mixture95 0 0.005 0.005 0.005 0.005 0 0.004
Mixture96 0.006 0.005 0.005 0.005 0.005 0 0.004
Mixture97 0 0 0 0 0 0.01 0.006
Mixture98 0.007 0 0 0 0 0.01 0.006
Mixture99 0 0.01 0 0 0 0.01 0.006
Mixture100 0 0.005 0 0 0 0.005 0.004
Mixture101 0.006 0.005 0 0 0 0.005 0.004
Mixture102 0.006 0 0.005 0 0 0.005 0.004
Mixture103 0 0.005 0.005 0 0 0.005 0.004
Mixture104 0.006 0.005 0.005 0 0 0.005 0.004
Mixture105 0 0 0 0.01 0 0.01 0.006
Mixture106 0.006 0 0 0.005 0 0.005 0.004
Mixture107 0 0.005 0 0.005 0 0.005 0.004
Mixture108 0.006 0.005 0 0.005 0 0.005 0.004
Mixture109 0 0 0.005 0.005 0 0.005 0.004
Mixture110 0.006 0 0.005 0.005 0 0.005 0.004
Mixture111 0 0.005 0.005 0.005 0 0.005 0.004
Mixture112 0.006 0.005 0.005 0.005 0 0.005 0.004
Mixture113 0 0 0 0 0.005 0.005 0.004
Mixture114 0.006 0 0 0 0.005 0.005 0.004
Mixture115 0 0.005 0 0 0.005 0.005 0.004
Mixture116 0.006 0.005 0 0 0.005 0.005 0.004
Mixture117 0 0 0.005 0 0.005 0.005 0.004
Mixture118 0.006 0 0.005 0 0.005 0.005 0.004
Mixture119 0 0.005 0.005 0 0.005 0.005 0.004
Mixture120 0.006 0.005 0.005 0 0.005 0.005 0.004
Mixture121 0 0 0 0.005 0.005 0.005 0.004
Mixture122 0.006 0 0 0.005 0.005 0.005 0.004
Mixture123 0 0.005 0 0.005 0.005 0.005 0.004
Mixture124 0.006 0.005 0 0.005 0.005 0.005 0.004
Mixture125 0 0 0.005 0.005 0.005 0.005 0.004
Mixture126 0.006 0 0.005 0.005 0.005 0.005 0.004
Mixture127 0 0.005 0.005 0.005 0.005 0.005 0.004
Mixture128 0.006 0.005 0.005 0.005 0.005 0.005 0.004
Mixture129 0.003 0.0025 0.0025 0.0025 0.0025 0.0025 0.002
Mixture130 0.003 0.0025 0.0025 0.0025 0.0025 0.0025 0.002
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